var title_f39_6_40032="Total pelvic exenteration";
var content_f39_6_40032=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F52560&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F52560&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Total pelvic exenteration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 389px; height: 255px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gross fixed specimen from total pelvic exenteration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_6_40032=[""].join("\n");
var outline_f39_6_40032=null;
var title_f39_6_40033="Gram stain lung biopsy 1";
var content_f39_6_40033=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F59274&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F59274&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gram stain lung biopsy 1",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 289px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_6_40033=[""].join("\n");
var outline_f39_6_40033=null;
var title_f39_6_40034="Enterocele examination";
var content_f39_6_40034=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F76450&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F76450&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pelvic examination technique for enterocele",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 418px; height: 416px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGgAaIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiub1Lx34S0yaSHUfFGh208f3opb+JXH/AS2aAOkorzW6+Ofw3tpfLfxRbu3/TGCaUfmiEVF/wAL6+G3fxJt92sblR+sdAHp9FcXYfFTwHfJvg8X6Go9JrxIT+TkGussL211C1S5sLmC6t35WWCQOjfQjg0AWKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiud8a+MdG8G6fHda1csskzGO1tYVMk91JxiOKMcsxJA9BkZIril0bxl8RQJvE91ceEvDUgBTR7CXF7cIR/wAvEw/1YP8AzzTnDEMQRmgDb8UfFPw9omptpFkbrXtfGR/Zejwm5mUgkHfj5UxjkMQQOcVlD/havijkNo/gexbkDaNSvgR69IQD+JFdx4W8MaJ4U01bDw7pltp9qMZWFMFyOMux5Y+7EmtmgDzIfBrQ9QQnxfqniDxRISGxqWoyCJG7lI4yqqD6HNdNpfw/8H6UY20/wtokEkYwsi2Me8f8Cxk/nXT0UAIiqihUUKo4AAwBS0UUAZWr+HdE1oAaxo+m6gB0+1WqS/8AoQNcjf8Awb8D3F4b2y0c6Rf4wlzpNxJZtGfVRGwXP4V6HRQB5efB/j7w7hvCXjcarbJwth4ng87OepNzHiT6DBpE+KlxoDpB8SvDd/4cyQo1GH/TLBz0H71BlCxzhWHA6mvTLvz/ALJN9jERudjeV5udm/HG7HOM4zisLwV4gt/F/haG+e3EUrh7e+spRlredCVlhcH0YEcjkYPegDZ06/s9TsorzTbq3vLOUZjnt5BJG4zjIYEg8g9Ks15nqXwuGk3surfDTUW8M6mx8ySzUF9OuyP4ZIOi54G5MFQSQCateF/iKW1qPw344sP+Ee8TNhYVd91rqHbdby9DnI+Q/MNwHJBwAehUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcV4/wDGr6HcW2h+HrMat4u1BC1pYA4SJM4M87D7kSn8WPA7kHxG8aSeHvsWkaFapqXizVSY9PsWOFGPvTSkcrEgyT3OMDHJFvwB4Qj8L2dxNdXLal4g1BxNqeqSjEl1Jjgf7Maj5VQcKOnfIBneBvAC6Rf/APCQeJrw654wmQrLqEo+S3U5/dW6dI4xkjjk5YnGcDu6KKACiiigBsoZo3EbBXIIViM4PY4rJ8G6p/bXhXSdQaVJpZ7ZGldOnmYw4x2wwYY7YrYrzj4a6oll4x8b+EHZiNOvxfWzbcIIrtfOMYxwCrmT6g8dDgA7q41AQ6paWRtbt/tKuwnSLdFHtxw7fwk54z1wau0UUAFFFFABXn3gpTpPxN8d6Psiit7t7XW7ZF6t5sflSsf+2kGf+BV6DXnrWssXx9jvJBtiuvDbwR8/fMVyjMf/ACOBj/GgD0KsfxZ4a0jxZo0uleILGK9spDu2PwUYdGVhyrDJ5BB5PrWxRQB5PY65rPwy1OLS/G17LqnhK4kEVh4hnOZbRicLFeH0PQTdM/exn5fWOtQX9nbahZT2d9BFcWs6GOWGVQyOpGCCDwRXlulX9z8K9ds/DutTST+Cb+QQ6PqMzFm06Q9LOZj1jwP3bnkY2nIGVAPWaKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArE8a+JrDwf4Yv9c1ZmFtapu2IMvK5OFRR/eZiAO3POBk1t15Xg/EL4sMG+fwx4MmGMH5bnVSPxBECnpwQ7dxQBq/C7wzqFsbzxV4uEcni3WVVpgBxY2/WO0j9AvBbH3m5JbAY9/RRQAUUUUAFFFFABXkXhvVGT4ieOtQt4ZP7NvNTg0yS+jGTC8NtGmcnK8SORyMDnPTFdncarceIrhrHw5KVsQSt3qyfdTBwY4Ozydi33U92G2tC88PWzeGJtE01jp8DRNHG8ShihbOSQfvZJO7PJyTnJzQBLpWps9y2najtj1ONS2AMLOgwPMj9RyAR1U8HggnVrh9B0LUpdNh0nxFEDDaqRZ3sM+LiJ1+XIcc8hvlOAdoKsD1btLeNoogjzSTMP43Cgn/vkAfpQBISACTwBUUEyXEcU1u8csEi7lkR8hgehGOCD65qK/sLfUYBDfR+dCG3GMkhW9mGcMPY5HtWXpk0urXyXVrIYdGtSUgWPgXTY2l/+uY5Cj+I/N0CkgG1byNLEHeF4WJPyOQSBng8Ejnr+Ned/ES5j0/4nfDa8Z5kaS6u7FguNsiSwHg/R0jP516RXkvxzaMa/wDDUHiYeI7dlO3nbvVWGewyy8d+KAPWqKKKACs7xFoun+ItEvdI1i2S50+7jMUsTjqOxHoQcEEcggEcitGigDzb4Y61qGmate+AvFd01zrOmRiawvXGDqFiThJCe8iH5H9xnLcmvSa4L4veHr7UdIs9e8OrnxP4elN9p45/fjH723IHJEiArgYyQvIGa6bwj4gsvFPhnTdc0t91pfQrMmSCVJ6o2ONykFT7g0Aa9FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHKfFPxQfB/gXVNWhXzL5Y/JsogAxkuJDsiULn5vmIJA5wDUnw08Lr4P8FaZpBbzbuNPMvJ87jNcOd0rljycsTjPOAB2rlvGmPEfxl8HeHGw1npEMniO7jcEBnU+VbEEfxLIWbHTAr1CgAooooAKKKKACuOv2l8Yald6XbytF4es5DBfzRPh7yUY3W6MPuoucOw5J+QYw1O8e65d25svD/h+QL4j1cskD7N4tIR/rblx0wgPyg/ecqOea3/D2j2egaJZ6Vpsey0tYxGgPVvVmPdicknuST3oAuW8MVtbxwW8aRQxKESNFCqigYAAHAAHapKKKAM/XbCHUNNlin3AqPMjkRSXjcDKuoHJIPIxXD6D41ljdkuJPtKKcNFJIokRSB5bJIwRXVhg4fa3PG6vQru6gsraS5u5o4LeMbnkkYKqj1JNfLGtaoda8b6hdfDXRL/WLFJpPtUlmp8oqQjhlc4UOZGmG35srj5Rt5APctf8Y2l21zolpZ6k95PbONptpIjuaNiqAkDrg5boMdckV2WmWgsdOtbRXaRYIliDt1baAMn8q8B+FOuf278VNNs1t72wuNOsbu5vLK6BjaJyYY1UoeeN7c9DnjpX0PQAV578ZiBa+DyRn/iqNNH5y4r0KvMv2j5ns/hFqmo24H2uwuLO6gb+463UWD+RNAHptFFFABRRRQAV5d4Ex4P+J3iLwe3yaZqS/wBu6Qv8Kbm23MI6AYfDqijhWJNeo15f8dB/Y1t4b8bR/K/hvU45Lhwu5vsc5EM6qvQkhlPtigD1CiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDzH4W7dX8e/EjxFuJzqiaNGjDJjW1iAbB9GeRjj2r06vNP2c2kuPhLpeo3KbbzUp7q9uGxy7yXEh3H/AIDtr0ugAooooAKz/EGsWWgaNd6pqcvlWlsm92xknsFUd2JIAHUkgVoVxui26eL7+DxFffvdKgk36PbOuF4yPtbA9WbnZn7q4I5Y4AIvhzoV+k2oeKPE8QTxFrBB8ksX/s+1HMVqp6fLks5AG52PXANdvRRQAVxnjzx/pvhVFt8tdapKfLhtYEMkjyEZVAi8sx4wo9QSVU7hyeq+N/EXjPUrjSvhrZCSxhkaKbW5m2WhIyDtlGS/I6RAnkHenNdT4B+HmneFHe+uJ5NW8QTLtm1O5UBwOSUiXpEhJJ2r1J+YtwaAOc0zwJrfjNhffFC7l+xMQ8fh22nKwDHINwynDtkj5V+UbRkvk16lY2dtp9pFaWFvDbWsS7Y4YUCIg9Ao4A+lT0UAcDMrf8L7s2b7n/CMzhfr9qiz/wCy131cH46zpvjzwJrZm8uBrmfSJwB94XEe6PJ9PNgjH1au8oAK81/aMgN38H9atEP7y5ktIUHU5a6iHTv1r0qvOPjDqE63HhHRrdFkXUdcshMuMtsjmWY/hiJifpQB6PRRRQAUUUUAFY3jTRV8R+ENa0Ztn+n2ctupcZCsyEK34Eg/hWzRQBxPwU1pvEHwp8MahIXaU2awSs5yzSRZidifdkJ/Gu2rzL4EN5Ol+LtNjTy7XTPE+oWltGOkcW8SBR7fvDXptABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFZvia4Nn4b1a5UkNDaSyAjrwhP9K0qzPFNu134Z1e2QEtNZzRjHXJQjigDA+DNutr8JvB8aAAHSraTj1aMMf1NdlXH/AAcnW4+E/g90xgaTbJx6rEqn9RXYUAFFFFABXI/C5Ws/C39jSSzzPotzLpvmTLhmSNv3R/79GPmuurlNOlOm/ETVrCZ28vV7ePUbYEYG+ILDMo9cKLc/8CPpQB0eoXX2KzkuPJnn2YxHAm92JOMAfj+HU15dp3274o6xq9h4mjl0bR9IuDby6EkuLi83KCklxIp/1JGcInDENlmCgV6zXDePVGga5o/jCEhFhlj0zUssFWS0mkCqxyDzHKyuMdi470Adpa28NpbQ21rDHBbwoI44o1CoigYCqBwAAMACpaKKACiiigDkPizbTz+ANUnsQhvdPCalb7h/y0t5FmGPc+Xj8a6u3mjubeKeBg8Uqh0Yd1IyDRcwR3NtLBOoeKVCjqe6kYIrB+HLhvAXh9Q28xWMULNnOWRQh/VTQB0Veca1cQ6x8bfDOnQSMJNEs7vUbldmAS6pDEM9+JpT+B9K9HryX4SyLrPxG8ea4IyYUe3sIJGySMB5pEJzjIMqAgdNooA9aooooAKKKKACiiigDzn4aqtp4++JlhHkRrqlvdY7bprWNmP5ivRq85+HBW5+IfxMvYjmNtStrbI6borWNWH1ya9GoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoIBGD0oooA80/Zy86P4QaLZ3bZu7GS5s5lzyjR3Ei7T9ABXpdeZfCfbpfjP4k+HiHLw6wurK56Ml3Er4H0ZHFem0AFFFFABXDfEhYNO1Twn4luLdZI9L1HyZpS4X7PDcoYTJk9g7RZ9sntXc1m+JdIh1/w9qWkXRxDfW0luzYyV3KRuA9RnI9xQBpV5r8fHaXwfY6ZBJtudT1S0tY03Y8wmVePTrjrXV+A9RutU8I6ZcakrrqKx+ReB1wftEZMcvHpvVse2K534t2cV3ceBfNfZ5Xia1kGFzuISUgfTIB/AUAeg0UUUAFFFFABXK/DlkTRb2xRiWsNTvLcgj7o893Qf98OldVXD+FZNSh+JvjeymijXSm+x3sDYIcu8PltjsV/cfgR3zwAdL4lllh0G+a23faGiMcRUgHzG+VcE9OSK4P4FWUunJ48t51ZX/wCEoupNp7B4oGA9xhhz3r02SNZFCuoYAhsH1ByD+YFcP8P7pX8Y/ES1DLui1eGQqo6BrK3AP1+Q/lQB3VFFFABRRRQAUUVleLNYTw/4X1fWJFDLYWkt1tJxu2IWx+OMUAcR8ClaSz8aX4YSQX/inUJ4JFOQ8YZYwQe4+Q16ZXC/AzSH0T4SeF7OUsZWsxcvuGCGmJlIPuDIR+Fd1QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5f4s/4pv42+FNeb5bLXbWXQLl24SOUHzrc+7uQ6DPavUK4/4s+GJvFfga/sdPYx6vDtvNOlUgNHdRHfGQTwpJG3PYMau/DzxPD4x8F6VrsChGuoQZohkeVKPlkTnnhww/DNAHR0UUUAFFFFAHE+HLj+y/iT4l0FjGIr2KLW7VVByN37mYH/gcaN/20NV/iu6tL4SRHHnQ6/ZTsmMnyzJ5RP03SqPxp2q6ir/GXw7aWCCeWPTb5L9o1z9nRmgaPe3bLJwOvOcYOarfGuyuLnw+JLNmE4inCBAS++NPtSbOeu+0QY54Y0Aei0VyVj4tuXtIL270S6bTLlEmt73Tj9rR43UMrMgAlHB6BGHvW9pGs6drETSaZewXIThxG+WjPoy9VPsQDQBfooooAK5iaV7P4k26tLEIdT0t1CMcMZLeUEY9fluHP/Aa6evNfGMFxqnxh8KQWEgiudHsLrUxuOFlDyQwlG4OAUMuD67fSgDvdIvmv7TzJbWe0mVjHLDMhBVx1wcYdfRhwa5aGKPQ/itLhUSHxFYBtxJLNc2zHIz7xSjA9IjjpXW6dfQahbvNaSeZGs0sBOCMPHI0bjn0ZWH4VwfxPuYtP8T+B7xYgbr+1Y4Vl3HhZP3LLjpyJic9floA9FooooAKKKKACvMfjwx1XR9E8GQEm48TalFayBDiRLWMiWeRe3yqgBz2avTq8u8JH/hMfi3rviVvn0rw+raHpueVafIa6lAPQg7Yww4IBoA9RHAxRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRTY3SWNZI2V0YBlZTkEHoQaAHUUUUAFFFFABRRQeAeM0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeV2DHwB8WLmxl/d+GvGExurWQ8Jb6nj95GSf+ewAYZPLAqo616pXP+PPC1p4y8MXej3rNCZMPb3KfftplOUlQgghlODwRkZHQmgDoKK4X4X+LLrWbe80PxIFg8XaKwg1GIDCzD+C4j4GUcYPQYJIwBjPTa7rlpo0cP2jzZrm4JS3tYF3zTsBkhF9u5OAOpIFAGjNLHDE8szrHEilndzgKByST2FcxLqV14ijlXSJXsNGX/W6ow2tMvVhAD0GP+Wp4/ug/eD7bQ7rWGju/FeyTB3xaXG2beDnI3n/ls4wOT8oP3R/EcnXTf+LL+6trIM/h/TZ/Ku4I2VX1KRVJeEMTgRhtisDjcS4JAU7gCfwDY2bvea7awfZ9PlUQaeGyM2yZJmYn5iZHZny2SQEJ5q9qGpf2vCXsDFb6bbFpJdWuVHloqghjDu6/KWHmHCgEkFulZ2s+ORo6ppktrFq3iy4yYtF0x97ICRt8124jXDLmRwoOeAelRaT4QvfEIj1H4jOt7cb98Wjof9BtccDKAkTP1O9yevCrigB3wdaIeHtRg0xpH0CDUpk0iRlIV7UhWGwnlo1dpEU91UY4xW34rs/D4iS91yCITblihnjVluS56JG0f7zccdFOeKk1XXRbXQ0zSLf7dquFzAp2x26kHDzOAQi4HA5Y9ge3M6bbXWuXontLw3MuWWbXAgWOJc4aGyQ5HbBk56dXIwoBL4G12Z/El5ot1dzzMYDdQ28ziaSzRWVSksoHMh3glCWKjHJzmu+ry34ULFFdxw24cJEb8Mz5LSsWtWMhY8sSSck8k59K9SoAK5O7iS3+Kem3DtGDeaRcQLnO4mOWJsD8HY/8BrrK5fxzJ9gGi6wTCqWGoRCZ5eMRTZgbntgyq3p8tAFjwQVOj3QXHGp6gCPQ/a5j/WuX+JcNve+Ofh/pjFxc3OpNd5AyBFaxvKfpmQxDrXUeCo2isNRVxhv7UvGxnPBncj9CK4bwlcz+IPj34ou5ZT9n8P2CafHAxyEknkLF19MrAuf96gD1miiigAooqnrGp2Wi6VdalqlwltY2sZlmmfoijqff6Dk0Acn8WvEt5oegQ2Hh/EnijWpfsGlxZGVkYfNMRz8ka5YnBA+XPWt3wT4ctPCPhPS9B0/mCxhEe8jBkfq7kZ4LMWY+5rjfhrp934m12f4heIIGiku4vI0OylXDWVlnO9h0Esv3ieSFwM4JA9NoAKKKKACiiigAooooAKKKKACimySJFG8krqkaAszMcBQOpJpUZXRWRgysMgg5BFAC0UUUAR3LvHbyvEgkkVCyoW2hiBwM9vrVPw/c2d3oljPphtPsbwr5QtJFkhUYxtRl+UgdOOOKwfiT4nn8L6PDcQ2sMqTS+XJLMdyRLjJxGvzysQGwijsSxUAmr/gLVrLXPB2k6jpVkbDTp4AbW22qvlxAkIAF4A2gEAdM4oA36KKKACiiigAooqKOdHuJYQsgaIKWLRsFOc4wxGG6c4Jx3oAlooooAKKKKACiiigAopsaCONUXOFAAyST+JPJp1ABRRRQAUUUUAFFFFAHDfEbwpfahNZ+JPCbxW3i/S1ItncYjvITy1rN0yjdRn7rcgjk1wNl4107V9dvNUaw1Szu5vstleR28wjvNMu/32YmVsB4yIgeeG+X5SeB7vXjXxysE077drGmPY22qT2Cybrhflkkt7mDYzDuQksq7sZAPXFAHW6P4nvAZUSWLXooP9csEf2bUIf+uls+M/UbT6IaybDw7b61eajbab498QwWclxLdy6VA8VvPbvJIXYbjEJ0TLH5cjr1q14Z8Q6D4+uJdP1vSzpnizTQDcafO2y5tuR88My4LRk4w6HBBGcZGbGt+FdQ8tQVtvEdrECYo79vIvYehAiukGeo7gHpl6ANrQfCnhrwjbzT6Vptlp4VWea6YZkI6sXlbLEd8saztU16XULF54bltI0FgFGouv7+5LdFt4yCeezEEnPyqeGrhDr9tJq6WE0Gu6xGjRR21jrC7I7W4a5aAmeQLiVFfYFbMuDnGTyvqOk6B5V6up6xcnUdWG7ZKw2xW4bgrDHkhBjgnlj3JHFAGPo/h1r+1Ed1avpuiOzSnTt5aa7Zur3T5JJPdMnP8RP3R2ccaRRpHEipGgCqqjAUDoAKdRQB5b8Ohdx+NtSgm8swxvf85O4H7REB7Y2qtepV474euNZ0f4peITPouq3NoxkZXigPlhXcMrKx+VshQCAcgjpXr1vKJ4UkCSJuGdsi7WH1FAElZnifSl13w3quku/lrfWsttvxkpvUruHuM5/CtOigDmvhtftqvgLQNQmwbq6sopbltoUvMVHmEgcZLZrlPg7as3in4k6lKSZJ9cFrz12xQpj9JK1PgddPefDLS5JAoKy3UI2/3UuZUX9FFSeBHih8afEGyCkTrqcF0TtwCklnCFx68xvQB3FFFUNe1nTvD+k3Op61eQ2VhbrukmlbAHt7k9AByTwMmgC3cTxW1vLPcypDBEpeSSRgqooGSSTwAB3ryiz874va1FeXMLx/DvT5hJbQyrj+2p1PEjqf+XdSMqp4c8tnG1RLHVPi7JBc6zb3OkeAUcSQ6dJlLnVyDlZJh1jh4BVOrfePG3HrEEMdvBHDBGkUMahERFCqqgYAAHQAUAPooooAKKKRs44xn3oAWisPSfE9hqGrXOkuJ7LVYMsbO7Ty5JI8kCSPkiRDj7yk44BweK3KACisfUtTl0Oyur7VBJdWonUItjZu7wxEgZdQzF9pySygYH8PGa0bG8ttQs4ruxuIrm1lXdHLE4ZXHqCODQBPRRRQBC09u9w1m0sLTmPzDAWBYoTjdt64zxnpXFeFbj/hFfEM3hK/kKWExM+hSyPkNFjL2oJ/ijOSoySY2XH3DU2sNDo/xN03Vr+YRWmoae+mRyuMIk4kEiqW6AuCwGepTHUgVn/H7S/7U+GV+sYkF3bzQXNrLGxV4pVlXDKQc7sEgY5y3FAHotVdU1C10qwmvdQmWC1hG55GycdhwOSSSAAOSTivla1+IfjLwjf6jomteIhHFbSlUvLsmdSVZkI8xo3IO6Njg5zg7cDgWdU+IuuTWCTXXiO51ApmQw2LtAoUA5LbIoHx0OfNwOSRQBb+OfiG3kt9Z1GaOSKRoTBDa38pFwqMgAPlcfZ0ZsMEP72QjLYjRgc34T/FO60vStNsNAtXlsU8uKaG9ZYraNiPmYP96HpkkCRGJ3bUZiK4b4eeD9X+LXiP7Q1uIdEtyxjjkkEUWV27yCFO5uU3EKx+Zdx5BP1z4a+Gvhbw+lsbXS4ri5t8GO6u/wB9KpByCpP3ccfdA6UAW/DOg6nbalc6v4g1ie71C6RV+x28jpY2oAHEcZJySRy7cnsF6V01FFABRRWN4o12Lw9Z2t3dIDavdRW80pbaIVc7Q546bio/GgDZqKKVGlliRXDRkbsxsqknngkYb3xmud03xtpN7c3FuzywzRTSRqGQuJUXyT5qlcjyytxC244wGJOApIm8DXUmpaK+rSKyrqU8l1CGXafJJ2xE+5jVG/HHagDoaKKKACiiigAooooAKKKKACiiigAooooAKKKKACvPfjVHbnw3E08aMZBc225wDtD2k36blQ/hXoVZPinQbTxLolxpl+ZkhlHEkD7JI2HRlPOD+BB5BBBIoA5e/wDCGjeP/CGgXtyJrTUEtIbix1Ozfy7q1JQEFJBzjnlTkH64Ixx4x8S+AP3HxItG1PRl+54l0y3JVVzx9qgXmM+rJleQAM5Nd14N8LaX4Q0S30vRonSCJFUvI255CBjcx7n8h2GAAK3KAPEb3VrW8uxc6VfQ6lpr3s81vcWrLIi4msbvbkcZDCTryOa9urxP4g6dp/hubWrfRjb6VHcR/bQkMSqkUrWd4jSKg4JJhiJ9SBnqa3F1r4k+GFA1jQ7Hxdpy8/btHkFvdeWB957d/lZz/djbFAHqFFeb2Pxn8HvdR2etXN74c1J8f6HrdnJaOoPQsxGwA+u6u20fXtI1pC+jarYago6taXCSgf8AfJNAGlRRRQAU2R1jjZ3OFUFifQCm3E8VtC01xLHFEgyzyMFUD3Jritd+LHgLR1Av/FOlyFzt8u2k+1Nn0KxBiPxFAFX4C3sd58N7MR2zWrxXFwJIWXG0vK0oI9QVkVsj1o065QfHvW7aGdE3eH7R5oOhkdZ5gH99qsB/wIVk/B7xFZRWEOj2dheWtnbzvbJLfwmGdomJe0kYNglHTegbu0f+1xi/GzwjpreO/C+u6g989pq19DoN/bW1y0InhlDbQ7JghBIsZIzznscEgHX+IPijYR6jJovg2zm8VeIl4NtYMPJt+cZnn+5GOo7nPGBmo9E+Ht5qmrQa/wDEu+g1rVYCWtdPhQjT7E+qRtzI/X5356cfKDXcaDommeH9Nj0/Q7C2sLKP7sNvGEXPqcdScck8nvWhQAUVT1W8ewthOtrNcorDzFhG51TuwXq2OOBzjOATwZbK7t7+0iurOaOe3lG5JIzkMPrQBPWJD4p0aTXJdGe9W31RCALa5VoXlBzgx7wPMHB5TIHfFbdZPiax0W80md/EllZXWn2yNPJ9rgWVEVQSWwQegB6UAa1FeJQaJK2j2V/oFr4j0exvp0k0+00a8lmJtiMl5Y5JFhhLLgqBnbuGQxyBf1HwhNHZaXPJqPxLuisjTqiX1u72zhsgyKeG9h84A7CgDu/Hmm6HfaBNP4kcW1vZjz475HMc1o46SRSD5lbOMY69MEHB80+Enxhe/wBSh8L+OHjt9acYtL4qI4r7/YI6JKDwVHBIOOwOR4u8H+GbPxJNFrmueM47qSVcagy28il3G75NsZYcseVUYOcEVwXivwX4JvrGCxtvFHijUzZhjDHBYxrHCSo5YOI8khUBbJOFUEjAAAPsKvMfFl5N8M9WbXrKzu7vwvqMzyatbxEH7DKcYuI1PZzkOvdiCOThuV8O+DviloWkWknhLx/Z61Zsm4Wuu2xBT5eF3qZGyOm3cAK89+Jdt8a9USNPE+i3F3p0blli0cJKpbsQkZL/AELg46jB5oA+i/F188/hzT/Enh+6luYbGVL/AG2r7lu7YgrKuM4b92zMv+0q4qSfx5o0jxwaDI/iC9kGVt9KKzbR6u+QkY6feYfjXy58Pvi7H8PbhovMuE04n/SNBnhkBg6AmJyMLKTuZlwsZ5+6SAv1B4O+IXhHxVYxT6DrFlJ5jKDbswjlV2P3TGcHJPtg9iaAMzxV480my8N6ynibS5LK4hs5Zhp2rInl3m1N2xHUvHJkkAgEkd1Fa/hJ9O8O+D9Dt7vXLWaKdVFtcS3GEmMhLKkRdiWUBgEGSdoXk9a2Hv8AS9QOo2Ek1tcrBHtvImIZEVgwKv26Bsg9uvBFYXh3wd4bgtmNsg1G0mtwlvFdOJ4oLV+RFEp4WM46Y5AAJIUAAHj37QOiabpup3CQSO76zHLdXVt5e8eeI/ItEUKuFDSTSN8xG5kJySuD8/eL9O1DTrFoI9U1Ofw1DfPZSK9wWjcxsuXjXoU+YYyOor7Z8R+FdJ0nwRrdlomhWJS+jEc6SyCOPb93fI5YHy41JbAOcA7eTXzF8YDDqeiyWumgmwtIkhscqVknWNHnkmYHoCGeQjjAkgGByAAfTPwetNOsPDclhpFrLBZ2ExtYxczmSfhVJ8xdoWNjkMUXOCfmw+5R20V1bzXE8EM8Uk8BAmjVwWjJGRuHUZHIz2rzH9na/N94GtZCI40lgikjiWUjau3YdkR+5GGQjcSS7iRj1Gdj4mo/h+2PjXSIof7U0yPbcRMNovbZiAYnYcgg4dW5wQRjDGgDvK5PwjNqOu3s+v3lw8OnsZbbT7CMFVMSykefJn77vsBXsqnjJYmqnxYlv30fSdL0yWOGTV9ThsZXkZ1HlFXkdcoQw3CMpkEH5uoq7osviSDztKuNI061jt7cfZL61fNrwAFjMORIuPQfLgDDZ4oA6qvGPirrNtbz6zdFGiSCNba9jkZSHkgltriBgPdJpB6kkDtXo+p69J4e8KvqniOGL7Rbx+ZcQ2DmQY3BSU3hSQAwJyBivnz4lpqnxJ8cT+DfD0KxzyXguNSvgD5VrHBLPEBIvcsqQMBnkqMcHIAKGhw6l4xvbDwr4buNl3CJI9TuzETFa2DW9pEASMbmZYNgUckZJI5I+ptHsE0vS7axjnuLhYECebcSb5H92P8AQAAdAAMCsjwH4P0vwVoKaZpKMcsZLi4kwZbiU9Xc9yfyAwBWbq3iS+1rULzQvBQU3MDmC91iRN9tYN/EqjpLMB/APlUkbz/CQDpnl+135t4ZbmL7KUld4wuyTO8eUSQeRgMQMEZTnmr9Zvh7RrTQdKisLHzGRSXeWVt8k0jHLySN/E7Ekk+prSoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDzT4veHNR1LyL7SNFGsTrF5LW4uVhJO8FSSxAK4aUHv8w611PhR/EZjSPXrTT7WOOJVAt5WkYsAAeT26+9dFRQBFd20F5bSW93DFPbyDa8UqBlYehB4NcTrHwh+H+rY+1+E9KQjvaxfZj+cW3Nd3RQB5vD8FvBlpg6Xbappsg6PaavdIR9P3h7cVJJ8IfDtwuzUL3xHfRdRHc63dMoPrgOK7bRtTttXsFu7ORXTc0bhTnZIjFXQ+6sCD9KvUAeb23wP+HUE4mHhqKaQc/6Rczzj8nciu00Xw7omg7/AOw9H03Td/D/AGO1SHd9doGa1KKAOH8SaRby+P7Ceaa4hGq6ZNpxaIkfvonWeFhxgOo89gT6Vl/FjRLzU/hTrs+rzImqWFhNcRSWrEIHiKSrIM8hiYFP+zuK5PU9v4l0ca1pZt1nNrdRyLPbXKoHMEyHKOAeCM8EdwSO9cd4k0zxh4w0ifw5qVnpukafcqsd7qNveNO0sf8AGkURRdu/G0lm4Vj940Ad5pN2L/S7S7G0efCkuFOQNyg9fxq1VPSNOt9J023srRFSKFFQYULuwAMkAAZ4q5QBgatq97ol3Lc6hbifQyATcWyEyWvqZEySyd9y8r3XALVUutPubUvrXg17adboC4msjJi3vcjPmI4yEkI/jGVb+IdGHVVw2o2dx4JvX1XRYJZvD0rFtQ02FSxtiTk3ECDn3eMdfvKN2QwB0Hh7xJp+umeK2aSG/tsC5sblfLuLckcb0PY9mGVPYmtmvNfiHeaLq1roUukWsuqa/qe7+x7rTLpbaZUVS0kguOixqp5UhgxIG09k0e4+KejiMa3p+g+IbUDBNldGC85OctvRYmxyONmeDxQBf12wTx2dV0K8vdQ0eXTZ9pgtLnaLmNkBjlfADFCSw2hgMqwJJHHi3iT4kaH4Q1TW/C+raB4p1G2gYWl1PPefZ2aHp5kaoFO0/wAPzcrg5GcV63qureEvEWo2Q19bjQ9XjBRbfVofs32iNjzAxYGOZGYA7VZuVBBBGa47TfAGk6jqk2ieNotVSOaWQ2On3EJntbaUjO+0vAv3SFJEUmOwZSVBIB5NHqvwQ1nUHaS58Y6LDI/7xJsSRMpzxhTI2BwOc8AdeTWr4gtdJ1y4h0vwB8SbZ9FMaxx6dqepy2iQqQQQFYAOM87R83zYxgZrofHn7O2m6bYyajYa9bAJ8kcGqiOCM5zhRIu0BjwBlTn1HWvH/FvwyutFAk1LSZNESaFGgklvo54JGGA5WVflHPRGIIXnJxyAe9QeGruy8I6LpttoXhvxPr0Lul1dWCQyokQH7vePMgOSOMsW+6STlqmi11tB8K6hql34O1LS9TguzHcRWS3en2zRgH97iATR8EYJ5B+9nnFfLcvhLUrG1ttU0O8NxBM8kUU0DiNi8aqXAw3P3wBgkt6VPY/EHx54Xum+y+JtXjYFkAkuGmibBwSFfKnnPagD6f0Lxl4W8W+Cb288e2D6xFa3CRs1xYiU2qyA7QJRFH3UgsFBywGTmuU8P+CfhP431q9i8CalrnhzVLeNmBUsInXIViPMzuGSPlDDr0xXl8Hx98W3GjXOk+JYNI8S2NwwZo9Utc4wQQB5ZQYyM8g16v8ADrWfhn8Qrv8AszStMk0PxRNEz28dygaBHAyyRbWGVwMkfKSB3xQAuofDnx94eiJ0S/8ADvieKJX2/aZWgfYcEhoS/lFQQCQSQe4NJHdfFnTvtC3HhrWRc6nt+2ahb3EN1LJgHakflsqwr8zcjJXjBFVptb1HQ/FstnoVpomoeILEOkmmWUV87EAYkBRtqvkZ+7kfWvpPwtrMeu6NHexW8lsRJJBJC+Dskjdo3UEcMAynBHBFAHzb4r1P4i6vZR2+peDPECWUcSRCC0iVjchPumZgSTgkkDGOemRuHm/ieTxbJo9/PB4P123RoJIru6lspNkC5bzVzzgcsWZjnls5Jdn+mvFeo3es3T2cst1ZRgvfswi2S6ZZQ70afB586YhhHkHaPmAyhzyfhLxgkOt6VLZmfR/CtjHPcPZQR+ZHHAIFBDbV3OTKrPubLfMTnrQBc/ZI1GCbwCtrmP7Uo3ttX5mUMy8sTyQAowAFAK8lt2PRvi/A8/w08QeWN3k2/wBpZf7yRMJGH4qpFeXfCqOLwn8Xdb0PT3EejXri8s4SeRHKGJiCLk/upY5F5wqASbjucV7P41vF0/wfrl2yxOILGaTZKAyMQhwpB4IJ4x3zQBi6RZ3viyfStf1d1t9NicXunabGoLAlCqSzP3ba7HYuApIyWIzXaVmeFtNbR/DOkaZIwd7Kzhtiw6EogXP6Vi/E7xpb+B/DEuoOi3V/Iyw2ViG/eXUzMFCIo5Y85IHYUAed/tCaxcrqmn6JpUVu2sXVpLHbGQsoEUySR3BkbOFiRAshJ6FFPatn4OQR6TfX2k2bQ3Fy2b7VNQuD/pF/M01xE0q4OPL3wHaOykdSTXP+EfD5e81+PxDqNonj7X7N59Uk2o8dnAY9q2YO7KkAq5wDkJnJAUnzvxH4ym8R6fJ4T8JTiDw+nyapqiP895JkySQW5xv8ncznKoxAJJGzO4A9R1bxPrPjy/u/DXw3SLTvDwkmtLvXljYq8oKtKkDRghPlcnzGxuJO0ggMfVfCehWnhnw5YaPp0aRW1pGEVU3bc5yxG5mbBJJwWPXrXzZpNjNaxQLo19eW3lwpY28cVywByocQAF2QO4y6ZZ4Jw3yGJsV1XwuGq+MNfufLu5bvw5bW0lndastxOrXYdHCwRHeN2wSB/MdTIh+TccbiAe6214J7u8txBcRm2ZVMkkRVJMqGyjdGAzg46EEVaqCws4NPsLaytEMdtbxLDEhYttVQABk5J4A5NT0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHlmvTj4a+O4tZU7PCXiS5EOpr92OxvSAEufQLJja5OBkBiTnFep1n+INGsPEOi3mk6xbJc2F3GYpYn7g9x6EHBBHIIBHIrzb4beIL3wpr3/AArnxjOXu4FLaJqchwNRtR91CT/y1QfKR3A7/eYA9ZooooAKKKKACiq+o2iX9jPayvNGkqlS8MhjdfdWXkEeorL0ePV9Lt7tNZu01K2gUvb3McRFy6jJ2yRqNrMOBlMbv7o7gG5RXFXcui+OIo30nWbiw1yx3iBkkeG4tJCRkS27EbhlRlXXBHTrmtXw9rN3qumRrNCtpq0M32e9iaJ2jR0K+ZtPGAykMhJ5DKeeRQBxHi7wy/hPxjpnjTRopZNHtZJm1LTLeMsYxMoWS5iUd8qjOoHO0sOSc7ev3On6v4p8GXTXsj6JdRXDW01tdSRxS3J8lofmjYBiUWfAY4PzDkkCtnWddfTtR0e6EkEugXbtazTp83kysR5LlhkbCwZD/tOnPWuR8UaPaeGJ5Y7otF4K1a4DzlG8s6NelgUuYnH3EZ8E9kfDZwzUAb3iye1tpn0mK1v9YvtVcXD6eoS4UQxlPMJE7COOM4C4yMs2VBOcczaxaDFdJb6HquteBdVl3GOwul2W7sSFwsMu6FuccREH3qzNea1p3inThqESXOvWkEsETKBFHrdqcO3ln7qXKGMMYzgHLEEKxKZ/iX4hzTvqHm6XpU3hldqKdSjl23DhQXilYKywSBvl2SqOgPQ8AFTxJDc+D9Eu7PX7NLHQ7q48ybWdFtlltkYjA+02Uu/y0PVmjyM7eVNd/wCHPCWj6V9mvvD91La6fInmtbWk+bK43L9/Y24AHIOVIzxya4r4deK9K1GCSLRhewwTQyxw6DfOkkE0igZjt5ySFwM5iY8BgQqryaNjd33w726v4fgu5vh1JMTqWlTwP9q0JyMu0S5z5QZgzKNwAyy8EmgDU1z4S+CPGsF7Lplpb2I3lFn06RGt5W2rljEp2g5wCRtY7evSvBPHvwP8UW2nW9/pthba7bThD5unRtHMEwArmIgHcygFs7juJJNfYayWWr6G1xpeoLHa3aeal9ZOhyCPvqxBU9OpBrP0NtdtZJP7YvdMvtJSLdBfITHPLkgqXUDyxwSMqcHAOBnAAPzY1AFbl0kjeOVG2MrjBUjAwRgHIOc1337PGk3msfF7QIdPvZbGWF2uDcRKCyqiEkYII+YfLzx83fofSf2vvCVpZ6tpviiCM2k+qwn7RauqhhKnljcSpIJ2sAQDjKkgnJra/Z20W48DeCT4lWxim1/xCDFYxXc6whYVI2lV/wBY+9yDhQchV5HBIB6Zod/4t8Q/EMrcqum29iwW9itsbSqkMqGby2LMd4OzcPlJ4U5r0bxRrtv4f0z7VMjzzyOIbW1j/wBZczNnbGg9Tjr0ABJwATVa+nsfDunf2zrAhgutiLcGzRsXEzbVCqg5kYt8qA5POB1ryzxz4xh0jSfEN14sM39tNYH7LZ24T/iWmYFIoFfqZ5FLs7rkARtjhRuAOT8f+ONN0vwzewXN0134g1jUSbuW0bEdyoRoXSMjLNBHxGueXKsRgliuV4I+IGo6vrNr4E1nTBoMOrxqlpdDTmtpYXTDwsQXJlUurDn1BJ5YV6z8DfhlH4bsR4i8Q2sL+K9RUSv+7wLBCOIYwfukA4Y9SeMnGTkftUW5TTvBGp2IxrNr4ggjtHU/MN4YkD6tHH+VAHIafe6NafEL4e/8I9rUOv7IJ9MmnMYhJMcwnjBVnRc4dgpO7puAZtte6eMYxrGtaL4cmYLZXYkvrsHrNHbtFiIZ/vPJGT6qrDvXiuv23h7wZ4v+G+o6JZSxQXOqapM/2mLzpZ3I2qFWPJPLBYxxj5SccmvU9X1a6uvGPhCa/wBBv9ItY7uVRe3c0BDM8EirBtjkfG9ipBbAygHUigDutUvodM064vbk4hgQu3zBc+gBJAyTwMkcmvFPtU/iJLn4jXVvDczWML23hq38goZAZQjXbRkluWdVUE4VRux84x1fxtkuruw0Xw/YF1n1u8FkJEAJhBUlpOHVwVQSOCAw+XDDkVi6V4kXRovG3iDS7l38N6Lp5trKybmBZLYNGsasCQvKBuM7lnTOCuKAPFfijrM3hqA+BrXU5Jdf1oxSeJNQM2SFGdkG4nqEI3nPIwOhIp/hTUNAsbB9P0A29xAmGlt1uBmboWJkCrnByVkKh4WCsrvGJAvqPwW+DGkNosXijx1aRa54i1jF/ILxN8cIk+bBQ8M53ZYsODwMYyeU/a58E6Zp1r4c1jw1Yw2Oqz3R08w2MIjNyHUleFxyMFemTvx2FAFXw9po8Z6reaPa362fh63iSXW9UGyFfJLiVYQOVR3KpIQCohdrnAwwWvofwJqnhy4sZNJ8JIkdjpeIVSGIrCBzgo+NrgkE5BJJyT1zXieqaLc+HPD2gfC7wWLy41batzrc1hIUjV5MDM8gTIQ88ZVtgT2z7b8PPB9p4M8Px2FsRNcuTJc3RB3zuSTkkknAzgAnp+NAHT0Vi33iO0t9VGl20V1f6iNpkgtI93kqwJDSOSEQHBwGIJ7A1etL77Rf3lqbW6iNsEJlkjxHJuBPyN/FjGD6GgC5RRRQAUUUUAIGBYgEZHUelLXJ+Bka8vNe1/EX2bVrmN7KSOQOJbVIUVHyOm472x2BFdZQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFct8RfBVh440I2N472t5C3nWN/DxNZzjlZEIIPBAyMjPscEdTRQB434K+K02ka+3gr4pmHTPEtvhYdQ+7a6ih+7IrcBSw9cDII+U/IPZK8V/ap8DweJfh5PrVvAp1fQx9pRwuS8A/1qHnoB8/f7mBjcaz/AALJ4p0jwNpfiX4eyDxB4YuoBM/hy9mPn2ZHDxWtwcllVgyhHzwnGSaAPeqK4HwV8WvCniu6+wQ3rabrSv5Uml6kn2e4STJGza3DNkdFJI74rvqACs3V0utS0i6h0TUo7O7Y+Wt2I1m8khgGwpOCwGQM8A4yDjFaR5Fec6R4dvPh0u3QILDUdIlMcLQyLFaXgPyqgEoCpOeW4cKxJ5djQA/V/hlHfqs8mu6ld6hFGEhfU0huYiB/DJH5ah1PfkN3BB5rK0A6sLX/AIRjwpa2PhvUobiVtXuAGvVgcCMxtGrkFlmU/KzEbVRlxleOxn8ZW1lapcavpetadGc7zLZNKIgO7tDvUD3zisjT7NPGGq61rEcV1aWU9pbWmn3Tq0buYpHl89Y2AO0Oybdww2w8bW5AKunaNrfhTw2dFvtPg8V6Ewk894f3d2wkLPIWidikmWY/ddTzgKa2NA1KDW2j0zSlguNCtrcwXq3rO10j7SogmhlUMMght7E52sCDu3VreIdYu9GNtLHo97qVkQ32mSz2vLBgrtPlZDODls7MsNvCnPHF+Ldf8Fa3ZNe2OtWyeJIoSLF7NyNQVznYgiX94w3NzGykcnIoAr69o6+FbJrHVorjUfAnmLLBNG7m60Jl5VlcHd5KkZDg7oxxyvRt74a1eRYtV0q6g8Qo0YEGp2N0tlqDxbhhWkUGC6XCjAdVH4816HHq6Wfhy21PxG9vpJMEb3QnmVUgdgMqXJxwxx71wlro/gXV11G+8JG+t5v3aS3HhyWe3VtzYDKIyIpO5Jw2BkmgDFZ9MtmtIPEmu63pFna3kd4tlf6Nb24Mkbq6lZ4Yth5ABKNkgkcZro/EXjOx1y3to/BF5PqWtwXUTxJaRSNDjcFdZ3xsVChYHccjgjkCrB8KeJLaZ7fRfHWuRJGqvu1O0trxHyTwG2o/G3kE9xUssHxJhBFvqXhC8AOA0tjcQEj3xK4BoAx9c8E6x4UubrWPhf8AZws+5rzw3dHFlck9XiGQIZD0/unjOMc2vhJqVpqvw3lvU/0yzEkhGlJGZGsAgH+h7W5LKQcA4xuAX5QtPuH+LRY/ZrfwIF7GSe7J/RK5nwp4Guvh7ZeIvF/ifUnvtZu7yTUDY6c8iWhuJCyoioeXJaTaCw4yPTNAGR+03ob+JYPhzod9JAuqahqi27zwoQEDKolZFJJ25KnBPYV2mk6Np+keKtY8XvdxjSLNF0+1trW3kLIY1SIg4AMh3AoFw49DngefXFrcj4o6ZI0surWngDw7/psaSF2l1CZJF8tW673+Ug9to6HFdjpvie48KNq994gubh7azVLeS1WQ3Dz30oUw2VsDyxjj2Akcu8rMx+UkAFjxzc3OgamviTxNewjTdPuzIryALFaQgfIsERBM1xIMoXJ+XcwUDqeb+F/gzVfFvi2Pxz4us5NO023me40bSJQN5kclmuZh2Yk5A6g4xtVVB7bQ/B19r+t2/if4hpFJfQHfp+jRyeba6b6E9pZ/V8YB+70Br0SgArwX9pJheeN/hdpTyiOB9Te8uG8zYY44jEWfPYBS5z7V71Xy78dNTa9+M1ylihmuND8PtCiEkD7TdN5KjjvtuEYdORyQOaANWz1Ntd+M/wANrS6up559M0MXs8kUjsfOuFB2k7g2Nu0knOVPIxnHrSG58Xa5cqbhbfQdIvkTyUGZbu5hKyZcn7kavtwo5YrkkLgHyn9mcnxf4p8YeNr+SCWaa6SCBGz5qKibUcjIGCny525yGwQNwPdSbrG5vfG9jrbSLqU0cUNnFay/ZZY0YrmRUR5DLsVh5gAAIUYIHIBl3WtWt18X9Y1q/ikfT/B9ksO5EjZkkuWCtIGU5KoiSFgxyNzfLnrymp+H5pmsPh08l21x4h1ubUdYaTgmxt2AL+3nMisGH8RIPStHSrua78M/EbWrkSi/1bWP7PSFYJAJhBEi+TtfLKHxKhBx97ACkgDa+B1vJrXiXxR4rubl76OFo/D+m3UoIke3th+8k+kkhDH3B4FAHsSgKoCgADgAdq8h+L8VvL8Tvh7cagjSadpEWpaxcqvUeRHEUYepDleK9frxT4zWMuq+PLG2he7lSHw/eT3FjZxLJNeRefbgwrnJTeeN4BICnFAHWfCLxVeeK9Lu9Q1SOCzkubh2tbUDbIYUVFLt/eO44JGQD8vUYrV1jxxpunxao9vb6jqf9mbhdfYLVphG6ruKbhwWA6gEkd8UzUrxPDR8Ps+m2KG4aHSYobZCWid2X5UfAxEqI7Y2jOxelaq2dr4Z8Ky2+iw2lrb2Nu7QpcSlIVIBbMj8kAnJZzk8knJoAqfD2P8A4o/TLx2ElzqMK39xKMHzJZQHJyOoGQo/2VUdBWk+2XxDEN9+rQWzHYFItpA7DknGGdfLOBngOeORWdb3LeKvDNtNpOrpAZHj826sRvB2MPNRCw4zhl3EZAPTNSaTothpNz9m0a6ktiJ2vru3MvnNOZQy7nMm5wCy5BBHKEdMigDeormfF95d22q+GItPuJlluNR8uWCMpiSHy3LlgRnauAcqRgkfSumoAK80+NWr3txYWXgrw44/t/xIWt9wGfstpj9/O3oAuVHQkn5eRXV+O/Fen+DPDdxq+psWCkRwW6cyXMzfciQDksx/IZJ4BNc98L/C2p2txfeK/GTRyeLdYVRJGnKWFuOUtYz6DqxHVv72NxAOu8M6LZ+HPD+n6NpistnYwrBHuOWIA6k+p6n3NadFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAAYAHp6miiigCK7t4by1mtrqNZYJkaORG6MpGCD7EGvOv2cbKTT/gx4ctpgQQLhlJ7q1xIyn8VIP411nj7VxoPgnXdU80RPa2UskbH/nptOwD3LYA9zUvgzS30Pwfoeky7fMsbGC2cr0LJGqk/mKAOL+MHwd0H4kWpmmA0/XUAEWoxJliB/DIuRvX8iOxxkHzf4ew/EDwvqLeGL7xQtlrsOfsVnram60/VoxgA28/EiFRgmMEnkHaBkL9K1k+KPDuleKNJfTdctEurVmDqCSrRuOjow5Vh2IINAHDP8T7rw1KkHxL8PXWgxs2xdVtW+2WEh93UboyT0Vl6dTW/wCJT/b+laRrnhVrDWn067+2QRpcBorkBXjdVcHaHAdirHIDKAcZJrBXVtW+H0i2XjW5fWPCEpEEGuyqDLaZ4WO9AGCp+75wGM43gbs1LefC7TEvDrPgHVLnwpqEyh9+mbWs7jj5TJbH924wTjG3rnOaAOz1rX7PR7/SLS981X1S4NrA4X92H2FgGY4AztwB1YkAA81f8iT7eLj7VN5Qj2fZsJ5ZbOd+du7d2+9jHbPNeTy+JoNLe+0/4u+HhYrqOyKbVIy91pV1t4Tkk/ZznJCsByN2c81tpFrWm6Ul34L13+3dGkb91DJEl88Kck+XN50ZkUcDDs7ehOMUAXbvxDrmg6u0/iWzgTQpx5MdzZs0y20gJKvMNgZUcMq5+YKycnDAhf8AhKodV1vTbbw5HBf3kUgXULvyH8m2tyNzgS4A3MVXaoJyRkjAyMaPU76a+s9Y1S81SWezQiGwtfDV3CMuQHMgLNuO3IUhgoJz83Su30zVn1OzSS40XUrNJpPKEd3HHuKlc7mVXbC9ucHPagDj/CEkHjrVIvFmreUdOSaWDQLGXsI2ZXumU9ZWKnbx8iAY5ZjXWar4isdHgtrnVp1sIpi0SW0iF7iWTcAojRCS3f5VDHkHjBrxq38GCea38HNqr6Rr+l25a1gYE219ArvsuYsHKSZJLckqScADmus8Ii90TxxZ2fj65s5tVk01INIvAzFXw7efGHfBMpzCT3ZQPQ0Abx8e3E1w1vp/gzxXcTEExtJaJbxMecZeR12g47jPPTtTPhVbpY+H9UuPMtQs19LcNY6c5nhsTtXMEZA+cjG5towXZsCtnU9Y1XS9Tb7RpJvNId1C3Fi5knhBwCZIcZIDZ5Qscfw8E1l6DfQeBfC9lpfinUtOSW2zb2gt9xkuYVYLGREBuMmCu4KG570AdPpc8d7Ab62nuHguQGRJozH5eBjG1lDDkchuc+ledfGXxOPDnh0ahfQyvqOnPE+nwgL5OoX0iuihU5dhGT5mOOg5JFXLnWtX0608Q6myzWr6vcwwaLaXzAPG/lKjSsmTsQbWkKnkLGxIBJrzrwDaad4q8RHxlq906eCPCBNro0lyxP2y43ZlvHJ5LM5BGByxUdVIIBZ8A+FNQ022ttNUyP4i89NS1e8eEzD+07hHePzhkZWGPLY3YMkkZHJrovhXodtrutt4kWSS60LTZZ4dHknAL3tw7f6TqDkDkuwKJ0AVTgDIqrNp1xretap4H8O6tdS6U5V/EGo7FVodwJkhVxy9xMT8xOFjjAULkYr2PT7O206xt7KxhjgtLeNYoooxhURRgKB6ACgCxRRWTrOm3V5IJIdav7CFUIaK3EIVj6lnjZh+BHSgBnjDxHp3hLw3fa3rUpisbRNzkDLMSQFUDuSSAPrXy78NNO1fxaPFviydyde16x1C6s7NZyGaJY3hQhAp3ASSBFyRjy84JxiPw3o2p/Gz4g3Frc3WfBuj3Ja4uYXlJvSpYIS0jMxZhkDnCJnAUt83rGi6zo/hTxpqbeSotxPHo1vJGdsFpawJuaNF5JKvKhcnAJc4/wBWxIB5P+zn4h0iHwrPomsvarZXJb7Sk1y1qWKMXUB1IRt2dpWQpkYG51+VfSfiJ8QbbRdIkj0qeyXSrdB5b2089rgogTbGqugKf3VRiOh96wviP8FPEen67fax8OJbO5tL+drifSLranlyMcs0LnG0H/ZZCBgZI4DPhr8Etdv/ABHba18Rbaws7C0fzI9Gt5WmE0gOVaUlmBUHnG45xgjGcgGgs3/CB/A/SxqDhbyxRdWv7VgULT3HnS2yjuWW4WIEA9EbORnPoXwL0i98MeA9O8OalaXcU9nbx3BmlVQjtPuldAQTyjl0IPPCnowrjrPTz8SPjlcX1yZm0HwukCz2zsDE2oqGIjGAA4iLyEk5O4kfdIr3WgAr5v8AHHi+4g+JXiK60ohr24lt/DGn3UPLxBAstyoABbeZJ40BA4xwchc/Rd3cQ2lrNc3MixwQoZJHboqgZJP4Cvn/AEyOGL4ZeG9Q1mziOoa3dXeu3Led5bETb2O0Z4UxyKpc8IpJHzlAQD1fxbbTRJYa3oiNPOL21kuvIUytPbAsjbV56LKzfLyQO9YvivxnpXiSz1bwj4cabUNeuo5LCaBbeVVtA2Y3kmcrtRVBJ5OW425yKh1eTWD8NY7fUrO8ZL28itrhbO12m2sWkUPthUFlQRgpg5cBtzYOVXdsdUi1TxNqnhrT7G60200+GC5lu1Q2xkd5DtWNSo3IRE4Zxx2HrQBzmgalr/hSy0zwovh6WeVZmgGqwv59soJ3mSRV+dDhx8rhQSfvY5qh8PfiP4WtPD8eqa7cSWetas5kupntJ2Nw6koqK+wq5UDaFQ4BDYUZIrr5r3QPBeqX7JexRtqcwm/sq3Uy3E125IaRVBLHcAgIwFG0txkmp2j0bw9JBJrsmlvqU19cTWAS2jSYtK5G2JR8zPtYBnHJ5JwKAE8JRXurazfeJdUtJ7JZYxaadaXClZYbcHczuuflaR8Er1CxpnnIGfrXje0e1l1W01q1sPDOmSK97qjoJEuiDzbwdmzjBdc8kKoLZK4PxU1uHS3ki8Y35urW5kMWm+GNHDfaNTz8q+cw+YqSTlFATsS5IWjwx8P9S8TahZ698SEijitCraV4YtiPsenKowpcDiSQD8BzjjAUAXwTpmo/EDxPbeO/FdnJZ6XaZPh7SZx80QPW6lH/AD0b+EfwjkcgNXpB13Tx4mXQBMTqpszfGIKflh3hAxPQZYkAdeD6UnifXLHw14fv9Z1aXyrGyhaaRsjJA6KMkZYnAA7kgVjfDmHVLjSpNd8S2VvZa3qu2WS3ijw1tAM+TA7HlmUMSSQPmdhgYoA62iiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOJ+IOdW1nwv4aiJK3d6uoXi7Aw+zWpEmGz0DTfZ198mu2rg/h+w8R+INb8ZHa1tO39maWwIINpC7bpAQefMl3n/dRK7ygAooooAjuIYriCSC4jSWGRSjxuoZXUjBBB4II7V5lJaXfwoeS601Li+8Asxe5sUBkm0fJyZoR1e37vH1T7y5G4V6jRQBUtbiy1fTI57aWC9sLqPcroRJHKjD8iCK818RfA7wzeSzXvhiS+8J6w2St3o87wqGI4zGCF2+y7frVq88Pap4B1C41fwRbNe6BM/m3/hyPAZSfvTWeeFfuYuFbnGDiux8J+J9J8V6WL/RLtZ4gxjlQgrJBIOsciHlGHoR79CDQB8w+JvA/wAWvByNqWqeMte1PS48s8mmalcO0Srg5kRgdqlc/MocKRk8c1S0bxR4u/d3lh471u4tJWHkysY5gDg5jkRlI3dPUHBIz0H2LXnXiT4NeCtdurq8bS307UZ+t3p0727Buu7Yp8st7spzQB49e61481OC2kPjqKGSPIivRo8KtvyGCsyZKrhTuVVJwM4kTLjVfQPiP480eXSbrxrod/BIf9Itr/SYRLHGVyky7VZWBOQroSOhDZyF6eH4V6t4fjW6trq08RsCBc2csRtGuohk7dxdo927awyg5GQyHBrsdH1y10OS4guPCWvaLHMxuP3Vp9riZjgNgWzSiM8ZIwoPXkk0AcLo3wV1/wANWltJonjZry9tQ7RR6nZ74g7KVOx1fzIQcnO1jnjIOK1dF8aa54Ttb2D4h6ZrSzRhmg1IWwvLRUAAAaW3j3gFhn54wcEZzXdaf448PXt+tiuofZr5mCJbX0MlpK7HoFSVVLE+wNdJQB83+KNcs/iP4lsfDmlX91BfajZg6hqd3G9tFbWZ2rLHZRShWJmfCliCSAQSRwrrPw5cav4yu9M8C3kFxpmmKllbaksP+iaGgALLFkkT3ZJJ3A4UncTuYhd34g+G9P8AjN4yg0u2tEXSvD9wU1LW04kkfB3WUJ743AuT90+/X2TRNJsND0m10zSLWK0sLZNkUMQwqj+pJySTySSTzQBV8KeHdO8LaHBpWkRMltFklnbdJK55aR2/iZjyTWvRXA+IviZYWuoPo/hWyuPFXiFeDZacw8uHkjM85+SIZGOSTnHHNAHYa5q+n6FpVxqWsXkNlY267pJpm2qo/qT0AHJJwK8U1zVvFfxssLjTPBaN4f8ABMxMVxrd6jLNfJnDLBGMHYec5I3AYJX5lPRad8OdT8V6nb638WLq31GSBhJaaFa5+wWp9XB5mf13cdRyMY9UijSGJIoUWONFCqijAUDgADsKAPB7T4Lat8O9HbU/ht4m1STW7cCaawvGU2mo7RzGYwBtJGQpJJGeq/eEfii60z4meFNP8XaCs8Gv2LNa3Ollj5iyKrs0Ww4zIjZkU4G4KVxk4Hv9eNfE3Qr3wL4hf4leDYGfaMeIdMj+5eW46zKO0idc/if4gwBfuddvvB/grRzBM816tpFvtbmQP5bv+82MuA4xGJQpLADywMEmuGv/AIl+K7fRpL37U91cTTvZaRFbxIBfXTZgRQQvzKrCWVgO6xDI3YOsuj3njvxhDqkUE954avyLmLUbd41RVPl4J3HdlUiERTaSGaTtmrPwn0638W+OZvE1tGq+FvDSPo3h+MdJX6T3fGAS3TcB8wPPK0Adx8HfC03gvwbHoV3GrXcEryT3ifdvHc7zIMndkZCHdg/J6YruKKKAOB+POpSaX8I/ErwDM9zb/Yo1B5Zp2EXHv85P4VjfELxTH4B0bRPD2lpA14lqkcHmAMRHHhR8uchcqCSfQBeTlM/9pLxPa6HD4Mt5o7i5f+24NSmtraPe721sS8hx7Ep1wODyMVy/jn4gfCbxreadqM/i2XTbu3ieF2XTJWkKNyFJ8sjKtyPvDBbjJyADv/gdqmr6lY6vLq+oXuoW6SRiG5uVVQTs+cDHI7HHTGOhJrZ+Itr4Gma1k8arYvcKNsCMzefICfuoifO4J/hAP0ryGDxP4Y1TSpLLwl4D8ceJYJC0QkJlt7aWNgMo0it9w4BIZeSSTkkk9Bovhn4l3u5tK0/wl8PLSU7Ga1tlu77y+wdvuN+YP0oA6q41LT9J8J3d/bRWfw9si6pFd3tpCs00YXJ2w5G1uyhtzcH5Oa5ax8VeIvGKW1v8MdIllghVov8AhMfEcYXKsW3GFdoZ8kDoAoIwVAxXR+HfgvoNrfJqniu5vfF2tAY+1axIZUTrwkRyoHPRt2McEV6gqhVCqAFAwAOABQBw3gH4bad4WvJtXvrq413xRc/8fGsX/wA0p4xtjHIjTHG0duCSAMd1RXAfEvxRqMN1aeEvCAWTxXqsZZZCMpp1tna91J7DooP3m45+6QDN1IH4i/EQ6UCX8J+F50lvccpfagMMkORwViGGZc/eIBXjNeo1ieC/DNh4R8OWmj6UreTAuXlkOZJpDy8jnuzHJP5DAAFbdABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFU9asE1bR77TpJp4Eu4JLdprdtskYdSpZDg4YZyDjrVyigCnoum2+jaNYaZZBha2UEdtCGOSERQq5P0Aq5RRQAUUUUAFFFFABXFeLfAqahqZ1/w1etoXipVC/b4U3JcqOPLuI+kq4wMn5lwpB4xXa0UAebWPxLOi6lBovxLso/D2py5WC+Vy+nXmOpjlP3D1Ox8EDHJyK9IVgyhlIIPII71V1bTLHWNPmsdVs4LyzmGJIJ4w6N9QeK8mu/ht4r8Gubj4T+JGjsVO7/hH9ZZp7XHJ2xOctGOgxwSeS4oA9korxWL41al4czD8TvBOsaGyFUa/tE+02jMRnO8cD6Aua7fQfil4G12IPpvinSmz0SacQP/AN8SbW/SgDp9X0ux1nTprDVbSG8s5hh4ZkDKecjg9wcEHqCM15B8S/DMMV7onhjwZrHiLTdf1J8qbfWbporO0QgyzvGXIwBhFGVyzAA8EV6zreuafougXetahcxx6dbQm4eYEEFQM/L6k9gOpIArk/hdpF7OLzxh4khaPX9cCssD5JsLMZMNsuemAdz4Ay7HI4oA6vwzodh4a0Cx0bSIRDY2cYjjXue5YnuxJJJ7kk1a1K+tdL0+5vtQnS3s7aNpZpXOFRFGST+FWa8y8VY8feN4PCkQMvh3R3S811sfJPNw0Fpz94ZxI4wRgKMgnFAEGn6bqnxSQan4hlu9M8GTAmy0eF2hmvozwJbp1wwVhyIlIGCCScc+jaNpGnaHYJY6NY2thZpysNtEI0B7nAHX3rN8X+MNF8JW0Mms3eya4bZbWsSGW4uX7LHGuWY5IHAwMjJFcuE8ceNlJkkbwVoMo4RAsuqTIQercpbkgjpudSOooA2vFnjrT9CvotJs4J9Z8RzjMOlWG1pccYeQkhYo+R87kDGcZwa5+8v/AIuRKNQg0bwjPbg720hLqb7SVOPkE7AR7x0zt28d67Lwp4U0bwpZy2+h2Swec3mTzMxea4fk75JGJZzknknvW5QByfw+8cWHjO0uhBBc2Gq2LiK/0y7XbPayHsw7qcHDDqPQ5A6wgEEEZB6g15f8UvDup6brFr4/8F23na9p0Ziv7FCR/adn1aPjrIuMqcE8Yw2FFdx4R8Sab4t8O2WtaLN51ldJuXPDIe6MOzA5BHtQB8q/GXwl4j8F60fD2ja/ead4D1o3E1rAjnyo5vLZzaHGDh2AVQTg7+5DGvoT4LwWOl+EjoemH/RNOmY2+5ss0E/+kRMfU4lxnplTWt8TPCNt448FalodyVSSZN1vMRzDOvKOD1GD1xyQSO9cJ8ENVbVbGznmL2es6RCPD2s6WIt2JImJil+U/IOZOcbTuYDG3kA9jqK6uIbS2muLqVIbeFDJJJIwVUUDJYk9AAM5qWvM/itPJ4k1rR/h7YyyR/2qDeavJExVotOjOGXI5BlfEYPPG7PBoA4rw94Pv/ipr15451S7axsLqVItMgMLC4isow5TBbhTIzRy7lyeflYV65p3gfw/Yah9ujsZJ7zbsEt5cy3RUZB481mwcjqOa37O2gsrSC1tIkht4EWKKNBhUVRgKB2AAxU1ABRRRQAUUVxPxX+I+kfDjw5Jf6k6zX0gK2dir4kuH/oo7tjAHqSAQCX4j+NB4Vs7W0061OpeJdTYw6XpqdZ5O7Mf4Y1zlmJAA7im/DbwbJ4at73UNZuxqXinVnE+p3wGFZgMLHGD0jQfKo49cDgDE+DfhnUvLm8a+Mm87xbrcQZlKFVsLY/MltGp5UdCw654OSCx9OoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooACARg8g1wfiX4Q+AvEcpl1PwzY+cc5ktg1sxJ7kxldx+ua7yigD5p1b4IeDdP+KXhPSNChvGmaR9Uv45rgSxx2kOMKUIyfMkKJnJwA3B7fS1eb/C0jxHr3iXxyx8y21GYafpTHDYsrcld6nqBJKZHwfRT6V6RQBwPxW8dP4YsY9L0CA6j4w1JGXTdPjG5uASZnHZFAJ/2iMDuQiNpnwl8ARpI02o30kuPlXNzq1/Kcnjks7tn1wo9FrgvDsGh+Cvit8U/FniCeSQ209tDbSyEyS5niErQxL3YkoqgdAuOBmu58EaHqms64PGnjODyNRMbR6VpbHcNLgbqT/02cY3N1A+XgZFAFr4d+EJdPluPEnieOG48Y6mfMuphhhaJ/DbQn+FEGAcfeOSSeMdzXBa18TtLi1GfSPC9rdeKNfiOxrPTBujhbn/XTn93GMjBySQe1UIvDHjnxPGsvizxS2g2sgydL8PKEdO6hrpsuW7NsAHoe9AHX+JfF/h3wwmfEGt6fp7Fd6x3E6q7j1VM7m/AGua0n4z+AdW1e20yz8QR/bLkhYVntpoVkJ4ADugXk8Dnk8Ctrwz8P/CvhiQS6LodnBdbi/2p1MtwSev718v+taHi3w1pXi3QbnR9etUubKcYIYfMjdnU/wALDsRQBsV4x4ngk+EfjCTxZpoc+C9auFXXbRVJWynYgLdoB0BJw4/nlQt/4YeINS8O+I7j4c+M7v7RqNsnnaPqMhIOpWnYHPWVACCOpAPXaWb0/UrG21PT7mxv4UntLmJoZon6OjDBB+oNAE0Msc8Mc0EiSRSKHR0IKsp5BBHUV57rnhO/0z4p6V4w8MxvIL/Gn69ah0VZYdp8u4+Yj5oyFBxkleBj5s4nww1G78DeKZfhp4inkltwrXHhy9lYH7Ra5JMDH+/H6egPAAXPsFAHE/Fdvt/wm8R3Nr50bw2El5EXRonV4R5q5VsMOUHBrnPgNcXfi2DVfiHq9utvda4yW9rAr71gtYMphSeRuk8xiO/Bra+NmvLoPgu4a4MQs72K6tJy4OQDZzuu3HcvGq/8CrT+Etn/AGf8LvCVt5RhdNKti6EYIcxKWyPXcTQB1lFFFABRnkcVwXiz4seFPDl42n/bJdW1gZA03SYjdXGQeQQvCkejEGvMrnxD8Rviw72nh6D/AIRzQGJSSaCbMjAY+/cgYHb5YgzdQxA5oA7T4pfGGx8L3X9h+HIo9a8VSsIktUJaO3Y8DzSvJbPSNfnPTjINeK+CvAmr+NPj+f8AhOpZb+40e3ivdV80hozK3zw24AG1Vw65TkHZJzzXv3w1+Ffh34f24ntokudSUEvfTLgpkYbYCTsGM5OSxHVjxjA/ZsgbUNG8TeMJoikniXWJ7qIk5/0dGKov4N5goA9hooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK4H4x6jdjQLTw5o8hj1fxLcDTIXXloImUmebGQSEiDdOhK131edX+dS+P2lW88atDo2gTXsLdxLcTCI/wDjkTD/AIEaAO60jTrbSNKs9NsI/Ks7OFLeFM52oihVGfoBU9xNHb28k87rHDEpd3Y4CqBkk1JXJ+PPAekeMoA18bm21GKGSK2v7Wd4pYA4wcbSAQc8qcgigDx/4QeGn+IvjzX/AIjau94NHbUxLosBYosjQ4RZmTodqKqDryX7ivQ/Ft/f+M/Elx4L8OXUtlYWqq2vapEcPErDK2sJ/wCerjlm6Ip7scVwng/xprPhTw1H8MV08t8QrJjYWHyH7LLCcsl4Xxjy0TkjG4lQMZLbfYPh54ZXwn4Us9NdxNfkGe/uslmurp/mllZjyxLZwTzgAdqANTQNF03w9pNvpmiWUNlYW67Y4YlwB7nuSe5OSTySTWhXOePfEa+EtBbXboO2m2cim8SKLe5jYhNw+YY2lgx4YkKQBzkc5/wu34c/ZftH/CVWWzGcbJN//fO3d+lAHo1FeV+Efi7ovxD8WnQfCLaiFto/tk9+0SJG0aOg2BXyxDbsE4UjqPb1SgDkPiZ4ItPHGhLbPK9nqto/2jTdRiOJbOccq6kc4yBkd/YgEZHwk8cXmu/bvDviuFbPxlo2EvoeALhP4biMd1bgnHAJHQMK9Grzr4reC9R1W603xT4Pkit/GGi5Nt5mBHeQn71tIePlOTjJwCT0zuAB0XjfwbpHjLT4bbWIpVltpPOtbu3kMVxayjo8bjlSMA9xwMg4q/Yf2nBqElvdiO4sSuYLhBtdAoQbZct8zMSxDKAMA5AOM1vBXiEeJ/DltqTWN1p1w2Y7izukKyW8qnDocgZwRwccjB46Vu0AeQ/tP26aj8PtP0kyJFPqmsWllC7naod2PJPYbQ2TXda/418L+GoD/a2u6VZLCPmie4UOAB0WMZYnpwBXjPxNtl+MfxNh8CGefSIPD8U13dmWMyLPKWRYgFDLwYzvDZzhyPWui8K/s/8Ah7R9Rgu7r7HMYJFkWGCyGxiMHD+e0zEf7rLQBK/xql8QXIs/hr4V1LxDM5cLd3BFlaHA6h35bHdSFP506bwF458YxtL4+8VLZ2hU40TQC1vC/A+WWc5dgeQy4I7g160bK1a4gna2hM8CskMhjG6NWxkKeoBwMgegqegDzfwj8JNA0W3CXVpaTR/L/ocEPl2ox03qSzTEZPzSs+OwXpXo0caRRpHEipGgCqqjAUDoAPSnUUAcd8Y9XTQvhZ4pv3coV0+WKNh2kkXy0/8AHmWpfhPov/CPfDTwzphga3lhsIjNE+crKyhpM56HezcVzPx1hj8QL4U8E+eEk1/VEaaMgjzLS3HmzYYAgEYTAPUn616lQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAUdc1aw0HSLvVNXuo7WwtYzJNM/RVHsOSewA5JIAya8g8Dahrt98cZdX8VWP8AZEOsaI8ejWc+FmEMUysUkH/PXD+YUySobBxg0z9oBNQ8RXTaNYyzQ2OiWces3XllQLidpvLtoST0A2TOeoOF9iO/+IVm8M+heJLS3M13ot3l1VGdmtZh5c4AHcKVk/7ZCgDsaKKKAPFNAt7Hw3+0l4tu9eme2uNZ0+GTSp7iUCKWJQgnQE/xB0Uheygnpiul8ffGXwZ4MtpPteqw31+FyllYsJpGPoSDtT/gRHtmqP7TPhqDxF8ItZd4Y2vNNQX1vIxwYyhBfB903jB46egriP2efg9Hpdja6x4k0+ykkmtop4MwpMJVkXfh/MDFHTIB2BO3Lc0AeV+MvFniz4u6ig1GL7Jokcge20WF2DOD0c4A8xsY5YqOeMZNVfDPwhv7zxVLa3Wn6lBZR2gkL3OkS7nYnBCKjFGx03bx19a+5ooo4Y1jhRY41GFVRgAewrKvfDGh39411faTZXM7dWniD5/A8UAfJXg63k+GH7QHhlbiyuNOstTi+ySBwUWXzCyAgHkKH8skH+7n0r7Nr4d+ONydT8TS6fp0dlJpmg309rA1pbLbO7MyecW2naPLdokDbQCck98/Rfwg+KMWvRR+H/FLGw8W2oEMkdwpi+1kDBZQQMPkHcnUEEjK80Aer0UUUAZUGiW1pr11qtjFDBcXwX7c4jy9zsXbHls8bRntzWrRXlvxl8T6/p+reH/DPg94TrHiFLm2XeP+PYAJ/pO4HI2LvIGDn324IBD8EmfV/E/xI8TvtK32tfYYWUYDxWqeWjD1BDdfUGvWKxvBvh2y8JeF9N0LS1ItLKIRqW+856s592Ylj7k1s0AFFFFABRRRQBg6l4U03UfF+j+JLlZTqWlRTRW2HwgEoAYkdzgED/ePXjG9RRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVieMfFGkeDtBn1jX7pbaziwo4y0jHoiL1Zjjp7EnABI264Kfwe3i3xTHrPjOziNnpkkkelaWzCRPvYNzNj5WdtoKpyEXrlj8oB5FYa9c+O/Dnxc8TWNlPYx3FvYyWsVxy/k24dt5xgfMFY4BOPU8E/TKsGUMpBUjII5BFYtj4eht9Z1++nkFwmrmIPA8Y2oiR7Nv+0DyefXFZnguSbRJ38J35kb7HHv024cDFxZjAVc93iyEbuRsb+LgA66iiigDC8d2iah4O1myllgiS6tngLz52DeNvzYB45rbjRY41SNQiKAqqowAB2Ap1FABWD4819PC/g3WNaYKWs7Z5IkbOJJcYjT/AIE5VfxreqlqtnLewwxw3P2cpcRTMfKWTeqOGKYYHGcY3DkdRyKAPJvDfwdj8KaBZ3dhjVdfWM/2jb6hKHgvkkUefAOMKpfLqWB+YDdkE46a4+HNo7RQ7ba+0do1gew1eH7Q8EWR8sM+d67eoBLAH7pWvQKKAKtsLWxS00+OUKyxbYY5JS0jIgAJyxLNjK5JyeRnrVqiqM76bpTS3c5tbRrqVFklbahmkICICf4mwAoHXoBQBauJoreCSe4kSKGNS7yOwVVUDJJJ4AA715n8Lom8WeJdW+It3G6w3if2boiOMFLCNsmTHBzLJubDDIAABINZXiPV7z4n36eB7CGSytInD+J7iGYSLbxhsiyWReDK+AHwcINw+bkV7Ba28NpbQ21rDHBbwoI44o1CqigYCqBwAAMACgCWiiigAooooAKKKKACiiigAooooAKQjJBOeOetLRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWH4t0JtasI2s5/smrWb+fYXYH+plAI5H8SMCVZe6k9DgjcooARc7RuxuxzjpmloooAKKKKACiiigAoorlvHvjXTvB2lvNdMk186M1vZiQI0mOrMx4SMfxSHge5IUgFrxh4mtvDdlEWie71G6Yx2VhEwEly4GTgnhUUcs5+VVBJrxXTLHxD8UPExvLXVGj063Zo5tftsiOLnD2+lhh142tdEbiQduFAVpfC3hHV/ihqMmueJLi4g8O3SgSOoaGbVYs5EUan5oLLPReHl++5yV2e/WVpb2FnBaWUEVvawII4oYlCoigYCgDgADtQBneFPDmleFNEt9J0GzjtLGEcIvVj3Zj1Zj3JrXoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKDnsKKACiiigAooooAKKKKACisfxP4gtPDVlHe6lFdfYjJsmnghMq267SfMkC8hOMFsHGRnA5FC68b6TDNbmGPUL+xniMqahptlJe22ASCC8IbB+U0AdPRXOab400TUXcW014qR7jJLPYXEMUe0EndI6BV6HqRXl/jj4l3Ouamnh7wQ8mrXbxI81toUpeUE9Vlu/9XbxgkAuhdieMx9aAOr+JHxT03wrb3kNi8F1fWw2zyO/+j2bN91ZCOWkPJEKZcgEnauWHI+BvhrqPinUU8Q/EKKYWjstxHpl2QZruTqst4BwFH8FsPkjHBBO8v0Hw6+E8elXFlq/iyS2vtVtCWsbG1QrYaZnBPkoeWfIBMrZZiATyNx9WoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooqG9llgtZJILd7mVRlYkZVLewLEAfiaAOd1Pxn4W/s27L+IrHYEZX+yXQeZex2qhL7h7DINfN3xd8Knw3pd3q1h4p8JXTQKWt7ps2mqZJ+UK1swE8nTLuvPJOOTXtnj4a3rOmNHYfDq2vr9yUWfVHs5EhGOXClzuPYDgepwMV4v4Y+FWp6p8W/D9t4h8JWem6JpsTXNxbRtFKGQbvKM0iqFlaSQHK+isNqKAKAD4QfCPxD8RrGx1/4na1rFzoWRLZ6fdXcryXK/3yWOY424xj5mHIwNpP1F4f0DSfDtgtloOm2mn2q4/d20QQE4xk46njqck1p0UAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAA4HXNFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABVSw02z0+W8ks4FikvJjcXDDOZJCqruP4Ko/CrdFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Rectovaginal examination, standing - An enterocele is detected during standing rectovaginal examination by palpating small bowel between thumb and index finger.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: LifeART. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_6_40034=[""].join("\n");
var outline_f39_6_40034=null;
var title_f39_6_40035="Epidermoid cyst";
var content_f39_6_40035=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F50581&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F50581&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Epidermoid cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 364px; height: 375px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A skin-colored nodule is present on the chest. This particular lesion does not have a visible punctum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Stedman's Medical Dictionary. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_6_40035=[""].join("\n");
var outline_f39_6_40035=null;
var title_f39_6_40036="Actinic keratosis histopathology";
var content_f39_6_40036=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F76208&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F76208&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Actinic keratosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 364px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Partial thickness epidermal dysplasia and a mild lymphocytic infiltrate in the superficial dermis are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_6_40036=[""].join("\n");
var outline_f39_6_40036=null;
var title_f39_6_40037="Tick sizes and appearances";
var content_f39_6_40037=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F68309&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F68309&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 484px\">",
"   <div class=\"ttl\">",
"    Tick sizes and appearances",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 464px; height: 456px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Centers for Disease Control and Prevention.",
"     <a href=\"file://www.cdc.gov/lyme/transmission/blacklegged.html\">",
"      file://www.cdc.gov/lyme/transmission/blacklegged.html",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_6_40037=[""].join("\n");
var outline_f39_6_40037=null;
var title_f39_6_40038="Pathogenesis of Guillain-Barré syndrome in adults";
var content_f39_6_40038=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of Guillain-Barr&eacute; syndrome in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/6/40038/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/6/40038/contributors\">",
"     Francine J Vriesendorp, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/6/40038/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/6/40038/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/6/40038/contributors\">",
"     Ira N Targoff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/6/40038/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/6/40038/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/6/40038/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acute immune-mediated polyneuropathies are classified under the eponym Guillain-Barr&eacute; syndrome (GBS), after the authors of early descriptions of the disease. GBS is an acute monophasic paralyzing illness, usually provoked by a preceding infection. GBS occurs world-wide and all age groups are affected.",
"   </p>",
"   <p>",
"    Historically, the Guillain-Barr&eacute; syndrome (GBS) was considered a single disorder. It now is recognized as a heterogeneous syndrome with several variant forms. The major forms are acute inflammatory demyelinating polyradiculoneuropathy (AIDP), the Miller Fisher syndrome (MFS), acute motor axonal neuropathy (AMAN), and acute sensorimotor axonal neuropathy (AMSAN). Each form of GBS has distinguishing clinical, pathophysiologic, and pathologic features. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/22/5481?source=see_link\">",
"     \"Clinical features and diagnosis of Guillain-Barr&eacute; syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathogenesis of GBS will be reviewed here. Other aspects of GBS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/22/5481?source=see_link\">",
"     \"Clinical features and diagnosis of Guillain-Barr&eacute; syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/16/265?source=see_link\">",
"     \"Treatment and prognosis of Guillain-Barr&eacute; syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;One proposed mechanism for Guillain-Barr&eacute; syndrome (GBS) is that an antecedent infection evokes an immune response, which in turn cross-reacts with peripheral nerve components because of the sharing of cross-reactive epitopes (molecular mimicry) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40038/abstract/1\">",
"     1",
"    </a>",
"    ]. The end result is an acute polyneuropathy. This immune response can be directed towards the myelin or the axon of peripheral nerve.",
"   </p>",
"   <p>",
"    Immune reactions directed against epitopes in Schwann cell surface membrane or myelin can cause acute inflammatory demyelinating neuropathy (AIDP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40038/abstract/2\">",
"     2",
"    </a>",
"    ]. The pathology is that of multifocal inflammatory demyelination starting at the level of the nerve roots. The earliest changes are frequently seen at the nodes of Ranvier. Both the cellular and humoral immune responses participate in the process. Invasion by activated T-cells is followed by macrophage-mediated demyelination with evidence of complement and immunoglobulin deposition on myelin and Schwann cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40038/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. No specific myelin antigen(s) have been identified.",
"   </p>",
"   <p>",
"    Immune reactions against epitopes contained in the axonal membrane cause the acute axonal forms of GBS: acute motor axonal neuropathy (AMAN) and acute motor and sensory axonal neuropathy (AMSAN) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40038/abstract/2\">",
"     2",
"    </a>",
"    ]. These forms are uncommon in the United States, but the pathophysiology of these variants is better understood than that of AIDP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Molecular mimicry",
"    </span>",
"    &nbsp;&mdash;&nbsp;A case report from Japan in 1990 linking AMAN to a preceding infection with Campylobacter jejuni and antibodies to GM1 (monosialoganglioside) prompted interest in the role of Campylobacter and antiganglioside antibodies in GBS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40038/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Studies in Chinese patients with AMAN have shown antibody and complement deposition on peripheral nerve axons, followed by attachment of macrophages and axonal collapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40038/abstract/9\">",
"     9",
"    </a>",
"    ]. In AMSAN, the same process is more severe and leads to full axonal degeneration.",
"   </p>",
"   <p>",
"    The following observations provide insight into the mechanism of nerve dysfunction, and support the hypothesis that GBS is evoked by antecedent infection that triggers the immune system to attack components of the peripheral nerve through molecular mimicry:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most cases of GBS are preceded by infection (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Antecedent events'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      Infection with C. jejuni can generate antibodies to specific gangliosides, including GM1, GD1a, GalNac-GD1a, and GD1b, that are strongly associated with AMAN or AMSAN [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40038/abstract/10\">",
"       10",
"      </a>",
"      ]. Similarly, C. jejuni infection can generate antibodies to GQ1b ganglioside, a component of oculomotor nerve myelin, that are associated with MFS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40038/abstract/11\">",
"       11",
"      </a>",
"      ]. Patients with C. jejuni enteritis not complicated by GBS do not produce the specific anti-ganglioside antibodies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40038/abstract/7\">",
"       7",
"      </a>",
"      ]. Genetic polymorphisms in C. jejuni that modify ganglioside expression as well as immunogenetic factors in the host are thought to play a role in the development of GBS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40038/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There are shared ganglioside antigens between peripheral nerve components and the outer core of the lipo-oligosaccharide coat of the Campylobacter jejuni bacterium [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40038/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Rabbits sensitized with C. jejuni lipooligosaccharide or GM1 develop anti-GM1 IgG antibodies, flaccid limb weakness, and pathologic changes in peripheral nerves identical with those present in patients with axonal GBS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40038/abstract/14,15\">",
"       14,15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further studies in this rabbit model have emphasized that anti-GM1 antibodies bind to voltage-gated sodium channels at the nodes of Ranvier. Similarly, the anti-GQ1b antibodies in a mouse model of MFS bind to sodium channels at the presynaptic nerve terminal. This process causes sodium channel blockade that may lead to reversible nerve conduction failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40038/abstract/16\">",
"     16",
"    </a>",
"    ]. The antibody binding is complement dependent and ameliorated by complement inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40038/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is also an association between infection with Haemophilus influenzae, Mycoplasma pneumoniae, cytomegalovirus, and specific glycolipid antigens in GBS, but these relationships are not as well documented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40038/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Antecedent events",
"    </span>",
"    &nbsp;&mdash;&nbsp;As already noted, antecedent infections are common with GBS, and are thought to trigger the immune response that leads to acute polyneuropathy. Approximately two-thirds of patients give a history of an antecedent respiratory tract or gastrointestinal infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40038/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Campylobacter",
"    </span>",
"    &nbsp;&mdash;&nbsp;Campylobacter jejuni infection is the most commonly identified precipitant of GBS. A case-control study from the United Kingdom involving 103 patients with the disease found that 26 percent of affected individuals had evidence of recent C. jejuni infection, compared with 2 percent of household and 1 percent of age-matched controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40038/abstract/18\">",
"     18",
"    </a>",
"    ]. Of note, only 70 percent of those infected with C. jejuni reported a diarrheal illness within 12 weeks before GBS onset.",
"   </p>",
"   <p>",
"    Other studies have found that about 60 to 70 percent of AMAN and AMSAN cases and up to 30 percent of AIDP cases are preceded by C. jejuni infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40038/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Furthermore, campylobacter-associated GBS appears to have a worse prognosis, manifested by slower recovery and greater residual neurologic disability, than other forms of the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40038/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study from Sweden estimated that the risk for developing GBS during the two months following a symptomatic episode of C. jejuni infection was approximately 100-fold higher than the risk in the general population, with GBS developing in an estimated 0.03 percent of patients with C. jejuni enteritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40038/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are geographical differences in Campylobacter jejuni infection. Certain strains of Campylobacter jejuni have been associated with GBS in Japan (strain O-19) and South Africa (strain O-41) but not in Europe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40038/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     HIV",
"    </span>",
"    &nbsp;&mdash;&nbsp;GBS also occurs in association with human immunodeficiency virus (HIV) infection, predominantly in those who are not profoundly immunocompromised. The clinical course and prognosis of GBS in patients with HIV infection appears to be similar to GBS in patients without HIV infection.",
"   </p>",
"   <p>",
"    GBS can occur in any stage of HIV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40038/abstract/24\">",
"     24",
"    </a>",
"    ]. GBS has been reported after acute HIV seroconversion and following immune reconstitution from highly-active antiretroviral therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40038/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Other infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to Campylobacter, several other agents including cytomegalovirus have been associated with antecedent infections in GBS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40038/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. To assess the strength of these associations, a case-control study in the Netherlands evaluated 308 patients for serologic evidence of infection with 16 agents, and found that recent infection with C. jejuni, cytomegalovirus, and Epstein-Barr virus was significantly more common on multivariate analysis among patients who developed GBS than among matched control patients who had other neurologic diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40038/abstract/29\">",
"     29",
"    </a>",
"    ]. Mycoplasma pneumoniae was associated with GBS in univariate analysis only. Patients with HIV infection were excluded from this series.",
"   </p>",
"   <p>",
"    Less commonly, GBS has been reported following infection with varicella-zoster virus, herpes simplex virus, hepatitis A, B, and C virus, influenza virus, and the bacteria Haemophilus influenzae and Escherichia coli [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40038/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. The importance of these infectious agents as triggers of GBS is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Other triggering events",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small percentage of patients develop GBS after another triggering event such as immunization, surgery, trauma, and bone-marrow transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40038/abstract/33\">",
"     33",
"    </a>",
"    ]. In one report, GBS was associated with tumor necrosis factor alpha antagonist therapy in 16 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40038/abstract/34\">",
"     34",
"    </a>",
"    ]. Another report noted two patients who developed GBS associated with the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    , but it is unclear whether there is any causal link [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40038/abstract/35\">",
"     35",
"    </a>",
"    ]. GBS has also been linked to systemic processes, including Hodgkin lymphoma, systemic lupus erythematosus, and sarcoidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40038/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guillain-Barr&eacute; syndrome has followed vaccinations, but this danger may be overstated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Influenza vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, an increased risk of GBS was associated with the swine influenza vaccine in 1976, although the severity of the risk has been controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40038/abstract/30,36\">",
"     30,36",
"    </a>",
"    ]. Subsequently, no increased risk was observed up to 1991. Other data suggest that influenza vaccination is associated with a low or negligible risk of GBS.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Individuals who received either the 1992-1993 or 1993-1994 influenza vaccinations were not at significantly increased risk for GBS, but combining the two seasons suggested that influenza vaccination resulted in approximately one additional case of GBS per million patients inoculated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40038/abstract/37\">",
"       37",
"      </a>",
"      ]. This risk appears to be substantially less than the overall health risk posed by naturally occurring influenza. The annual reporting rate of GBS following influenza vaccination in adults declined significantly from 1996-1997 through 2002-2003 in the US [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40038/abstract/38\">",
"       38",
"      </a>",
"      ]. Nevertheless, the long onset interval for post vaccination GBS compared with other post vaccination adverse events (median 13 days versus 1 day, respectively) is consistent with a possible causal association between GBS and influenza vaccine.",
"     </li>",
"     <li>",
"      In a self-matched case control series from Ontario, Canada that identified 269 hospital admissions for GBS diagnosed within 42 weeks of receiving influenza vaccination, the estimated relative incidence of GBS during the primary risk interval (weeks two through seven after vaccination) compared with the control interval (weeks 20 through 43) was 1.45 (95% CI 1.05-1.99) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40038/abstract/39\">",
"       39",
"      </a>",
"      ]. However, a separate time-series analysis of 2173 hospitalized cases of GBS showed no statistically significant increase in hospitalizations for GBS after institution of the universal influenza vaccination program in 2000.",
"     </li>",
"     <li>",
"      A European case-control study of 105 patients with GBS matched to one or more controls found that the 2009 pandemic H1N1 influenza A vaccine did not increase the risk of GBS (adjusted odds ratio 1, 95% CI 0.3-2.7) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40038/abstract/40\">",
"       40",
"      </a>",
"      ]. The confidence interval indicated that the absolute effect of the vaccine could range from one avoided case to three excess cases of GBS per one million people who received the vaccination. In contrast, a population-based cohort study from Quebec evaluating the H1N1 vaccination during the fall of 2009 found a small but significantly increased risk of GBS during the 8-week postvaccination period (adjusted relative risk [RR] 1.80, 95% CI 1.12-2.87) and during the 4-week postvaccination period (RR 2.75, 95% CI 1.63-4.62) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40038/abstract/41\">",
"       41",
"      </a>",
"      ]. The number of excess GBS cases attributable to the vaccine was approximately two per one million doses.",
"     </li>",
"     <li>",
"      In an analysis of 550 first-episode cases of GBS from 1995 to 2006 in a northern California healthcare database, a recurrent diagnosis of GBS was observed in 6 (1 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40038/abstract/42\">",
"       42",
"      </a>",
"      ]. There were no cases of recurrent GBS among 107 patients who received influenza vaccination after the initial diagnosis of GBS, and none of the six individuals with recurrent GBS had any vaccine exposure in the two months prior to the onset of the second episode of GBS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of influenza vaccination for the prevention of seasonal influenza is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=see_link\">",
"     \"Seasonal influenza vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Meningococcal vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cases of GBS have been reported following administration of the quadrivalent meningococcal conjugate vaccine MCV4 (Menactra). This issue, along with meningococcal vaccine recommendations, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23050?source=see_link&amp;anchor=H9#H9\">",
"     \"Meningococcal vaccines\", section on 'Possible association with Guillain-Barr&eacute; syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The United States FDA and Centers for Disease Control (CDC) request that practitioners report possible cases of GBS occurring after vaccination with MCV4 to the Vaccine Adverse Events Reporting System (VAERS) online at",
"    <a class=\"external\" href=\"file://www.vaers.hhs.gov/\">",
"     www.vaers.hhs.gov",
"    </a>",
"    or by telephone at 800-822-7967.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;There appears to be little or no risk of GBS associated with routine immunizations in the United Kingdom. In a study that analyzed a large database of 253 general practices in the United Kingdom with a mean of 1.8 million registered patients from 1992 to 2000, there were 228 incident cases of GBS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40038/abstract/43\">",
"     43",
"    </a>",
"    ]. Onset of GBS within 42 days of any immunization occurred in seven patients (3.1 percent), with an adjusted relative risk of 1.03 (95% CI 0.48-2.18).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/37/37457?source=see_link\">",
"       \"Patient information: Guillain-Barr&eacute; syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Guillain-Barr&eacute; syndrome (GBS) is an acute monophasic illness causing a rapidly progressive polyneuropathy with weakness or paralysis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Guillain-Barr&eacute; syndrome is thought to result from an immune response to a preceding infection that cross-reacts with peripheral nerve components because of molecular mimicry. The immune response can be directed towards the myelin or the axon of peripheral nerve, resulting in demyelinating and axonal forms of GBS. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mechanisms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Campylobacter jejuni infection is the most commonly identified precipitant of GBS. Cytomegalovirus, Epstein-Barr virus, and human immunodeficiency virus (HIV) infection have also been associated with GBS. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Antecedent events'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A small percentage of patients develop GBS after another triggering event such as immunization, surgery, trauma, and bone-marrow transplantation. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Other triggering events'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Vaccination'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40038/abstract/1\">",
"      Yuki N, Hartung HP. Guillain-Barr&eacute; syndrome. N Engl J Med 2012; 366:2294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40038/abstract/2\">",
"      Hahn AF. Guillain-Barr&eacute; syndrome. Lancet 1998; 352:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40038/abstract/3\">",
"      Asbury AK, Arnason BG, Adams RD. The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis. Medicine (Baltimore) 1969; 48:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40038/abstract/4\">",
"      Hafer-Macko CE, Sheikh KA, Li CY, et al. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol 1996; 39:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40038/abstract/5\">",
"      Kieseier BC, Kiefer R, Gold R, et al. Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve 2004; 30:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40038/abstract/6\">",
"      Yuki N, Yoshino H, Sato S, Miyatake T. Acute axonal polyneuropathy associated with anti-GM1 antibodies following Campylobacter enteritis. Neurology 1990; 40:1900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40038/abstract/7\">",
"      Rees JH, Gregson NA, Hughes RA. Anti-ganglioside GM1 antibodies in Guillain-Barr&eacute; syndrome and their relationship to Campylobacter jejuni infection. Ann Neurol 1995; 38:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40038/abstract/8\">",
"      Jacobs BC, van Doorn PA, Schmitz PI, et al. Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barr&eacute; syndrome. Ann Neurol 1996; 40:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40038/abstract/9\">",
"      Hafer-Macko C, Hsieh ST, Li CY, et al. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann Neurol 1996; 40:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40038/abstract/10\">",
"      Ogawara K, Kuwabara S, Mori M, et al. Axonal Guillain-Barr&eacute; syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol 2000; 48:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40038/abstract/11\">",
"      Jacobs BC, Hazenberg MP, van Doorn PA, et al. Cross-reactive antibodies against gangliosides and Campylobacter jejuni lipopolysaccharides in patients with Guillain-Barr&eacute; or Miller Fisher syndrome. J Infect Dis 1997; 175:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40038/abstract/12\">",
"      Koga M, Takahashi M, Masuda M, et al. Campylobacter gene polymorphism as a determinant of clinical features of Guillain-Barr&eacute; syndrome. Neurology 2005; 65:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40038/abstract/13\">",
"      Aspinall GO, Fujimoto S, McDonald AG, et al. Lipopolysaccharides from Campylobacter jejuni associated with Guillain-Barr&eacute; syndrome patients mimic human gangliosides in structure. Infect Immun 1994; 62:2122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40038/abstract/14\">",
"      Yuki N, Susuki K, Koga M, et al. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome. Proc Natl Acad Sci U S A 2004; 101:11404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40038/abstract/15\">",
"      Yuki N, Yamada M, Koga M, et al. Animal model of axonal Guillain-Barr&eacute; syndrome induced by sensitization with GM1 ganglioside. Ann Neurol 2001; 49:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40038/abstract/16\">",
"      Yuki N, Kuwabara S. Axonal Guillain-Barr&eacute; syndrome: carbohydrate mimicry and pathophysiology. J Peripher Nerv Syst 2007; 12:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40038/abstract/17\">",
"      Halstead SK, Zitman FM, Humphreys PD, et al. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain 2008; 131:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40038/abstract/18\">",
"      Rees JH, Soudain SE, Gregson NA, Hughes RA. Campylobacter jejuni infection and Guillain-Barr&eacute; syndrome. N Engl J Med 1995; 333:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40038/abstract/19\">",
"      Visser LH, Van der Mech&eacute; FG, Van Doorn PA, et al. Guillain-Barr&eacute; syndrome without sensory loss (acute motor neuropathy). A subgroup with specific clinical, electrodiagnostic and laboratory features. Dutch Guillain-Barr&eacute; Study Group. Brain 1995; 118 ( Pt 4):841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40038/abstract/20\">",
"      Griffin JW, Li CY, Ho TW, et al. Pathology of the motor-sensory axonal Guillain-Barr&eacute; syndrome. Ann Neurol 1996; 39:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40038/abstract/21\">",
"      McCarthy N, Giesecke J. Incidence of Guillain-Barr&eacute; syndrome following infection with Campylobacter jejuni. Am J Epidemiol 2001; 153:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40038/abstract/22\">",
"      Lastovica AJ, Goddard EA, Argent AC. Guillain-Barr&eacute; syndrome in South Africa associated with Campylobacter jejuni O:41 strains. J Infect Dis 1997; 176 Suppl 2:S139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40038/abstract/23\">",
"      Nishimura M, Nukina M, Kuroki S, et al. Characterization of Campylobacter jejuni isolates from patients with Guillain-Barr&eacute; syndrome. J Neurol Sci 1997; 153:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40038/abstract/24\">",
"      Brannagan TH 3rd, Zhou Y. HIV-associated Guillain-Barr&eacute; syndrome. J Neurol Sci 2003; 208:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40038/abstract/25\">",
"      Piliero PJ, Fish DG, Preston S, et al. Guillain-Barr&eacute; syndrome associated with immune reconstitution. Clin Infect Dis 2003; 36:e111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40038/abstract/26\">",
"      Winer JB, Hughes RA, Anderson MJ, et al. A prospective study of acute idiopathic neuropathy. II. Antecedent events. J Neurol Neurosurg Psychiatry 1988; 51:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40038/abstract/27\">",
"      Steininger C, Popow-Kraupp T, Seiser A, et al. Presence of cytomegalovirus in cerebrospinal fluid of patients with Guillain-Barre syndrome. J Infect Dis 2004; 189:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40038/abstract/28\">",
"      Orlikowski D, Porcher R, Sivadon-Tardy V, et al. Guillain-Barr&eacute; syndrome following primary cytomegalovirus infection: a prospective cohort study. Clin Infect Dis 2011; 52:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40038/abstract/29\">",
"      Jacobs BC, Rothbarth PH, van der Mech&eacute; FG, et al. The spectrum of antecedent infections in Guillain-Barr&eacute; syndrome: a case-control study. Neurology 1998; 51:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40038/abstract/30\">",
"      Ropper AH. The Guillain-Barr&eacute; syndrome. N Engl J Med 1992; 326:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40038/abstract/31\">",
"      Mori M, Kuwabara S, Miyake M, et al. Haemophilus influenzae infection and Guillain-Barr&eacute; syndrome. Brain 2000; 123 ( Pt 10):2171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40038/abstract/32\">",
"      Tam CC, O'Brien SJ, Rodrigues LC. Influenza, Campylobacter and Mycoplasma infections, and hospital admissions for Guillain-Barr&eacute; syndrome, England. Emerg Infect Dis 2006; 12:1880.",
"     </a>",
"    </li>",
"    <li>",
"     Ropper AH, Wijdicks EFM, Truax BT. Guillain-Barr&eacute; syndrome, FA Davis, Philadelphia 1991. p.57.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40038/abstract/34\">",
"      Shin IS, Baer AN, Kwon HJ, et al. Guillain-Barr&eacute; and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy. Arthritis Rheum 2006; 54:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40038/abstract/35\">",
"      Pritchard J, Appleton R, Howard R, Hughes RA. Guillain-Barr&eacute; syndrome seen in users of isotretinoin. BMJ 2004; 328:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40038/abstract/36\">",
"      Lehmann HC, Hartung HP, Kieseier BC, Hughes RA. Guillain-Barr&eacute; syndrome after exposure to influenza virus. Lancet Infect Dis 2010; 10:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40038/abstract/37\">",
"      Lasky T, Terracciano GJ, Magder L, et al. The Guillain-Barr&eacute; syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med 1998; 339:1797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40038/abstract/38\">",
"      Haber P, DeStefano F, Angulo FJ, et al. Guillain-Barr&eacute; syndrome following influenza vaccination. JAMA 2004; 292:2478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40038/abstract/39\">",
"      Juurlink DN, Stukel TA, Kwong J, et al. Guillain-Barr&eacute; syndrome after influenza vaccination in adults: a population-based study. Arch Intern Med 2006; 166:2217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40038/abstract/40\">",
"      Dieleman J, Romio S, Johansen K, et al. Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe. BMJ 2011; 343:d3908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40038/abstract/41\">",
"      De Wals P, Deceuninck G, Toth E, et al. Risk of Guillain-Barr&eacute; syndrome following H1N1 influenza vaccination in Quebec. JAMA 2012; 308:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40038/abstract/42\">",
"      Baxter R, Lewis N, Bakshi N, et al. Recurrent Guillain-Barre syndrome following vaccination. Clin Infect Dis 2012; 54:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40038/abstract/43\">",
"      Hughes RA, Charlton J, Latinovic R, Gulliford MC. No association between immunization and Guillain-Barr&eacute; syndrome in the United Kingdom, 1992 to 2000. Arch Intern Med 2006; 166:1301.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5141 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-C08C8C0CB4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_6_40038=[""].join("\n");
var outline_f39_6_40038=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Molecular mimicry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Antecedent events",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Campylobacter",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - HIV",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Other infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Other triggering events",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Vaccination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Influenza vaccination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Meningococcal vaccination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Others",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/22/5481?source=related_link\">",
"      Clinical features and diagnosis of Guillain-Barr&eacute; syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23050?source=related_link\">",
"      Meningococcal vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/37/37457?source=related_link\">",
"      Patient information: Guillain-Barr&eacute; syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/16/265?source=related_link\">",
"      Treatment and prognosis of Guillain-Barr&eacute; syndrome in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_6_40039="Nipple inversion";
var content_f39_6_40039=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nipple inversion",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/6/40039/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/6/40039/contributors\">",
"     Brigid Killelea, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/6/40039/contributors\">",
"     Michelle Sowden, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/6/40039/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/6/40039/contributors\">",
"     Anees B Chagpar, MD, MSc, MA, MPH, FACS, FRCS(C)",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/6/40039/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/6/40039/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/6/40039/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H14508206\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nipple is the central projection in the areola. When the nipple is pulled in and points inward instead of out, it is termed nipple inversion or retraction. Nipple inversion can affect one breast or both, and can be congenital or acquired. Acquired nipple inversion can be due to benign or malignant causes. Benign nipple inversion is usually a gradual process, occurring over a few years. When nipple inversion occurs rapidly, the underlying cause can be inflammation, postsurgical changes, or an underlying malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40039/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The evaluation and management of nipple inversion will be reviewed here. Nipple discharge, common breast problems, and the diagnostic evaluation of a suspected breast cancer are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/23/3449?source=see_link\">",
"     \"Nipple discharge\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/15/24825?source=see_link\">",
"     \"Breast masses and other common breast problems\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/36/24138?source=see_link\">",
"     \"Diagnostic evaluation of women with suspected breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13131663\">",
"    <span class=\"h1\">",
"     NIPPLE DEVELOPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The breast and nipple begin to form during the second month of gestation from lines of thickened ectoderm running from the axilla to the groin (",
"    <a class=\"graphic graphic_figure graphicRef61921 \" href=\"mobipreview.htm?4/39/4720\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40039/abstract/2\">",
"     2",
"    </a>",
"    ]. The nipple is initially an epidermal pit and eventually everts as the fetus nears gestation. An inverted nipple may represent a failure of this eversion during development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40039/abstract/2\">",
"     2",
"    </a>",
"    ]. Breast development and Tanner staging are depicted in the figure and are discussed in detail elsewhere (",
"    <a class=\"graphic graphic_picture graphicRef72038 \" href=\"mobipreview.htm?10/43/10932\">",
"     picture 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/10/20649?source=see_link\">",
"     \"Breast development and morphology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The color of the nipple and areola is initially imparted by blood vessels coursing near the skin. Melanin is deposited in the basal cells as part of the aging process, thereby darkening the nipple-areolar complex [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40039/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13131670\">",
"    <span class=\"h1\">",
"     NIPPLE ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal nipple projects from the central area of the areola (",
"    <a class=\"graphic graphic_figure graphicRef53212 \" href=\"mobipreview.htm?36/26/37280\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef64544 \" href=\"mobipreview.htm?27/7/27774\">",
"     figure 3",
"    </a>",
"    ). The darkly pigmented areola, located in the center of the breast, contains dense collagen fibers and a thin layer of contractile muscle. While there is significant variation in color, shape, size, and projection of the nipple-areola complex, a study of morphologic characteristics in 300 women reported a mean nipple height of 0.9 cm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40039/abstract/3\">",
"     3",
"    </a>",
"    ]. Differences in nipple projection can be affected by age, race, weight, and hormonal changes.",
"   </p>",
"   <p>",
"    In the normal nipple, areolar muscle contraction results in nipple projection. Nipple inversion occurs when the contractile forces of the areolar muscles are unable to overcome tension between the central ducts and the skin of the nipple.",
"   </p>",
"   <p>",
"    On the surface of the nipple, approximately five to nine central ductal orifices extend posteriorly toward the pectoralis muscle. A smaller number of ducts originate within the areola itself. Below the level of the areolar skin, the ducts of the central bundle taper down to a narrowed area or &ldquo;waist&rdquo; at the level of the superficial fascia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40039/abstract/4\">",
"     4",
"    </a>",
"    ]. Each orifice communicates with a separate ductal system of the breast, and connects to terminal duct lobular units within the breast parenchyma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40039/abstract/5\">",
"     5",
"    </a>",
"    ]. During lactation, milk produced in the terminal duct lobular units travels through lactiferous ducts and sinuses and is ejected from ductal orifices in the nipple papilla as shown in the figure (",
"    <a class=\"graphic graphic_figure graphicRef71740 \" href=\"mobipreview.htm?14/3/14394\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The vascular supply to the breast is derived from the external mammary artery, cutaneous perforators of the internal mammary and fourth and fifth intercostal arteries, and musculocutaneous perforators of the thoracoacromial artery. The vascular supply to the nipple areolar complex is derived from branches of the internal mammary artery, with contributions from branches of both the anterior intercostal arteries and the lateral thoracic artery. These branches travel in the subcutaneous tissue and communicate transversely above and below the areola. Branches from the communicating vessels above and below the areola run toward the base of the nipple and give off smaller vessels to the areolar skin in a circular distribution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40039/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14508220\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classification of nipple inversion is based upon appearance, whether the nipple can be pulled out manually, and how well projection is maintained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31853443\">",
"    <span class=\"h2\">",
"     Nipple retraction versus nipple inversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the terms &ldquo;nipple inversion&rdquo; and &ldquo;nipple retraction&rdquo; are often used interchangeably, there is a distinct difference [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40039/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nipple retraction occurs when only a part of the nipple is drawn in because it is tethered by a single duct, resulting in a slit-like appearance (",
"      <a class=\"graphic graphic_picture graphicRef75440 \" href=\"mobipreview.htm?6/9/6303\">",
"       picture 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Nipple inversion occurs when the entire nipple is pulled in.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31853515\">",
"    <span class=\"h2\">",
"     Umbilicated versus invaginated nipples",
"    </span>",
"    &nbsp;&mdash;&nbsp;Umbilicated nipples can be pulled out from beneath the alveolar surface without maximal force, while invaginated nipples cannot be extracted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40039/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31853508\">",
"    <span class=\"h2\">",
"     Grading system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical grading system for nipple inversion is based upon how difficult it is to pull the nipple out manually and how well projection is subsequently maintained [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40039/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Grade I &ndash; The nipple is easily pulled out with gentle squeezing of the areolar skin. Nipple projection is well maintained for several minutes but then the nipple reverts to an inverted state (",
"      <a class=\"graphic graphic_picture graphicRef51390 \" href=\"mobipreview.htm?35/49/36639\">",
"       picture 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Grade II &ndash; Forceful manipulation is required to pull the nipple out, and inversion recurs quickly as shown in the figure (",
"      <a class=\"graphic graphic_picture graphicRef64187 \" href=\"mobipreview.htm?33/33/34323\">",
"       picture 4",
"      </a>",
"      ). The majority of patients with nipple inversion have grade II inversion.",
"     </li>",
"     <li>",
"      Grade III &ndash; There is no projection of the nipple and the papilla is buried below the level of the skin. Despite maximal manipulation, the nipple cannot be pulled out and is described as invaginated (",
"      <a class=\"graphic graphic_picture graphicRef76984 \" href=\"mobipreview.htm?4/33/4639\">",
"       picture 5",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40039/abstract/11,12\">",
"       11,12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14509235\">",
"    <span class=\"h1\">",
"     CONGENITAL NIPPLE INVERSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A congenitally inverted nipple is present in approximately 3 percent of women ages 19 to 26 without a history of infection, inflammation, trauma, tumor, periareolar surgery, or pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40039/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. Congenital nipple inversion is benign and usually bilateral (87 percent of cases in one report) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40039/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cause of congenital nipple inversion is a failure of the underlying mesenchymal tissue to proliferate and project the nipple papilla outward [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40039/abstract/11\">",
"     11",
"    </a>",
"    ]. In the majority of cases, the inverted nipple is umbilicated (96 percent) rather than invaginated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40039/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5417448\">",
"    <span class=\"h2\">",
"     Genetic disorders associated with nipple inversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;While most cases of congenital inverted nipples are sporadic, some are associated with inherited genetic disorders:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Chromosome 2q37 deletion",
"      </strong>",
"      &ndash; Terminal deletions of chromosome 2 with breakpoints at or within band 2q37 results in mild to moderate mental retardation, a degree of autism, prominent forehead, deficient nasal alae, thin upper lip, and abnormal nipples, including inverted nipples [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40039/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Ulnar mammary syndrome",
"      </strong>",
"      &ndash; Ulnar mammary syndrome is a rare pleiotropic autosomal dominant disorder resulting from a loss of critical levels of a T-box gene called TBX3. T-box genes encode for a family of developmental transcription factors. Ulnar mammary syndrome is characterized by ulnar defects, mammary and apocrine gland hypoplasia, inverted nipples, genital abnormalities, and short stature [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40039/abstract/15,16\">",
"       15,16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Congenital disorders of glycosylation",
"      </strong>",
"      &ndash; Nipple inversion may result from congenital disorders of glycosylation (CDG). CDG delineates a number of inherited disorders characterized by defective glycoprotein biosynthesis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40039/abstract/17\">",
"       17",
"      </a>",
"      ]. CDG-1a is the most common deficiency in this heterogeneous group of autosomal recessive disorders. This defect is associated with inverted nipples, abnormal distribution of fat, and dysmorphic facial features.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14508235\">",
"    <span class=\"h1\">",
"     ACQUIRED NIPPLE INVERSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquired nipple inversion can be a result of inflammation, malignancy, or surgery. Each of these is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H456919971\">",
"    <span class=\"h2\">",
"     Inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nipple inversion is commonly associated with mammary duct-associated inflammatory disease sequence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40039/abstract/18\">",
"     18",
"    </a>",
"    ]. This disorder is a progression of inflammatory changes from normal breast ducts to duct ectasia, followed by periductal mastitis, subareolar abscess, and periareolar fistula formation. Chronic inflammation of the duct wall and periductal tissue may be sterile or bacterial, and can lead to subsequent fibrosis of the duct wall and nipple inversion.",
"   </p>",
"   <p>",
"    The etiology of ductal inflammation is unclear, although a number of hypotheses have been proposed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40039/abstract/19-23\">",
"     19-23",
"    </a>",
"    ]. However, no single mechanism clearly explains the pathogenesis of ductal inflammation, and a number of processes probably occur independently or together and are modified by age, anatomy, and smoking history [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40039/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14509242\">",
"    <span class=\"h3\">",
"     Duct ectasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nipple inversion associated with duct ectasia usually involves the nipple but not the areola, as shown in the figure (",
"    <a class=\"graphic graphic_picture graphicRef57055 \" href=\"mobipreview.htm?20/28/20928\">",
"     picture 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40039/abstract/21\">",
"     21",
"    </a>",
"    ]. The nipples are usually easily everted. In contrast, nipple inversion from a carcinoma tends to distort the areola when the breast is examined in different positions. Duct ectasia presents with a longstanding history of bilateral symmetrical central nipple inversion and a creamy or greenish nipple discharge. Progressive inflammatory changes are associated with noncyclical mastalgia, a subareolar breast mass, and localized infection",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fistula. Duct ectasia is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/53/857?source=see_link&amp;anchor=H8#H8\">",
"     \"Erythematous disorders of the breast\", section on 'Noninfectious mastitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H561448155\">",
"    <span class=\"h3\">",
"     Periductal mastitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periductal mastitis is an inflammatory condition of the subareolar ducts. The majority of patients who develop periductal mastitis are smokers. It is likely that smoking leads to damage of the subareolar ducts with subsequent tissue necrosis and later infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40039/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Details of the management of periductal mastitis are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/53/857?source=see_link&amp;anchor=H10#H10\">",
"     \"Erythematous disorders of the breast\", section on 'Periductal mastitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14508251\">",
"    <span class=\"h3\">",
"     Subareolar abscess and periareolar fistula",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nipple inversion can be associated with subareolar abscess and fistula formation. In a study of 60 patients with recurrent abscesses, nipple inversion was noted in 8 percent of patients after their first abscess, in 22 percent with recurrent disease, and 47 percent with a fistula [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40039/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/53/857?source=see_link&amp;anchor=H8#H8\">",
"     \"Erythematous disorders of the breast\", section on 'Noninfectious mastitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14508258\">",
"    <span class=\"h3\">",
"     Tuberculous mastitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of tuberculosis (TB) of the breast is usually with a solitary, ill-defined, unilateral hard mass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40039/abstract/27\">",
"     27",
"    </a>",
"    ]. TB can also present with nipple inversion, discharging sinuses in the breast or axilla, skin thickening, or a decrease in breast size (",
"    <a class=\"graphic graphic_picture graphicRef68120 \" href=\"mobipreview.htm?18/53/19280\">",
"     picture 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40039/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/53/857?source=see_link&amp;anchor=H6#H6\">",
"     \"Erythematous disorders of the breast\", section on 'Tuberculous mastitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14508265\">",
"    <span class=\"h3\">",
"     Other inflammatory causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periductal fibrosis can develop from inflammation due to fat necrosis, thrombophlebitis of the thoracoepigastric vein (Mondor's disease), or idiopathic granulomatous mastitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/52/11081?source=see_link&amp;anchor=H21#H21\">",
"     \"Overview of benign breast disease\", section on 'Fat necrosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/53/857?source=see_link&amp;anchor=H18#H18\">",
"     \"Erythematous disorders of the breast\", section on 'Idiopathic granulomatous mastitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14508272\">",
"    <span class=\"h2\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nipple inversion can occur with subareolar or central malignancies. The incidence of associated malignancy in patients with acquired nipple inversion ranges from 5 to 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40039/abstract/29\">",
"     29",
"    </a>",
"    ]. Nipple inversion associated with a malignancy tends to be asymmetric and distorts the areola as shown in the figure (",
"    <a class=\"graphic graphic_picture graphicRef69802 \" href=\"mobipreview.htm?34/14/35043\">",
"     picture 8",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A complete breast examination and radiologic evaluation with mammogram and ultrasound should be performed to look for the underlying cause. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39482?source=see_link\">",
"     \"Breast imaging: Mammography and ultrasonography\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/36/24138?source=see_link\">",
"     \"Diagnostic evaluation of women with suspected breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with a centrally located tumor and associated nipple inversion are eligible for breast conservation therapy. The 10-year actuarial survival, distant disease-free survival, and breast recurrence-free survival for central tumors are not significantly different from patients who present with breast cancer elsewhere in the breast [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40039/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/42/31402?source=see_link&amp;anchor=H8#H8\">",
"     \"Breast conserving therapy\", section on 'Selection criteria for BCT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14508279\">",
"    <span class=\"h2\">",
"     Postoperative nipple inversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative inversion of the nipple can occur after reduction mammoplasty or a breast biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40039/abstract/33\">",
"     33",
"    </a>",
"    ]. The breast may pull on the nipple-areola complex leading to inversion, particularly if the nipple was inverted or flat initially (",
"    <a class=\"graphic graphic_picture graphicRef78443 \" href=\"mobipreview.htm?28/54/29550\">",
"     picture 9",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14508286\">",
"    <span class=\"h1\">",
"     ASSESSMENT OF NIPPLE INVERSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough evaluation is required for new onset acquired nipple inversion. This work-up should include physical exam, imaging, and biopsy of any suspicious findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14509263\">",
"    <span class=\"h2\">",
"     Mammogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquired nipple inversion in an adult woman requires evaluation by physical examination and imaging studies, starting with diagnostic mammography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40039/abstract/34\">",
"     34",
"    </a>",
"    ]. Retroareolar breast cancers, within 2 cm of the nipple areolar complex, are most likely to be associated with nipple inversion as shown in the radiograph (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54436 \" href=\"mobipreview.htm?40/40/41600\">",
"     image 1",
"    </a>",
"    ). However, retroareolar breast cancers are more difficult to identify with mammography than tumors elsewhere in the breast due to dense retroareolar tissue. It is important that the radiologist is informed that the patient has inverted nipples because the nipple can be erroneously identified as a subareolar mass. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39482?source=see_link&amp;anchor=H27#H27\">",
"     \"Breast imaging: Mammography and ultrasonography\", section on 'Diagnostic mammogram'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14508294\">",
"    <span class=\"h2\">",
"     Ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound is a useful adjunct to mammography in the evaluation of nipple inversion and may identify a retroareolar mass that is not visible on mammography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40039/abstract/35\">",
"     35",
"    </a>",
"    ]. The use of a standoff pad moves the focal zone of the ultrasound beam by 1.5 cm and improves the detectability of a retroareolar mass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40039/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39482?source=see_link&amp;anchor=H29#H29\">",
"     \"Breast imaging: Mammography and ultrasonography\", section on 'Role of ultrasound'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14508301\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging (MRI)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contrast-enhanced MRI would not be part of the usual evaluation of nipple inversion, but may be useful when mammographic and sonographic findings are inconclusive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40039/abstract/1,36\">",
"     1,36",
"    </a>",
"    ].",
"    <sup>",
"    </sup>",
"    Breast MRI can differentiate tumor confined to the retroareolar location from the nipple areolar complex.",
"   </p>",
"   <p>",
"    The normal appearance of the nipple on MRI consists of a &ldquo;two-layered&rdquo; effect with an intense 1 to 2 mm enhancement of the superficial layer and a nonenhancing layer deep to this zone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40039/abstract/37\">",
"     37",
"    </a>",
"    ]. The nipple with tumor involvement shows increased thickening and enhancement of the nipple-areolar complex and the retroareolar tissue with disruption of the &ldquo;two-layered&rdquo; rim. Comparing the morphology and enhancement pattern in the nipple pairs is important, since normal nipples have a symmetrical enhancement. False positive retroareolar enhancement may be induced by benign inflammation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/29/23002?source=see_link\">",
"     \"MRI of the breast and emerging technologies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H669739542\">",
"    <span class=\"h2\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nipple inversion and carcinoma are both common and can coexist. Thus, management of new nipple inversion should include a careful physical examination as well as mammography and ultrasound. Any suspicious abnormality should prompt a biopsy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/59/24504?source=see_link\">",
"     \"Breast biopsy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/36/24138?source=see_link\">",
"     \"Diagnostic evaluation of women with suspected breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14508308\">",
"    <span class=\"h1\">",
"     SURGICAL CORRECTION OF BENIGN NIPPLE INVERSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the majority of patients with nipple inversion have benign disease, some may wish to have correction of their inversion for cosmetic reasons. For many women, inverted nipples can be a source of aesthetic and functional concern, leading to self-consciousness and psychological distress.",
"   </p>",
"   <p>",
"    The goal of surgical correction is to restore projection while maintaining the ductal anatomy as much as possible. Several techniques for surgical correction have been described:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31853240\">",
"    <span class=\"h2\">",
"     Purse-string",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the simplest techniques described is a purse-string suture which is placed around the neck of the nipple through a periareolar incision at the 6 o&rsquo;clock position [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40039/abstract/10\">",
"     10",
"    </a>",
"    ]. This technique tightens the neck of the nipple, and works well for those with less severe cases of nipple inversion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31853248\">",
"    <span class=\"h2\">",
"     Selective ductal division",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selective division of ducts that restrict nipple projection involves blunt dissection through vertical spreading of fibrous tissue parallel to the lactiferous ducts through an inferior periareolar incision. The vertical dissection under the nipple is followed by two internal sutures, one from the 12 o&rsquo;clock to the 6 o&rsquo;clock positions and one from the 3 o&rsquo;clock to the 9 o&rsquo;clock positions, to reduce dead space and stabilize the nipple base [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40039/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The repair is completed by placing the nipple on traction for two to five days with a stent. The stent consisted of a nylon suture placed through the skin of the nipple and affixed to a specimen cup over the nipple areolar complex to maintain traction. In an observational series of 21 patients who underwent selective ductal division, there was no recurrence of nipple inversion at one year follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40039/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31853262\">",
"    <span class=\"h2\">",
"     Endoscope assisted ductal division",
"    </span>",
"    &nbsp;&mdash;&nbsp;An endoscope can be used as an adjunct for surgical correction of nipple inversion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40039/abstract/39\">",
"     39",
"    </a>",
"    ]. For this technique, a small incision is made at the 6 o&rsquo;clock position and a 4 mm 30 degree endoscope is advanced to better differentiate between subcutaneous normal ducts, contracted ducts, fibrous band, vessels and nerves. With improved visualization, normal ducts can be preserved while successfully dividing fibrous bands and retracted ducts. In an observational series of 23 such procedures, the nipples were judged to have an excellent result and there were no changes in sensation reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40039/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31853272\">",
"    <span class=\"h2\">",
"     Skin flaps",
"    </span>",
"    &nbsp;&mdash;&nbsp;Triangular skin flaps can be mobilized to add bulk to the base of the nipple, and, when closed, tighten the neck of the nipple. Another technique is to use two broad triangular, areolar skin flaps on opposite ends of the nipple [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40039/abstract/40\">",
"     40",
"    </a>",
"    ]. The restricting subareolar fibrous bands",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ducts are released and the flaps are then advanced through a tunnel beneath the nipple to fill dead space created by the dissection. The tip of each flap is fixed with the base of the other flap, and the tissue is reapproximated to tighten the nipple neck. In their series of 14 cases, there were no recurrences at follow-up ranging from 3 to 18 months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20903931\">",
"    <span class=\"h2\">",
"     Percutaneous release",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous release of nipple inversion can be accomplished with a wire subcision technique or with a simple minimally invasive technique using a needle tip for lysis of retracted ducts:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31853296\">",
"    <span class=\"h3\">",
"     Wire subcision",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subcision releases the dermis from the tissue below. In the wire subcision technique, entry and exit points are created at the 6 and 12 o&rsquo;clock positions with the introduction of a wire scalpel (Diamond wire scalpel, Innovative Med, Inc., Irvine, CA) after placing the nipple on traction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40039/abstract/41\">",
"     41",
"    </a>",
"    ]. The wire scalpel is inserted inferiorly, and directed around retracted tissue to exit superiorly at 12 o&rsquo;clock. A second wire is placed through the same sites. By pulling the two ends back and forth, tethered tissue between the two wires is divided. The wires are removed and a horizontal mattress suture with 4-0 chromic is placed to maintain the everted nipple in position [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40039/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31853308\">",
"    <span class=\"h3\">",
"     Needle tip lysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Needle tip lysis is a simple minimally invasive technique for lysis of retracted ducts. For this technique an 18-gauge needle tip is inserted at the 6 o&rsquo;clock position and used to lyse fibrous tissue and tethered glands until satisfactory nipple projection has been achieved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40039/abstract/42\">",
"     42",
"    </a>",
"    ]. Following this, a monofilament purse string suture is placed, starting at the entry site, with entry and exit through the same stitch point every 3 to 5 mm around the nipple base. The suture is then tied under moderate tension. In a series of 58 inverted nipples in 31 patients, there were 13 recurrences, of which 11 were successfully treated with a second purse-string suture and two required a third procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40039/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14508315\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The nipple is the central projection in the areola. When the nipple is pulled in and points inward instead of out, it is termed nipple inversion or retraction. Nipple inversion can affect one breast or both, and can be congenital or acquired. (See",
"      <a class=\"local\" href=\"#H14508206\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical grading system for nipple inversion is based on how difficult it is to pull the nipple out manually and how well projection is subsequently maintained. (See",
"      <a class=\"local\" href=\"#H14508220\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Congenital nipple inversion is benign and usually bilateral. The cause of congenital nipple inversion is a failure of the underlying mesenchymal tissue to proliferate and project the nipple papilla outward. (See",
"      <a class=\"local\" href=\"#H14509235\">",
"       'Congenital nipple inversion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acquired nipple inversion can be a result of inflammation, malignancy, or surgery. (See",
"      <a class=\"local\" href=\"#H14508235\">",
"       'Acquired nipple inversion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A thorough evaluation is required for new onset of acquired nipple inversion. This work-up should include physical exam, imaging, and biopsy of any suspicious findings. (See",
"      <a class=\"local\" href=\"#H14508286\">",
"       'Assessment of nipple inversion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women with benign disease may wish to have correction of their inversion for cosmetic reasons. For many women, inverted nipples can be a source of aesthetic and functional concern, leading to self-consciousness and psychological distress. The goal of surgical correction is to restore projection while maintaining the ductal anatomy as much as possible. (See",
"      <a class=\"local\" href=\"#H14508308\">",
"       'Surgical correction of benign nipple inversion'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H450792681\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Baiba Grube, who contributed to an earlier version of this topic review",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40039/abstract/1\">",
"      Da Costa D, Taddese A, Cure ML, et al. Common and unusual diseases of the nipple-areolar complex. Radiographics 2007; 27 Suppl 1:S65.",
"     </a>",
"    </li>",
"    <li>",
"     Skandalakis JE, Skandalakis PN, Weidman TA, Skandalakis LJ. Breast. In: Skandalakis' Surgical Anatomy, Skandalakis JE, Weidman TA, Foster RS Jr, et al (Eds), McGraw Hill, New York 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40039/abstract/3\">",
"      Sanuki J, Fukuma E, Uchida Y. Morphologic study of nipple-areola complex in 600 breasts. Aesthetic Plast Surg 2009; 33:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40039/abstract/4\">",
"      Rusby JE, Brachtel EF, Michaelson JS, et al. Breast duct anatomy in the human nipple: three-dimensional patterns and clinical implications. Breast Cancer Res Treat 2007; 106:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40039/abstract/5\">",
"      Love SM, Barsky SH. Anatomy of the nipple and breast ducts revisited. Cancer 2004; 101:1947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40039/abstract/6\">",
"      Nakajima H, Imanishi N, Aiso S. Arterial anatomy of the nipple-areola complex. Plast Reconstr Surg 1995; 96:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40039/abstract/7\">",
"      van Deventer PV. The blood supply to the nipple-areola complex of the human mammary gland. Aesthetic Plast Surg 2004; 28:393.",
"     </a>",
"    </li>",
"    <li>",
"     Dixon JM. Management of disorders of the ductal system and infections. In: Diseases of the Breast, Harris LM (Ed), Lippincott, Williams and Wilkins, Philadelphia 2007. p.46.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40039/abstract/9\">",
"      Nicholson BT, Harvey JA, Cohen MA. Nipple-areolar complex: normal anatomy and benign and malignant processes. Radiographics 2009; 29:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40039/abstract/10\">",
"      Han S, Hong YG. The inverted nipple: its grading and surgical correction. Plast Reconstr Surg 1999; 104:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40039/abstract/11\">",
"      Schwager RG, Smith JW, Gray GF, Goulian D Jr. Inversion of the human female nipple, with a simple method of treatment. Plast Reconstr Surg 1974; 54:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40039/abstract/12\">",
"      Crestinu JM. The correction of inverted nipples without scars: 17 Years' experience, 452 operations. Aesthetic Plast Surg 2000; 24:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40039/abstract/13\">",
"      Park HS, Yoon CH, Kim HJ. The prevalence of congenital inverted nipple. Aesthetic Plast Surg 1999; 23:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40039/abstract/14\">",
"      Falk RE, Casas KA. Chromosome 2q37 deletion: clinical and molecular aspects. Am J Med Genet C Semin Med Genet 2007; 145C:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40039/abstract/15\">",
"      Linden H, Williams R, King J, et al. Ulnar mammary sundrome and TX3: Expanding the phenotype. Am J Med Genet 2009; 149A:2809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40039/abstract/16\">",
"      Rowley M, Grothey E, Couch FJ. The role of Tbx2 and Tbx3 in mammary development and tumorigenesis. J Mammary Gland Biol Neoplasia 2004; 9:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40039/abstract/17\">",
"      Aronica E, van Kempen AA, van der Heide M, et al. Congenital disorder of glycosylation type Ia: a clinicopathological report of a newborn infant with cerebellar pathology. Acta Neuropathol 2005; 109:433.",
"     </a>",
"    </li>",
"    <li>",
"     Meguid M, Kort K, Numann P, Oler A. Subareolar breast abscess: the penultimate stage of the mammary duct-associated inflammatory disease sequence. In: The Breast, 4th edition, Bland K, Copeland III E (Eds), Elsevier, Philadelphia 2009. Vol 1, p.107.",
"    </li>",
"    <li>",
"     Mansel R, Webster D, Sweetland H. The duct ectasia/periductal mastitis complex. In: Hughes Mansel &amp; Webster's Benign Disorders and Diseases of the Breast, 3rd edition, Mnansel R, Webster D, Sweetland H (Eds), Saunders, China 2009. p.163.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40039/abstract/20\">",
"      HAAGENSEN CD. Mammary-duct ectasia; a disease that may simulate carcinoma. Cancer 1951; 4:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40039/abstract/21\">",
"      Rees BI, Gravelle IH, Hughes LE. Nipple retraction in duct ectasia. Br J Surg 1977; 64:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40039/abstract/22\">",
"      Dixon JM. Periductal mastitis/duct ectasia. World J Surg 1989; 13:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40039/abstract/23\">",
"      TEDESCHI LG, OUZOUNIAN G, BYRNE JJ. The role of ductal obstruction and hormonal stimulation in mammary duct ectasia. Surg Gynecol Obstet 1962; 114:741.",
"     </a>",
"    </li>",
"    <li>",
"     Dixon JM. Breast infection. In: ABC of Breast Diseases, Dixon JM (Ed), Blackwell Publishing, Oxford 2006. p.19.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40039/abstract/25\">",
"      Dixon JM, Ravisekar O, Chetty U, Anderson TJ. Periductal mastitis and duct ectasia: different conditions with different aetiologies. Br J Surg 1996; 83:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40039/abstract/26\">",
"      Sch&auml;fer P, F&uuml;rrer C, Mermillod B. An association of cigarette smoking with recurrent subareolar breast abscess. Int J Epidemiol 1988; 17:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40039/abstract/27\">",
"      Baharoon S. Tuberculosis of the breast. Ann Thorac Med 2008; 3:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40039/abstract/28\">",
"      Makanjuola D, Murshid K, Al Sulaimani S, Al Saleh M. Mammographic features of breast tuberculosis: the skin bulge and sinus tract sign. Clin Radiol 1996; 51:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40039/abstract/29\">",
"      Neville EM, Freeman AH, Adiseshiah M. Clinical significance of recent inversion of the nipple: a reappraisal. J R Soc Med 1982; 75:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40039/abstract/30\">",
"      Haffty BG, Wilson LD, Smith R, et al. Subareolar breast cancer: long-term results with conservative surgery and radiation therapy. Int J Radiat Oncol Biol Phys 1995; 33:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40039/abstract/31\">",
"      Fowble B, Solin LJ, Schultz DJ, Weiss MC. Breast recurrence and survival related to primary tumor location in patients undergoing conservative surgery and radiation for early-stage breast cancer. Int J Radiat Oncol Biol Phys 1992; 23:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40039/abstract/32\">",
"      Dale PS, Giuliano AE. Nipple-areolar preservation during breast-conserving therapy for subareolar breast carcinomas. Arch Surg 1996; 131:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40039/abstract/33\">",
"      Hinderer UT, del Rio JL. Treatment of the postoperative inverted nipple with or without asymmetry of the areola. Aesthetic Plast Surg 1983; 7:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40039/abstract/34\">",
"      Kalbhen CL, Kezdi-Rogus PC, Dowling MP, Flisak ME. Mammography in the evaluation of nipple inversion. AJR Am J Roentgenol 1998; 170:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40039/abstract/35\">",
"      Giess CS, Keating DM, Osborne MP, et al. Retroareolar breast carcinoma: clinical, imaging, and histopathologic features. Radiology 1998; 207:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40039/abstract/36\">",
"      An HY, Kim KS, Yu IK, et al. Image presentation. The nipple-areolar complex: a pictorial review of common and uncommon conditions. J Ultrasound Med 2010; 29:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40039/abstract/37\">",
"      Friedman EP, Hall-Craggs MA, Mumtaz H, Schneidau A. Breast MR and the appearance of the normal and abnormal nipple. Clin Radiol 1997; 52:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40039/abstract/38\">",
"      Stevens WG, Fellows DR, Vath SD, Stoker DA. An integrated approach to the repair of inverted nipples. Aesthet Surg J 2004; 24:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40039/abstract/39\">",
"      Chen SH, Gedebou T, Chen PH. The endoscope as an adjunct to correction of nipple inversion deformity. Plast Reconstr Surg 2007; 119:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40039/abstract/40\">",
"      Wu HL, Huang X, Zheng SS. A new procedure for correction of severe inverted nipple with two triangular areolar dermofibrous flaps. Aesthetic Plast Surg 2008; 32:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40039/abstract/41\">",
"      Szczerba SM, Paulius KL, Nadimi S, Maguina P. Wire subcision as a treatment for nipple inversion. Plast Reconstr Surg 2009; 123:206e.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40039/abstract/42\">",
"      Kolker AR, Torina PJ. Minimally invasive correction of inverted nipples: a safe and simple technique for reliable, sustainable projection. Ann Plast Surg 2009; 62:549.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14974 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-218.28.111.102-5CC63B1F68-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_6_40039=[""].join("\n");
var outline_f39_6_40039=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14508315\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14508206\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13131663\">",
"      NIPPLE DEVELOPMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13131670\">",
"      NIPPLE ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14508220\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31853443\">",
"      Nipple retraction versus nipple inversion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31853515\">",
"      Umbilicated versus invaginated nipples",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31853508\">",
"      Grading system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14509235\">",
"      CONGENITAL NIPPLE INVERSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5417448\">",
"      Genetic disorders associated with nipple inversion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14508235\">",
"      ACQUIRED NIPPLE INVERSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H456919971\">",
"      Inflammation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14509242\">",
"      - Duct ectasia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H561448155\">",
"      - Periductal mastitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14508251\">",
"      - Subareolar abscess and periareolar fistula",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14508258\">",
"      - Tuberculous mastitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14508265\">",
"      - Other inflammatory causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14508272\">",
"      Malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14508279\">",
"      Postoperative nipple inversion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14508286\">",
"      ASSESSMENT OF NIPPLE INVERSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14509263\">",
"      Mammogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14508294\">",
"      Ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14508301\">",
"      Magnetic resonance imaging (MRI)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H669739542\">",
"      Biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14508308\">",
"      SURGICAL CORRECTION OF BENIGN NIPPLE INVERSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31853240\">",
"      Purse-string",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31853248\">",
"      Selective ductal division",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31853262\">",
"      Endoscope assisted ductal division",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31853272\">",
"      Skin flaps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20903931\">",
"      Percutaneous release",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31853296\">",
"      - Wire subcision",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31853308\">",
"      - Needle tip lysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14508315\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H450792681\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/14974\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/14974|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?40/40/41600\" title=\"diagnostic image 1\">",
"      Mammogram of nipple inversion associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/14974|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/39/4720\" title=\"figure 1\">",
"      Mammary line",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/26/37280\" title=\"figure 2\">",
"      Anatomy of the breast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?27/7/27774\" title=\"figure 3\">",
"      Anatomy of the nipple",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/3/14394\" title=\"figure 4\">",
"      Changes in the ductal system with aging and reproduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/14974|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/43/10932\" title=\"picture 1\">",
"      Sexual maturity rating of breast development in girls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?6/9/6303\" title=\"picture 2\">",
"      Nipple retraction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/49/36639\" title=\"picture 3\">",
"      Grade I nipple inversion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/33/34323\" title=\"picture 4\">",
"      Grade II nipple inversion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/33/4639\" title=\"picture 5\">",
"      Grade III nipple inversion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/28/20928\" title=\"picture 6\">",
"      Nipple inversion associated with duct ectasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/53/19280\" title=\"picture 7\">",
"      TB breast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?34/14/35043\" title=\"picture 8\">",
"      Nipple inversion associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?28/54/29550\" title=\"picture 9\">",
"      Postoperative nipple inversion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/59/24504?source=related_link\">",
"      Breast biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/42/31402?source=related_link\">",
"      Breast conserving therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/10/20649?source=related_link\">",
"      Breast development and morphology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39482?source=related_link\">",
"      Breast imaging: Mammography and ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/15/24825?source=related_link\">",
"      Breast masses and other common breast problems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/36/24138?source=related_link\">",
"      Diagnostic evaluation of women with suspected breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/53/857?source=related_link\">",
"      Erythematous disorders of the breast",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/29/23002?source=related_link\">",
"      MRI of the breast and emerging technologies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/23/3449?source=related_link\">",
"      Nipple discharge",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/52/11081?source=related_link\">",
"      Overview of benign breast disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_6_40040="Calcium requirements in adolescents";
var content_f39_6_40040=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Calcium requirements in adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/6/40040/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/6/40040/contributors\">",
"     Steven A Abrams, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/6/40040/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/6/40040/contributors\">",
"     Kathleen J Motil, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/6/40040/contributors\">",
"     Amy B Middleman, MD, MPH, MS Ed",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/6/40040/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/6/40040/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/6/40040/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nutritional needs during adolescence are influenced by the onset of puberty, with its associated increased growth rate and changes in body composition. From the preadolescent years to the end of the second decade of life, bone size and bone mass increase rapidly. The accumulation of total bone mineral between the ages of 8 and 18 years is approximately 146 grams per year, with the greatest deposition occurring during puberty [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/1\">",
"     1",
"    </a>",
"    ]. Adequate calcium intake is necessary to maximize peak bone mass and to minimize both the risk of fractures in adolescence and the development of osteoporosis in adulthood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/2-5\">",
"     2-5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BONE GROWTH DURING PUBERTY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several important associations exist between pubertal events, peak height velocity, and bone mineralization. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/25/1434?source=see_link\">",
"     \"Normal puberty\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately one-half of total body calcium is laid down during puberty in females and one-half to two-thirds in males [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/6,7\">",
"       6,7",
"      </a>",
"      ]; by the end of puberty, males have nearly 30 percent more total body calcium than do females [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a longitudinal study, bone width increased before mineral content, which increased before bone density [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/6\">",
"       6",
"      </a>",
"      ]. The changes occurred earlier in girls than in boys, with most of the changes in girls occurring in the 12 months before and after menarche. The increase in bone density during puberty is greater in African-American girls than Caucasian girls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      During the pubertal growth spurt, bone growth outpaces bone mineralization, leading to a relative reduction in bone mineral content. In a longitudinal study, the nadir of bone mineral density coincided with peak height velocity in both boys and girls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/10\">",
"       10",
"      </a>",
"      ]. The same study reported that the incidence of distal radius fractures coincided with the same timepoint, suggesting that the relative paucity of bone mineral density is clinically significant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The peak bone mass attained by approximately age 30 years is the mass from which skeletal loss occurs later in life (",
"    <a class=\"graphic graphic_figure graphicRef77920 \" href=\"mobipreview.htm?37/7/38014\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Genetic factors influence skeletal structure and bone turnover and account for 40 to 80 percent of the differences in peak bone mass. Environmental factors are important during adolescence and are thought to account for 20 percent of the variance in peak bone mass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/11\">",
"     11",
"    </a>",
"    ]. Thus, factors such as adequate dietary calcium and increased weight-bearing activity during adolescence help to maximize peak bone mass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/53/3929?source=see_link\">",
"     \"Pathogenesis of osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CALCIUM HOMEOSTASIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcium homeostasis is a function of dietary intake, intestinal absorption, skeletal accretion and resorption, and urinary excretion. The large demand for bone minerals during adolescence is accompanied by an increase in the fractional absorption of dietary calcium during early puberty in girls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Fractional absorption decreases from its early pubertal peak approximately two to three years after menarche [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During adolescence, increased absorption and decreased excretion of calcium may partially, but not completely, compensate for low dietary intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/18\">",
"     18",
"    </a>",
"    ]. The increase in calcium absorption during adolescence is thought to be mediated by calcitriol (1,25 dihydroxyvitamin D, the most active metabolite of vitamin D), which also increases in concentration during the pubertal growth spurt [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/19\">",
"     19",
"    </a>",
"    ]. Vitamin D fortification of calcium-containing foods enhances intestinal absorption of calcium, whereas naturally occurring oxalate and phytate diminish it (",
"    <a class=\"graphic graphic_table graphicRef52445 \" href=\"mobipreview.htm?34/25/35229\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/15/9462?source=see_link\">",
"     \"Metabolism of vitamin D\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most of the body calcium and much of the phosphate exist as hydroxyapatite, Ca10(PO4)6(OH)2, the main mineral component of bone. Within the plasma, both calcium and phosphate circulate in different forms. Of the plasma calcium, for example, roughly 40 percent is bound to albumin; 10 percent is complexed with citrate, bicarbonate, or phosphate; and 50 percent exists as the physiologically important ionized (or free) calcium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although only a small fraction of the total body calcium and phosphate is located in the plasma, the plasma concentrations of ionized calcium and inorganic phosphate are regulated primarily by parathyroid hormone and vitamin D metabolites, both of which affect intestinal absorption, bone formation and resorption, and urinary excretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/36/2631?source=see_link\">",
"     \"Chapter 6F: Hormonal regulation of calcium and phosphate balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to the effects of parathyroid hormone and vitamin D, bone resorption of calcium is affected by certain medications. Vitamin A and synthetic retinoids increase bone resorption, whereas statins (HMG CoA reductase inhibitors), which are used for the treatment of hypercholesterolemia, can increase bone formation and decrease bone resorption. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/21/9562?source=see_link&amp;anchor=H24#H24\">",
"     \"Drugs that affect bone metabolism\", section on 'Statins'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The primary function of renal excretion of calcium is the maintenance of overall calcium balance, not plasma calcium concentration, which is regulated by changes in bone resorption via the effects of parathyroid hormone and vitamin D. Parathyroid hormone reduces urinary calcium excretion, an appropriate response if hypocalcemia has stimulated parathyroid hormone secretion. On the other hand, renal excretion of calcium is increased by dietary salt and protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/20,24-26\">",
"     20,24-26",
"    </a>",
"    ]. Diuretics also affect calcium excretion, which is increased by loop diuretics and reduced by thiazide diuretics. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/36/2631?source=see_link\">",
"     \"Chapter 6F: Hormonal regulation of calcium and phosphate balance\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/39/19061?source=see_link\">",
"     \"Diuretics and calcium balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CALCIUM REQUIREMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiologic studies have related bone mass or fractures in adolescents and adults to calcium intake during childhood and adolescence. The calcium requirement for adolescents is based upon the assumption that the dietary intake that leads to the greatest level of calcium retention is the intake that will lead to the greatest bone mineralization and will reduce the ultimate risk of fractures and osteoporosis.",
"   </p>",
"   <p>",
"    Markers of mineral status are used to assess the consequences of differing levels of calcium intake and to determine the recommended requirement. The primary markers that have been used to evaluate various levels of calcium intake are measurement of calcium balance (net retention) and bone density [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Calcium balance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because virtually all of the calcium that is retained by children is used to enhance bone mineralization, calcium balance is a useful method to assess calcium requirements. Stable isotopic methods can measure calcium absorption and excretion at various levels of calcium intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data from balance studies suggest that, for most healthy 9- to 18-year-old children, a threshold effect exists, with the maximal net calcium balance being achieved at intakes between 1200 and 1500",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/15,16,27-30\">",
"     15,16,27-30",
"    </a>",
"    ]. The data in these studies are derived from white children; little data are available for other ethnic groups.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One report measured calcium balance in 35 girls with a mean age of 12 who consumed 841 to 2173 mg of calcium per day [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/16\">",
"       16",
"      </a>",
"      ]. Mean maximal calcium retention was 473",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      Intake of 1200",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      the 1989 recommended dietary allowance (RDA) for calcium in adolescents, resulted in a mean calcium retention that was only 57 percent of the maximal value. An intake of 1300 mg per day was the lowest intake that allowed some female adolescents to achieve 100 percent of maximal calcium retention.",
"     </li>",
"     <li>",
"      Another study pooled calcium balances performed on 519 individuals from birth to 30 years of age, derived from 34 published reports [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/27\">",
"       27",
"      </a>",
"      ]. For subjects of all ages, calcium balance was highly correlated with intake at lower intakes and tended to plateau at higher intakes. The threshold at which calcium balance no longer rose with intake exceeded the 1989 RDA for calcium for all the age groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Comparing calcium balance in Caucasian and African-American girls who were on very low (400",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    versus higher calcium intakes (1200 to 1300",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    showed a small adaptation with increased absorption and decreased excretion in girls with low intakes, but this adaptation was not adequate to account for the large gap in intakes. Net calcium balance was much lower in the girls with low intakes. This suggests that intakes &lt;500",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    such as those of up to 20 percent of the US population, may lead to large calcium deficits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another study found that black girls had greater mean calcium retention than did white girls (185 &plusmn; 32",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    difference, P &lt;0.0001) at all calcium intakes studied (760 to 1981 mg",
"    <span class=\"nowrap\">",
"     Ca/day).",
"    </span>",
"    This difference was a result of significantly greater net calcium absorption and lower calcium excretion. Despite this difference in calcium retention, the authors concluded that dietary calcium requirements did not differ with race [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Bone density",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attempts have been made to calculate calcium requirements from measurements of the changes in bone mineral content during puberty. As an example, a cross-sectional study of bone mineral content of 228 children age 9.5 to 19.5 years using dual-energy X-ray absorption (DEXA) found that bone mineral content velocity peaked at age 11.4 in girls and 13.3 in boys [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/32\">",
"     32",
"    </a>",
"    ]. Peak bone mineral content velocity was greater in boys than in girls (320 versus 240",
"    <span class=\"nowrap\">",
"     g/year)",
"    </span>",
"    and, based upon the assumption that bone mineral is 32 percent calcium, corresponded to a net daily calcium retention requirement of 282 mg in boys and 212 mg in girls.",
"   </p>",
"   <p>",
"    More than 30 randomized placebo-controlled trials have examined whether increasing calcium intake with supplements improves bone density in healthy children and adolescents. Although many of these trials revealed increases in some measures of bone density, the increments were generally modest, as shown by the following results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A metaanalysis included 19 of the trials, in which 2859 participants were treated with calcium supplementation (300 to 1200 mg daily) or placebo for 0.7 to 7 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/33,34\">",
"       33,34",
"      </a>",
"      ]. There was a small effect on total body bone mineral content and upper limb bone mineral density (BMD). The treatment effect was small, with only a 1.7 percent increase in BMD in the upper limb, an increment of uncertain benefit on fracture risk in this age group.",
"     </li>",
"     <li>",
"      In a three-year, double-blind trial, each twin of 70 pairs of twins was randomly assigned to diet alone (mean calcium intake of 908",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or a diet supplemented with 1000 mg of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?29/2/29733?source=see_link\">",
"       calcium citrate",
"      </a>",
"      malate per day (mean calcium intake of 1612",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/35\">",
"       35",
"      </a>",
"      ]. Among the twin pairs who were prepubertal during the study, the twins given supplements had greater increases in bone mineral density (BMD). The mean difference in the increase in bone mineral density after three years was 5.1 percent at the midshaft radius, 3.8 percent at the distal radius, and 2.8 percent in the lumbar spine. The twins receiving supplements who went through puberty during the study period or were postpubertal received no benefit.",
"     </li>",
"     <li>",
"      When effects of calcium supplementation are detected, there are conflicting conclusions about whether they persist after treatment is stopped. Some studies show a lasting effect [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/36,37\">",
"       36,37",
"      </a>",
"      ], whereas others show reversal of the treatment effect [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/38,39\">",
"       38,39",
"      </a>",
"      ]. In one long-term study, the treatment effect waned after four years, despite continued supplementation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/40\">",
"       40",
"      </a>",
"      ]. In the metaanalysis cited above, the treatment effect disappeared after cessation of therapy except in one site [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/33,34\">",
"       33,34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A systematic review examined whether increasing calcium intake through fortified foods or other dietary changes increases measures of bone density [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/41\">",
"       41",
"      </a>",
"      ]. In longitudinal and cross-sectional studies and in clinical trials, most studies found little or no effect of increasing dietary calcium intake on measures of bone density. This review also concurred with the metaanalysis cited above that increasing calcium intake through supplements has minimal effect on bone density.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken as a whole, these data do not provide strong support for calcium supplementation for healthy girls whose usual calcium intake is similar to that of most of the US population, even if that intake is well below the recommendations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several epidemiologic studies suggest a link between calcium intake, percent body fat, bone mass, and fractures in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/2,3,42,43\">",
"     2,3,42,43",
"    </a>",
"    ]. As an example, one case-control study measured bone density in 100 Caucasian girls aged 3 to 15 years with distal forearm fractures, the most common fracture in childhood. Bone density was reduced throughout the skeleton in cases compared with age-matched controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, after adjusting for weight, osteopenia was more common in cases than controls (20 versus 12 percent). In another series of 76 girls and 51 boys approximately 14 years of age, a high intake of dietary calcium was protective, with an adjusted odds ratio of 0.28 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Osteoporosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;An association may exist between postmenopausal bone density and calcium intake in childhood and adolescence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. In one study, bone density was measured with computed tomography scans in 255 postmenopausal women and correlated with a retrospective dietary history of calcium intake in childhood, adolescence, and adulthood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/5\">",
"     5",
"    </a>",
"    ]. Women who reported drinking milk with every meal during childhood and adolescence had higher bone densities than did women who reported drinking milk less frequently. No correlation was found between current calcium intake and bone density. The obvious limitation of these studies is that they rely upon recall of dietary habits 30 to 40 years in the past.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     RECOMMENDED INTAKE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ideal calcium intake is not known. Dietary guidelines in the United States are based on permitting maximum positive calcium balance. The results of the calcium balance studies reviewed above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/16,27\">",
"     16,27",
"    </a>",
"    ] suggest that in children 9 to 18 years of age, this is achieved at intakes between 1200 and 1500",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/15,28-30\">",
"     15,28-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on these data, the Food and Nutrition Board of the National Academy of Sciences set 1300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    as the recommended dietary allowance (RDA) for calcium for boys and girls who are 9 to 18 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/30\">",
"     30",
"    </a>",
"    ]. This guideline is set to meet the needs of 95 percent of healthy children. The upper tolerable limit for calcium was set at 3000",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    A",
"    <a class=\"external\" href=\"file://ods.od.nih.gov/factsheets/Calcium-HealthProfessional/\">",
"     fact sheet",
"    </a>",
"    summarizing the recommendations for calcium intake and calcium content of foods is available from the National Institutes of Health [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/44\">",
"     44",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The failure of the short-term supplementation studies noted above to show a substantial long-term benefit in bone mineralization have led to concerns that the higher calcium balance achieved with high calcium intakes may have limited or no long-term benefits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/33,34,41\">",
"     33,34,41",
"    </a>",
"    ]. At this time, it is important to note that achieving 1200 to 1500",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    calcium intake in children is safe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/45\">",
"     45",
"    </a>",
"    ] and may have additional benefits such as decreasing body fat [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. Nonetheless, current data suggest the possibility of catch-up bone mineralization in later adolescence if calcium intake is moderate (eg, 800 to 1000",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    throughout growth, and that exercise may be the most important key to long-term bone mineralization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. Extremely low calcium intakes, such as less than about 600",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    may pose more substantial risks of inadequate mineralization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The calcium content on food labels usually is indicated as a percentage of the \"Daily Value\" in each serving. This \"Daily Value\" was set at 1000",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    although this value is not associated with the dietary requirement for calcium in adolescents. Because only the percent daily value and not total calcium intake is on the food label, it is important to teach families about the daily value and how to interpret it [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/13\">",
"     13",
"    </a>",
"    ]. The daily value for calcium is most important as a tool to compare different foods for calcium content.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Actual intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;A substantial gap exists between recommended calcium intake and the typical intake of children between the ages of 9 and 18 years. Most studies in this age group indicate the usual intake is between 500 and 1000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/15,17,19,35,51\">",
"     15,17,19,35,51",
"    </a>",
"    ]. Median intake in adolescent girls is approximately 700 to 800",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and is approximately 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    greater in adolescent boys [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preoccupation with being thin is common in adolescents, especially among girls, as is the misconception that dairy foods are fattening. Many children and adolescents are unaware that low-fat milk has at least as much calcium as does whole milk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/13\">",
"     13",
"    </a>",
"    ] or that low-fat milk may actually help them lose body fat [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/46\">",
"     46",
"    </a>",
"    ]. Children who consume strict vegetarian diets often have very low calcium intakes if they avoid milk and dairy products. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/4/8266?source=see_link\">",
"     \"Vegetarian diets for children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment of calcium intake and risk factors for osteoporosis can be achieved in the office setting by asking several questions related to dietary intake, activity, and medical history (",
"    <a class=\"graphic graphic_table graphicRef61849 \" href=\"mobipreview.htm?41/13/42204\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Increasing intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcium intake can be increased to achieve the recommended level through foods that are naturally rich in calcium, calcium-fortified foods, and calcium supplements. Most of the calcium needs of children and adolescents can be met by milk and dairy products, which provide approximately 75 percent of the calcium in the average American diet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/20\">",
"     20",
"    </a>",
"    ]. Low-lactose and lactose-free milks are available for children with lactose intolerance.",
"   </p>",
"   <p>",
"    Most vegetables contain calcium, although at low density. Thus, relatively large servings are needed to equal the total intake achieved with typical servings of dairy products. The bioavailability of calcium from vegetables generally is high [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/20\">",
"     20",
"    </a>",
"    ]. An exception is spinach, which is high in oxalate, rendering the calcium virtually non-bioavailable. Some high phytate foods, such as whole bran cereals, also may have calcium that is poorly bioavailable (",
"    <a class=\"graphic graphic_table graphicRef52445 \" href=\"mobipreview.htm?34/25/35229\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Numerous calcium-fortified foods are available, including soy milk, soy yogurt, and soy cheese, as well as calcium precipitated tofu and calcium-fortified cereals, breakfast bars, pastas, waffles, and juices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/53\">",
"     53",
"    </a>",
"    ]. Calcium bioavailability in most of these sources is equivalent to that of milk, although bioavailability of calcium from some soy milks has been shown to be somewhat lower [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/54\">",
"     54",
"    </a>",
"    ]. As an example, one 8-ounce (240 mL) glass of calcium-fortified orange juice provides 300 mg of calcium, equivalent to an 8-ounce glass of milk. The fractional absorption of calcium from calcium-fortified breakfast cereal was equivalent to that of milk in a double-blind, randomized trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/55\">",
"     55",
"    </a>",
"    ]. Neither iron absorption nor fractional absorption of calcium from milk were affected by ingestion of the calcium-fortified cereal. In contrast, the bioavailability of calcium in soy milk is only 75 percent of that in cow's milk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although foods that are rich in or fortified with calcium are preferred because they provide additional nutrients that are important for growth and development, calcium supplements can be considered for children and adolescents who have very low intakes of dietary calcium (",
"    <a class=\"graphic graphic_table graphicRef78814 \" href=\"mobipreview.htm?36/12/37068\">",
"     table 3",
"    </a>",
"    ). The bioavailability of calcium supplements has not been evaluated in children and adolescents. In adults,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?29/2/29733?source=see_link\">",
"     calcium citrate",
"    </a>",
"    and calcium citrate malate are more bioavailable than is",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/38/18024?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/56\">",
"     56",
"    </a>",
"    ]. However, the differences in salt-form bioavailability are relatively small for supplements and fortificants that are well solubilized, so the dose of a supplement can be selected based primarily on the content of elemental calcium (",
"    <a class=\"graphic graphic_table graphicRef65819 \" href=\"mobipreview.htm?30/30/31211\">",
"     table 4",
"    </a>",
"    ). The use of supplements should be individualized based upon the dietary habits of the adolescent, risk factors for osteoporosis, and the likelihood that supplementation usage will be maintained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Risk of calcium stones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although increased dietary calcium intake might raise the concern of calcium stone risk, the opposite effect is seen, as the incidence of stone formation appears to be reduced in both men and women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. Binding of dietary oxalate in the gut, leading to decreased oxalate absorption and excretion, may be responsible for this phenomenon. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33626?source=see_link&amp;anchor=H18#H18\">",
"     \"Risk factors for calcium stones in adults\", section on 'Calcium'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A report from the Nurses' Health Study is compatible with the importance of the change in oxalate excretion and suggests the risk of stones may vary with the source of calcium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/58\">",
"     58",
"    </a>",
"    ]. A high dietary calcium intake was associated with a lower incidence of stone disease (relative risk 0.65 for highest versus lowest quintile of calcium intake), whereas calcium supplements were associated with a small increase in risk (relative risk 1.2 highest versus lowest quintile). The discrepancy was thought to be caused, at least in part, by the timing of calcium intake. Dietary sources are taken with meals, maximally binding dietary oxalate, whereas calcium supplements often were taken between meals, which would diminish binding of dietary oxalate, both maintaining oxalate excretion and, by keeping calcium free in the intestinal lumen, possibly increasing calcium absorption and excretion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     OTHER FACTORS IN BONE HEALTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The importance of several other factors that impact bone density should be discussed when counseling adolescents and families about adequate calcium intake.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regular exercise produces significant skeletal benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/49,59-63\">",
"     49,59-63",
"    </a>",
"    ]. In a 15-year longitudinal study of 84 males and 98 females, regular weight bearing from age 13 to 27 and a normal age-related body weight in adolescence and young adulthood were the most important factors in reaching the highest lumbar peak bone mass at the age of 27 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/59\">",
"     59",
"    </a>",
"    ]. In another prospective study of 264 children aged 9 to 18 who were followed for 11 years, the important factors in achieving peak bone mass were non-smoking status, maintenance of normal weight, and exercise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/61\">",
"     61",
"    </a>",
"    ]. However, an excess of physical endurance training may interrupt menstrual function and have a detrimental effect on bone. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/3/36919?source=see_link\">",
"     \"Amenorrhea and infertility associated with exercise\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Carbonated beverages",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among physically active children, the use of carbonated beverages, particularly colas, may lead to an increase in the risk for fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/3,64\">",
"     3,64",
"    </a>",
"    ]. In a study of 460 9th- and 10th-grade girls in Australia, for example, carbonated beverage consumption was associated with an odds ratio for bone fractures of 3.14 overall and 4.94 among physically active girls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/64\">",
"     64",
"    </a>",
"    ]. The physiological basis for this is unclear and may be more related to very low mineral intake than an actual effect of any cola beverages. Furthermore, these data have not been confirmed at any other center or at any other site. Modest consumption of such beverages by adolescents, consistent with overall dietary guidelines and the primary use of low-calorie beverages, should not pose a risk of bone loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Caffeine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dietary consumption of caffeine is associated with increased renal excretion of calcium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. This effect is at least partially offset by decreased renal excretion of calcium during the night [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/68\">",
"     68",
"    </a>",
"    ]. In studies of postmenopausal women, loss of BMD was associated with low calcium intake (&lt;800",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    high caffeine intake (&gt;300 to 450",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    approximately two to three cups of brewed coffee, per day), and genetic predisposition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/66,69,70\">",
"     66,69,70",
"    </a>",
"    ]. Data in adolescents and young adults are limited, but two studies suggest that caffeine consumption (mean intake &lt;100",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    approximately two cans of caffeine-containing soda) is not a significant predictor of bone mineral density in white females [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/71,72\">",
"     71,72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, although caffeine consumption has been associated with increased urinary calcium excretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/66,67\">",
"     66,67",
"    </a>",
"    ], there is no evidence that it affects calcium homeostasis or bone mineral density in adolescents or young adult women, nor in individuals who ingest adequate calcium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40040/abstract/73,74\">",
"     73,74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Anorexia nervosa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extreme weight loss and anorexia nervosa are associated with diminished bone density. The effects of anorexia nervosa on bone mineral density are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/62/38890?source=see_link&amp;anchor=H27332237#H27332237\">",
"     \"Anorexia nervosa in adults and adolescents: Medical complications and their management\", section on 'Osteoporosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Medroxyprogesterone acetate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depot",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/49/36631?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    (DMPA, Depo-Provera) may exert negative effects on bone density. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/21/9562?source=see_link&amp;anchor=H8#H8\">",
"     \"Drugs that affect bone metabolism\", section on 'Medroxyprogesterone acetate'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/13/42201?source=see_link&amp;anchor=H10#H10\">",
"     \"Contraception: Overview of issues specific to adolescents\", section on 'Bone density'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies fail to show clinically significant effects of calcium supplementation on bone mineral density in healthy children with average calcium intakes at baseline. Nonetheless, a diet targeting calcium balance is safe and may yield beneficial long-term effects that are not detectable through the methods of these studies. Thus, we suggest the following multimodal approach in an effort to promote bone health:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For children 9 to 18 years of age, consume about 1300 mg of calcium per day from calcium-rich or calcium-fortified foods. If this is not possible, ensure that diets with very low calcium intakes, such as &lt;600",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      are avoided.",
"     </li>",
"     <li>",
"      Consume adequate vitamin D to promote intestinal absorption of calcium",
"     </li>",
"     <li>",
"      Engage in regular weight-bearing activity, but for girls post-menarche, avoid extremes in activity that may lead to amenorrhea",
"     </li>",
"     <li>",
"      Avoid the excessive ingestion of cola drinks or non-calcium fortified sweetened beverages",
"     </li>",
"     <li>",
"      Do not smoke cigarettes",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/1\">",
"      Matkovic V, Jelic T, Wardlaw GM, et al. Timing of peak bone mass in Caucasian females and its implication for the prevention of osteoporosis. Inference from a cross-sectional model. J Clin Invest 1994; 93:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/2\">",
"      Goulding A, Cannan R, Williams SM, et al. Bone mineral density in girls with forearm fractures. J Bone Miner Res 1998; 13:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/3\">",
"      Wyshak G, Frisch RE. Carbonated beverages, dietary calcium, the dietary calcium/phosphorus ratio, and bone fractures in girls and boys. J Adolesc Health 1994; 15:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/4\">",
"      Stracke H, Renner E, Knie G, et al. Osteoporosis and bone metabolic parameters in dependence upon calcium intake through milk and milk products. Eur J Clin Nutr 1993; 47:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/5\">",
"      Sandler RB, Slemenda CW, LaPorte RE, et al. Postmenopausal bone density and milk consumption in childhood and adolescence. Am J Clin Nutr 1985; 42:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/6\">",
"      Magarey AM, Boulton TJ, Chatterton BE, et al. Bone growth from 11 to 17 years: relationship to growth, gender and changes with pubertal status including timing of menarche. Acta Paediatr 1999; 88:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/7\">",
"      Lloyd T, Rollings N, Andon MB, et al. Determinants of bone density in young women. I. Relationships among pubertal development, total body bone mass, and total body bone density in premenarchal females. J Clin Endocrinol Metab 1992; 75:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/8\">",
"      Vatanparast H, Bailey DA, Baxter-Jones AD, Whiting SJ. Calcium requirements for bone growth in Canadian boys and girls during adolescence. Br J Nutr 2010; 103:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/9\">",
"      Gilsanz V, Roe TF, Mora S, et al. Changes in vertebral bone density in black girls and white girls during childhood and puberty. N Engl J Med 1991; 325:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/10\">",
"      Faulkner RA, Davison KS, Bailey DA, et al. Size-corrected BMD decreases during peak linear growth: implications for fracture incidence during adolescence. J Bone Miner Res 2006; 21:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/11\">",
"      Matkovic V, Ilich JZ. Calcium requirements for growth: are current recommendations adequate? Nutr Rev 1993; 51:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/12\">",
"      Miller GD, Weaver CM. Required versus optimal intakes: a look at calcium. J Nutr 1994; 124:1404S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/13\">",
"      Greer FR, Krebs NF, American Academy of Pediatrics Committee on Nutrition. Optimizing bone health and calcium intakes of infants, children, and adolescents. Pediatrics 2006; 117:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/14\">",
"      Abrams SA, Grusak MA, Stuff J, O'Brien KO. Calcium and magnesium balance in 9-14-y-old children. Am J Clin Nutr 1997; 66:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/15\">",
"      Abrams SA, Stuff JE. Calcium metabolism in girls: current dietary intakes lead to low rates of calcium absorption and retention during puberty. Am J Clin Nutr 1994; 60:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/16\">",
"      Jackman LA, Millane SS, Martin BR, et al. Calcium retention in relation to calcium intake and postmenarcheal age in adolescent females. Am J Clin Nutr 1997; 66:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/17\">",
"      Lloyd T, Martel JK, Rollings N, et al. The effect of calcium supplementation and Tanner stage on bone density, content and area in teenage women. Osteoporos Int 1996; 6:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/18\">",
"      Abrams SA, Griffin IJ, Hicks PD, Gunn SK. Pubertal girls only partially adapt to low dietary calcium intakes. J Bone Miner Res 2004; 19:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/19\">",
"      Ilich JZ, Badenhop NE, Jelic T, et al. Calcitriol and bone mass accumulation in females during puberty. Calcif Tissue Int 1997; 61:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/20\">",
"      Weaver CM, Proulx WR, Heaney R. Choices for achieving adequate dietary calcium with a vegetarian diet. Am J Clin Nutr 1999; 70:543S.",
"     </a>",
"    </li>",
"    <li>",
"     Marx, SJ, Bourdeau, JE. Calcium metabolism. In: Clinical Disorders of Fluid and Electrolyte Metabolism, 4th ed, Maxwell, MH, Kleeman, CR, Narins, RG (Eds), McGraw-Hill, New York 1987.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/22\">",
"      Holick MF. Vitamin D and the kidney. Kidney Int 1987; 32:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/23\">",
"      Reichel H, Koeffler HP, Norman AW. The role of the vitamin D endocrine system in health and disease. N Engl J Med 1989; 320:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/24\">",
"      Muldowney FP, Freaney R, Moloney MF. Importance of dietary sodium in the hypercalciuria syndrome. Kidney Int 1982; 22:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/25\">",
"      Kok DJ, Iestra JA, Doorenbos CJ, Papapoulos SE. The effects of dietary excesses in animal protein and in sodium on the composition and the crystallization kinetics of calcium oxalate monohydrate in urines of healthy men. J Clin Endocrinol Metab 1990; 71:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/26\">",
"      Heaney RP. Protein intake and the calcium economy. J Am Diet Assoc 1993; 93:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/27\">",
"      Matkovic V, Heaney RP. Calcium balance during human growth: evidence for threshold behavior. Am J Clin Nutr 1992; 55:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/28\">",
"      Andon MB, Lloyd T, Matkovic V. Supplementation trials with calcium citrate malate: evidence in favor of increasing the calcium RDA during childhood and adolescence. J Nutr 1994; 124:1412S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/29\">",
"      NIH Consensus conference. Optimal calcium intake. NIH Consensus Development Panel on Optimal Calcium Intake. JAMA 1994; 272:1942.",
"     </a>",
"    </li>",
"    <li>",
"     Institute of Medicine, Food and Nutrition Board. Dietary reference intakes for calcium and vitamin D. National Academy Press, Washington DC, 2010. Available at:  file://books.nap.edu/openbook.php?record_id=13050.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/31\">",
"      Braun M, Palacios C, Wigertz K, et al. Racial differences in skeletal calcium retention in adolescent girls with varied controlled calcium intakes. Am J Clin Nutr 2007; 85:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/32\">",
"      Martin AD, Bailey DA, McKay HA, Whiting S. Bone mineral and calcium accretion during puberty. Am J Clin Nutr 1997; 66:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/33\">",
"      Winzenberg TM, Shaw K, Fryer J, Jones G. Calcium supplementation for improving bone mineral density in children. Cochrane Database Syst Rev 2006; :CD005119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/34\">",
"      Winzenberg T, Shaw K, Fryer J, Jones G. Effects of calcium supplementation on bone density in healthy children: meta-analysis of randomised controlled trials. BMJ 2006; 333:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/35\">",
"      Johnston CC Jr, Miller JZ, Slemenda CW, et al. Calcium supplementation and increases in bone mineral density in children. N Engl J Med 1992; 327:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/36\">",
"      Bonjour JP, Chevalley T, Ammann P, et al. Gain in bone mineral mass in prepubertal girls 3.5 years after discontinuation of calcium supplementation: a follow-up study. Lancet 2001; 358:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/37\">",
"      Chevalley T, Rizzoli R, Hans D, et al. Interaction between calcium intake and menarcheal age on bone mass gain: an eight-year follow-up study from prepuberty to postmenarche. J Clin Endocrinol Metab 2005; 90:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/38\">",
"      Slemenda CW, Peacock M, Hui S, et al. Reduced rates of skeletal remodeling are associated with increased bone mineral density during the development of peak skeletal mass. J Bone Miner Res 1997; 12:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/39\">",
"      Lee WT, Leung SS, Leung DM, Cheng JC. A follow-up study on the effects of calcium-supplement withdrawal and puberty on bone acquisition of children. Am J Clin Nutr 1996; 64:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/40\">",
"      Matkovic V, Goel PK, Badenhop-Stevens NE, et al. Calcium supplementation and bone mineral density in females from childhood to young adulthood: a randomized controlled trial. Am J Clin Nutr 2005; 81:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/41\">",
"      Lanou AJ, Berkow SE, Barnard ND. Calcium, dairy products, and bone health in children and young adults: a reevaluation of the evidence. Pediatrics 2005; 115:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/42\">",
"      Goulding A, Jones IE, Taylor RW, et al. Bone mineral density and body composition in boys with distal forearm fractures: a dual-energy x-ray absorptiometry study. J Pediatr 2001; 139:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/43\">",
"      Specker BL, Johannsen N, Binkley T, Finn K. Total body bone mineral content and tibial cortical bone measures in preschool children. J Bone Miner Res 2001; 16:2298.",
"     </a>",
"    </li>",
"    <li>",
"     National Institutes of Health, Office of Dietary Supplements. Dietary supplement fact sheet: Calcium. Available at: file://ods.od.nih.gov/factsheets/Calcium-HealthProfessional/ (Accessed on May 30, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/45\">",
"      Greer FR. Bone health: it's more than calcium intake. Pediatrics 2005; 115:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/46\">",
"      Carruth BR, Skinner JD. The role of dietary calcium and other nutrients in moderating body fat in preschool children. Int J Obes Relat Metab Disord 2001; 25:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/47\">",
"      Skinner JD, Bounds W, Carruth BR, Ziegler P. Longitudinal calcium intake is negatively related to children's body fat indexes. J Am Diet Assoc 2003; 103:1626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/48\">",
"      Zemel MB, Shi H, Greer B, et al. Regulation of adiposity by dietary calcium. FASEB J 2000; 14:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/49\">",
"      Lloyd T, Petit MA, Lin HM, Beck TJ. Lifestyle factors and the development of bone mass and bone strength in young women. J Pediatr 2004; 144:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/50\">",
"      Lloyd T, Beck TJ, Lin HM, et al. Modifiable determinants of bone status in young women. Bone 2002; 30:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/51\">",
"      Harel Z, Riggs S, Vaz R, et al. Adolescents and calcium: what they do and do not know and how much they consume. J Adolesc Health 1998; 22:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/52\">",
"      Ervin RB, Wright JD, Wang CY, Kennedy-Stephenson J. Dietary intake of fats and fatty acids for the United States population: 1999-2000. Adv Data 2004; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/53\">",
"      Haddad EH. Meeting the RDAs with a vegetarian diet. Top Clin Nutr 1995; 10:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/54\">",
"      Heaney RP, Dowell MS, Rafferty K, Bierman J. Bioavailability of the calcium in fortified soy imitation milk, with some observations on method. Am J Clin Nutr 2000; 71:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/55\">",
"      Abrams SA, Griffin IJ, Davila P, Liang L. Calcium fortification of breakfast cereal enhances calcium absorption in children without affecting iron absorption. J Pediatr 2001; 139:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/56\">",
"      Miller JZ, Smith DL, Flora L, et al. Calcium absorption from calcium carbonate and a new form of calcium (CCM) in healthy male and female adolescents. Am J Clin Nutr 1988; 48:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/57\">",
"      Curhan GC, Willett WC, Rimm EB, Stampfer MJ. A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N Engl J Med 1993; 328:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/58\">",
"      Curhan GC, Willett WC, Speizer FE, et al. Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. Ann Intern Med 1997; 126:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/59\">",
"      Welten DC, Kemper HC, Post GB, et al. Weight-bearing activity during youth is a more important factor for peak bone mass than calcium intake. J Bone Miner Res 1994; 9:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/60\">",
"      Slemenda CW, Miller JZ, Hui SL, et al. Role of physical activity in the development of skeletal mass in children. J Bone Miner Res 1991; 6:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/61\">",
"      V&auml;lim&auml;ki MJ, K&auml;rkk&auml;inen M, Lamberg-Allardt C, et al. Exercise, smoking, and calcium intake during adolescence and early adulthood as determinants of peak bone mass. Cardiovascular Risk in Young Finns Study Group. BMJ 1994; 309:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/62\">",
"      MacKelvie KJ, Khan KM, Petit MA, et al. A school-based exercise intervention elicits substantial bone health benefits: a 2-year randomized controlled trial in girls. Pediatrics 2003; 112:e447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/63\">",
"      Rowlands AV, Ingledew DK, Powell SM, Eston RG. Interactive effects of habitual physical activity and calcium intake on bone density in boys and girls. J Appl Physiol 2004; 97:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/64\">",
"      Wyshak G. Teenaged girls, carbonated beverage consumption, and bone fractures. Arch Pediatr Adolesc Med 2000; 154:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/65\">",
"      Fitzpatrick L, Heaney RP. Got soda? J Bone Miner Res 2003; 18:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/66\">",
"      Harris SS, Dawson-Hughes B. Caffeine and bone loss in healthy postmenopausal women. Am J Clin Nutr 1994; 60:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/67\">",
"      Heaney RP, Rafferty K. Carbonated beverages and urinary calcium excretion. Am J Clin Nutr 2001; 74:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/68\">",
"      Kynast-Gales SA, Massey LK. Effect of caffeine on circadian excretion of urinary calcium and magnesium. J Am Coll Nutr 1994; 13:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/69\">",
"      Rapuri PB, Gallagher JC, Kinyamu HK, Ryschon KL. Caffeine intake increases the rate of bone loss in elderly women and interacts with vitamin D receptor genotypes. Am J Clin Nutr 2001; 74:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/70\">",
"      Krall EA, Parry P, Lichter JB, Dawson-Hughes B. Vitamin D receptor alleles and rates of bone loss: influences of years since menopause and calcium intake. J Bone Miner Res 1995; 10:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/71\">",
"      Lloyd T, Rollings NJ, Kieselhorst K, et al. Dietary caffeine intake is not correlated with adolescent bone gain. J Am Coll Nutr 1998; 17:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/72\">",
"      Conlisk AJ, Galuska DA. Is caffeine associated with bone mineral density in young adult women? Prev Med 2000; 31:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/73\">",
"      Heaney RP. Effects of caffeine on bone and the calcium economy. Food Chem Toxicol 2002; 40:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40040/abstract/74\">",
"      Massey LK, Whiting SJ. Caffeine, urinary calcium, calcium metabolism and bone. J Nutr 1993; 123:1611.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5355 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.167.4.114-2B3BC00349-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_6_40040=[""].join("\n");
var outline_f39_6_40040=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BONE GROWTH DURING PUBERTY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CALCIUM HOMEOSTASIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CALCIUM REQUIREMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Calcium balance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Bone density",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      RECOMMENDED INTAKE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Actual intake",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Increasing intake",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Risk of calcium stones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      OTHER FACTORS IN BONE HEALTH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Carbonated beverages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Caffeine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Anorexia nervosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Medroxyprogesterone acetate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5355\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5355|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?37/7/38014\" title=\"figure 1\">",
"      Bone mass lifeline",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5355|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/25/35229\" title=\"table 1\">",
"      Dietary sources of absorbable calcium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/13/42204\" title=\"table 2\">",
"      Assess calcium intake",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/12/37068\" title=\"table 3\">",
"      Calcium content of supplements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/30/31211\" title=\"table 4\">",
"      Compare elemental Ca",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/3/36919?source=related_link\">",
"      Amenorrhea and infertility associated with exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/62/38890?source=related_link\">",
"      Anorexia nervosa in adults and adolescents: Medical complications and their management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/36/2631?source=related_link\">",
"      Chapter 6F: Hormonal regulation of calcium and phosphate balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/13/42201?source=related_link\">",
"      Contraception: Overview of issues specific to adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/39/19061?source=related_link\">",
"      Diuretics and calcium balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/21/9562?source=related_link\">",
"      Drugs that affect bone metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/15/9462?source=related_link\">",
"      Metabolism of vitamin D",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/25/1434?source=related_link\">",
"      Normal puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/53/3929?source=related_link\">",
"      Pathogenesis of osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33626?source=related_link\">",
"      Risk factors for calcium stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/4/8266?source=related_link\">",
"      Vegetarian diets for children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_6_40041="Urine biomarkers for the detection of urothelial (transitional cell) carcinoma of the bladder";
var content_f39_6_40041=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Urine biomarkers for the detection of urothelial (transitional cell) carcinoma of the bladder",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/6/40041/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/6/40041/contributors\">",
"     Anirban P Mitra, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/6/40041/contributors\">",
"     Marc Birkhahn, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/6/40041/contributors\">",
"     David F Penson, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/6/40041/contributors\">",
"     Richard J Cote, MD, FRCPath",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/6/40041/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/6/40041/contributors\">",
"     Seth P Lerner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/6/40041/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/6/40041/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/6/40041/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Worldwide, bladder cancer accounted for 386,000 cases and 150,000 deaths in 2008 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/1\">",
"     1",
"    </a>",
"    ]. In developed areas of the world, such as North America and western Europe, these bladder cancers are predominantly urothelial. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26586?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Urine biomarkers that currently are approved or under development are discussed in this topic. The clinical presentation and initial diagnosis of bladder cancer and the rationale and overall approach to screening high-risk populations and to surveillance in patients who have been treated for non-muscle invasive disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/47/20217?source=see_link\">",
"     \"Clinical presentation, diagnosis, and staging of bladder cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22039?source=see_link\">",
"     \"Screening for bladder cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/11/40122?source=see_link&amp;anchor=H42#H42\">",
"     \"Treatment of non-muscle-invasive bladder cancer\", section on 'Posttreatment management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     POTENTIAL APPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urine biomarkers have potential applications in individuals in whom bladder cancer is suspected based upon the presence of hematuria, symptoms, or in whom there is an unusually high risk of tumor. Urine biomarkers may also have a role in detecting recurrences in patients who have been treated for non-muscle-invasive disease. They may also be used in the evaluation of upper tract radiographic abnormalities and for monitoring patients after treatment of ureteral or renal pelvic transitional cell carcinoma.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial diagnosis &mdash; The diagnosis of bladder cancer commonly is suggested by the presence of hematuria, which may be either gross or microscopic. However, hematuria is frequently seen in a wide range of benign conditions. The diagnosis of bladder cancer ultimately requires a histologic diagnosis, which usually comes from a biopsy that is obtained at cystoscopy. Cytology may provide strong evidence for the presence of malignancy, but it has a low sensitivity and occasional false positives are reported. Urine biomarkers could have a significant role in determining which individuals require cystoscopy, as well as those who might need evaluation of the upper urinary tract. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/45/1754?source=see_link\">",
"       \"Malignancies of the renal pelvis and ureter\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34746?source=see_link\">",
"       \"Etiology and evaluation of hematuria in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/47/20217?source=see_link&amp;anchor=H8#H8\">",
"       \"Clinical presentation, diagnosis, and staging of bladder cancer\", section on 'Diagnostic approach'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Surveillance &mdash; Patients who have been treated for non-muscle-invasive bladder cancer are at risk for recurrence in the bladder, as well as for the development of urothelial tumors in the renal pelvis, ureter, or urethra. These patients thus require prolonged follow-up. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/11/40122?source=see_link&amp;anchor=H42#H42\">",
"       \"Treatment of non-muscle-invasive bladder cancer\", section on 'Posttreatment management'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cystoscopy is the gold standard for surveillance in patients with a history of bladder cancer. Because it does not detect all recurrences nor does it visualize the upper urinary tract, a biomarker test should accompany cystoscopy in order to minimize the risk of missing a high grade tumor. Furthermore, cystoscopy is a minimally invasive procedure. Cystoscopy is easily performed in an office setting with flexible instrumentation. It can however be uncomfortable and promote anxiety, which can lead to suboptimal compliance with management recommendations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/11/40122?source=see_link&amp;anchor=H43#H43\">",
"     \"Treatment of non-muscle-invasive bladder cancer\", section on 'Cystoscopy and cytology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cytology of voided urine or bladder washings is commonly used as an adjunct to cystoscopy, particularly to detect lesions that might be missed by cystoscopy. While bladder wash urine cytology has a high sensitivity for high grade papillary tumors and CIS, it has relatively low sensitivity for low-grade tumors. Cytology may be complemented with another voided urine biomarker with better performance characteristics for low grade tumors as a supplement to or in lieu of cytology as long as the biomarkers have similar performance characteristics as cytology for high grade tumors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/11/40122?source=see_link&amp;anchor=H43#H43\">",
"     \"Treatment of non-muscle-invasive bladder cancer\", section on 'Cystoscopy and cytology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     URINE BIOMARKERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urine is exposed to the urothelium in the renal pelvis, ureters, bladder, and urethra, and thus can contain a variety of molecular markers that may be associated with neoplasia. Urine also contains cells that have been shed. These cells provide the basis for cytology, as well as newer techniques for protein and cellular analysis. A number of markers and techniques are being evaluated. Many of these are based upon immunologic detection of soluble molecules in the urine (",
"    <a class=\"graphic graphic_table graphicRef70530 \" href=\"mobipreview.htm?16/29/16859\">",
"     table 1",
"    </a>",
"    ). Other techniques analyze exfoliated cells that are isolated from urine or bladder washings by centrifugation (",
"    <a class=\"graphic graphic_table graphicRef59814 \" href=\"mobipreview.htm?13/17/13595\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    An ideal test to detect early urothelial neoplasia should be inexpensive, rapid, and require little or no training and no specialized instrumentation. Such a test would be both highly sensitive and specific. False negative results can lead to a missed diagnosis and disease progression, while false positive results cause unnecessary evaluations and associated patient anxiety. In some cases, a so-called false positive test may be anticipatory, heralding the development of a visible tumor on subsequent evaluation.",
"   </p>",
"   <p>",
"    The various approaches to develop urine biomarkers are discussed in this section. The relative performances of these tests have also been compared extensively in literature reviews [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Bladder tumor antigen (BTA) assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assays have been developed to detect human complement factor H-related protein (hCFHrp) in the urine. This marker is similar in composition, structure, and function to human complement factor H (hCFH).",
"   </p>",
"   <p>",
"    Two assays for hCFHrp are approved for use in combination with cystoscopy. The bladder tumor antigen (BTA)-stat assay is a point-of-care, qualitative assay, while the BTA-TRAK assay is a quantitative ELISA assay performed in a central laboratory. These tests employ two monoclonal antibodies: the capture antibody, which binds to domain 18 of hCFH and hCFHrp, and the detection antibody, which binds to domain 3 of hCFH and hCFHrp [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The point-of-care assay is performed by placing five drops of urine in the sample well and allowing the reaction to occur for five minutes. A pink or reddish-brown line in the test window indicates a positive result and a line in the control window indicates that the test is working properly.",
"   </p>",
"   <p>",
"    The reported sensitivity with the BTA assays generally has ranged between 50 and 90 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/5-17\">",
"     5-17",
"    </a>",
"    ], although lower sensitivities have been reported depending upon the cut-off for positivity with BTA-Trak [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/18\">",
"     18",
"    </a>",
"    ]. The BTA assay may be particularly sensitive for detecting bladder cancer in patients with a history of schistosomiasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While the specificity of these assays among healthy individuals is generally more than 90 percent, the specificity is only around 50 percent in patients with urinary tract infections, calculi, or benign prostatic hyperplasia (BPH). Prior treatment with intravesical BCG or chemotherapy is also associated with an increased incidence of false positive results. Many of the false positive results in patients with these benign conditions may be due to hematuria and the hCFH in human serum.",
"   </p>",
"   <p>",
"    This technology was systematically evaluated by the FinnBladder group, in a study in which both the BTA-stat assay and cytology were performed prior to cystoscopy in 501 patients with a history of bladder cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/20\">",
"     20",
"    </a>",
"    ]. Recurrent bladder cancer was detected by cystoscopy in 133 (27 percent). The BTA assay was more sensitive than cytology (56 versus 19 percent), but less specific (86 versus 98 percent). In six cases in which the BTA assay was positive and cystoscopy was negative, bladder cancer was found at the next cystoscopy, and in three additional cases upper urinary tract cancer (ureter, renal pelvis) was subsequently identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Nuclear matrix protein 22",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nuclear matrix proteins (NMPs) serve as a scaffold in the nucleus and help regulate mitosis. Several of the NMPs are overexpressed in urothelial tumors and released into the urine following apoptosis of tumor cells. NMP22 has been the most extensively evaluated nuclear matrix protein, and assays for this antigen are approved by the US Food and Drug Administration for bladder cancer surveillance and screening.",
"   </p>",
"   <p>",
"    The original assay was a quantitative enzyme-linked immunosorbent assay (ELISA) that used two monoclonal antibodies to measure NMP22 levels in the urine. However, the urine needed to be stabilized and transported to a reference laboratory for testing.",
"   </p>",
"   <p>",
"    The recommended cut-off limit on the quantitative assay is 10",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    to make a diagnosis of bladder cancer. The reported sensitivity has varied between 48 and 100 percent, while the specificity ranged from 70 to 91 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. However, these studies have used varying cut-off limits (3.6 to 12",
"    <span class=\"nowrap\">",
"     units/mL),",
"    </span>",
"    and lowering the cut-off limit increases the sensitivity while decreasing the specificity. The NMP22 assay has lower sensitivity for Ta tumors (42 to 76 percent) compared to muscle-invasive tumors (50 to 98 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/23\">",
"     23",
"    </a>",
"    ]. The NMP22 test may be more sensitive for schistosomal bladder cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/19,24\">",
"     19,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    NMP22 is abundant in leukocytes as well as dead and dying urothelial cells, and benign inflammatory conditions of the urinary tract appear to increase the frequency of false-positive results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/18,25\">",
"     18,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A newer, qualitative version of the assay (NMP22 BladderChek) is performed at the point-of-care and eliminates the need for urine stabilization, while providing a result in 30 to 50 minutes. The potential role of the point-of-care assay has been extensively evaluated in two multicenter studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The NMP22 assay and cytology were compared in a study of 1331 individuals at high risk for bladder cancer, all of whom underwent diagnostic cystoscopy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/22\">",
"       22",
"      </a>",
"      ]. Bladder cancer was diagnosed in 79 patients. The NMP22 assay detected 44 of these (56 percent), whereas cytology detected 12 (16 percent). The NMP22 assay had a lower specificity than cytology (86 versus 99 percent). In four cases, the NMP22 assay detected a bladder cancer that was missed on the initial cystoscopy.",
"     </li>",
"     <li>",
"      The NMP22 assay, cytology, and cystoscopy were performed in a study of 668 consecutive patients undergoing surveillance for bladder cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/26\">",
"       26",
"      </a>",
"      ]. The NMP22 assay and cystoscopy detected 50 and 91 percent of the 103 recurrences, respectively. The NMP22 test detected eight of the nine cancers initially missed by cystoscopy, for a combined sensitivity of 99 percent. Cytology detected three of the nine cases initially missed at cystoscopy. The NMP22 assay had a specificity of 87 percent (72 false positives in 565 patients without recurrence).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In another multicenter study of 2222 patients with history of non-muscle invasive bladder cancer and negative urine cytology, NMP22 levels were significantly associated with disease recurrence and progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/27\">",
"     27",
"    </a>",
"    ]. The general use of the NMP22 assay for screening high-risk populations (smokers, high-risk occupations) rather than for surveillance is more problematic because of the low prevalence of urothelial neoplasia in these populations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22039?source=see_link&amp;anchor=H2554149#H2554149\">",
"     \"Screening for bladder cancer\", section on 'Urine biomarkers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other NMPs",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Nuclear matrix protein 52",
"    </span>",
"    &nbsp;&mdash;&nbsp;NMP52 is a 52 kDa nuclear matrix protein similar to NMP22. NMP52 has been identified in the urine of bladder cancer patients, and a point-of-care assay was developed to detect this protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/28\">",
"     28",
"    </a>",
"    ]. The assay uses a rabbit polyclonal antibody that identifies the entire 52 kDa protein as well as the 40 kDa degradation fragment. The NMP52 assay can be performed in five minutes, and a colored dot indicates a positive test. The test is semiquantitative as the color intensity of the dot indicates the amount of protein present in the urine.",
"   </p>",
"   <p>",
"    In the one published study, which included 149 patients with bladder cancer, the test had an overall sensitivity and specificity of 97 percent and 94 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/28\">",
"     28",
"    </a>",
"    ]. However, most of the cases in this study were high-stage, high-grade tumors, and performance characteristics in low-stage, low-grade tumors have not been established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     BLCA-4 and BLCA-1",
"    </span>",
"    &nbsp;&mdash;&nbsp;BLCA-4 and BLCA-1 are protein components of the nuclear matrix that are present exclusively in the urothelium of patients with bladder tumors and are absent in normal individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/29\">",
"     29",
"    </a>",
"    ]. BLCA-1 is expressed in bladder tumor but not adjacent normal tissues. In contrast, BLCA-4 is present throughout the bladder in both tumor and normal tissue in patients with bladder cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Thus, BLCA-4 may reflect the field effect observed at the molecular level in normal tissues adjacent to tumors.",
"   </p>",
"   <p>",
"    A few studies have used variations of the ELISA to detect these proteins in the urine.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An initial study assaying for BLCA-4 in a series of 105 patients reported sensitivity and specificity of 96 percent and 100 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/31\">",
"       31",
"      </a>",
"      ]. A second study that included 75 patients with bladder cancer and 65 controls found a sensitivity of 89 percent and specificity of 95 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 25 patients with bladder cancer and 46 normal controls, urinary BLCA-1 detection with an ELISA assay had a sensitivity and specificity of 80 and 87 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Larger prospective studies are needed to determine the role of these markers in bladder cancer screening and surveillance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cytokeratins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytokeratins are proteins that are crucial components of the epithelial cellular cytoskeleton. Epithelium can be characterized by its chain-specific cytokeratin expression pattern, and overexpressions of certain cytokeratins are associated with bladder cancer.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cytokeratins 8 and 18 &mdash; Two assays are commercially available to measure cytokeratins 8 and 18 in the urine (UBC ELISA and UBC IRMA). Both are solid phase sandwich assays that use solid phase capture antibodies (6D7 and 3F3). The detection antibody in UBC II ELISA is horseradish peroxidase-conjugated, while that in UBC IRMA is 125I-labelled. The sensitivity of the UBC tests varies from 35 to 79 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/33\">",
"       33",
"      </a>",
"      ]. Detection sensitivity for low-stage and low-grade bladder tumors could be as low as 25 percent and 13 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/33\">",
"       33",
"      </a>",
"      ]. The specificity is lower in individuals where urinary tract infection is present.",
"     </li>",
"     <li>",
"      Cytokeratin 19 &mdash; CYFRA21-1 is an ELISA that measures soluble fragments of cytokeratin 19 using two monoclonal antibodies (BM19.21 and KS19.1). The reported sensitivity for this test ranges from 43 to 96 percent, although more studies are needed to validate its utility [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/34-38\">",
"       34-38",
"      </a>",
"      ].The assay is limited by high rate of false-positives in the presence of urinary tract calculi and infections, as well as after BCG therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/35-39\">",
"       35-39",
"      </a>",
"      ]. Furthermore, a standardized cut-off is unavailable, and studies usually employ normalization to urine creatinine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cytokeratin 20 &mdash; Reverse transcriptase-PCR (RT-PCR) and immunocytochemistry have been employed to measure cytokeratin 20 levels with reasonable sensitivity (78 to 87 percent) and modest specificity (55 to 80 percent) (40). Additional studies are required to characterize its utility [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     HA and HAase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyaluronic acid (HA) is a nonsulfated glycosaminoglycan that regulates cell adhesion, migration, and proliferation, and promotes tumor progression and metastasis. HA is cleaved by hyaluronidase (HAase) into small fragments that promote tumor angiogenesis.",
"   </p>",
"   <p>",
"    Urinary levels of HA and HAase are measured by ELISA-like assays [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/40\">",
"     40",
"    </a>",
"    ]. In the HA test, urinary HA competes with HA coated on microtiter wells to bind to HA-binding protein. After washing off the unbound HA-binding protein, the bound HA-binding protein is assayed by an avidin-biotin detection system. The HAase test is based on the degradation activity of urinary HAase on HA coated on microtiter wells. After the degraded HA is washed off, the remaining HA is assayed similar to the HA test. Both protein levels are normalized to total urinary protein.",
"   </p>",
"   <p>",
"    In a study of 513 individuals (261 urothelial carcinoma patients, 9 non-urothelial bladder tumors, and 243 controls), the HA and HAase tests had sensitivities of 83 percent and 82 percent, respectively, and specificities of 90 percent and 84 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/40\">",
"     40",
"    </a>",
"    ]. However, the high sensitivity of the HAase test was only observed for grade II and III bladder cancers. The combination of these tests resulted in an overall sensitivity and specificity of 92 percent and 84 percent, respectively. The sensitivity of the combined test to detect non-muscle-invasive and muscle-invasive tumors were 87 to 94 percent, and 93 to 100 percent, respectively, while that for Grade I, II, and III tumors were 86 percent, 96 percent and 93 percent, respectively. Another independent study showed that the urinary HA test had an overall sensitivity of 82 percent and an overall specificity of 81 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/41\">",
"     41",
"    </a>",
"    ]. Analysis of the cohort also indicated that every 1",
"    <span class=\"nowrap\">",
"     mug/L",
"    </span>",
"    increase in HA increased a patient's likelihood of having bladder cancer by 3.9 percent.",
"   </p>",
"   <p>",
"    These results are promising, especially because of the apparent ability to detect low-grade and low-stage disease with higher sensitivity than most other markers. Additional validation studies are required to confirm these observations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Telomerase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Telomeres are repeated DNA sequences (TTAGGG in humans) that cap the 5' ends of eukaryotic chromosomes. Up to 200 bases at the 5' end of the chromosome are potentially lost at the end of each cycle of DNA replication. The presence of these telomeres prevents the loss of crucial genetic information; if all telomeres are lost, chromosomal instability leads to cellular senescence.",
"   </p>",
"   <p>",
"    Telomerase is a ribonuclease-protein complex that adds telomeres to the 5' ends of chromosomes, thereby allowing cells to replicate indefinitely. Telomerase is expressed in germ cells, proliferating cells such as leukocytes, and tumor cells; normal somatic cells do not express telomerase. The presence of telomerase in the urine is a sensitive marker for urologic neoplasms.",
"   </p>",
"   <p>",
"    The telomeric repeat amplification protocol (TRAP) assay uses PCR amplification of a telomeric template by telomerase present in exfoliated cells and analysis by a telomerase PCR ELISA kit or real-time PCR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/42\">",
"     42",
"    </a>",
"    ]. This assay must be performed in a specialized laboratory and needs at least 50 telomerase-expressing cells to yield a positive result [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/43\">",
"     43",
"    </a>",
"    ]. A related assay measures the messenger RNA levels of human telomerase reverse transcriptase (hTERT), the catalytic subunit of telomerase, by RT-PCR.",
"   </p>",
"   <p>",
"    The reported sensitivity of both the TRAP and hTERT RT-PCR assays is between 70 and 100 percent, although degradation of telomerase and hTERT by urine may decrease the sensitivity dramatically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/33,44\">",
"     33,44",
"    </a>",
"    ]. The specificity of both tests is usually around 60 to 70 percent.",
"   </p>",
"   <p>",
"    Both assays are significantly affected by sample collection and processing that limits their clinical application. Benign conditions such as urinary tract infections and severe inflammation can lead to false-positive results, since telomerase is expressed in proliferating cells and leukocytes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Survivin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Survivin is an inhibitor of apoptosis. Survivin is elevated in human cancers but is almost undetectable in normal human tissues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Survivin has been assayed in urine using a biodot test. Urine samples are blotted as dots onto nitrocellulose membranes, and survivin in the samples is detected using an anti-survivin antibody and standard dot-blot detection reagents. Initial studies on this marker offer promising results, with sensitivity and specificity rates of 64 to 100 percent and 93 to 100 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/46-48\">",
"     46-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A quantitative reverse transcriptase PCR assay has been developed to detect survivin in urine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. This approach has demonstrated sensitivities of 79 to 94 percent in clinical studies, while maintaining a specificity of 93 to 95 percent.",
"   </p>",
"   <p>",
"    The survivin assay is not commercially available, and further studies with larger patient cohorts are needed to validate these results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Fibrin degradation products",
"    </span>",
"    &nbsp;&mdash;&nbsp;High levels of vascular endothelial growth factor in bladder cancer cells increase the permeability of the surrounding vasculature, which results in leakage of serum proteins, including plasminogen, fibrinogen, and clotting factors. Clotting factors convert plasminogen to plasmin and fibrinogen to fibrin. Plasmin can further degrade fibrin to fibrin degradation products (FDPs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A point-of-care immunoassay (Accu-Dx) to measure FDPs was developed, which had a sensitivity around 70 percent and a specificity between 68 and 86 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. This assay is no longer commercially available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Microsatellite analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microsatellites are highly polymorphic repeating units of one to six nucleotides. The number of repeats at any chromosomal locus is different in each individual and even between the maternal and paternal alleles in the same somatic cell.",
"   </p>",
"   <p>",
"    Observed microsatellite alterations in bladder tumor cells include loss of heterozygosity (74 percent), length alterations (24 percent) and additional alleles (2 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/55\">",
"     55",
"    </a>",
"    ]. In bladder cancer, loss of heterozygosity is most commonly seen on chromosomes 4p, 8p, 9p, 9q, 11p, 13p, 16q and 17p.",
"   </p>",
"   <p>",
"    Microsatellite alterations are detected by PCR. A panel of microsatellite markers using 15 to 20 loci on different chromosomes are tested in exfoliated bladder cancer cells in the urine and compared with corresponding sequences in peripheral lymphocytes. The detection of microsatellite alterations requires a ratio of tumor DNA to contaminating normal DNA of more than 0.5 to 25 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/33\">",
"     33",
"    </a>",
"    ]. The assay requires trained personnel and sophisticated laboratory equipment.",
"   </p>",
"   <p>",
"    Microsatellite analysis (MSA) is reported to be 72 to 97 percent sensitive and 80 to 100 percent specific [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/33,56\">",
"     33,56",
"    </a>",
"    ]. However, loss of heterozygosity and microsatellite alterations are also seen in cystitis and benign prostatic hyperplasia (BPH), and this is more pronounced when these benign conditions are present concurrently [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/57\">",
"     57",
"    </a>",
"    ]. Varying microsatellite markers have been used in different studies, and comparison of results between studies is difficult.",
"   </p>",
"   <p>",
"    A prospective multicenter study initiated at Johns Hopkins and supported by the Early Detection Research Network (EDRN) has evaluated a high throughput platform for evaluating the sensitivity and specificity for MSA to detect bladder cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     ImmunoCyt",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunofluorescence technology has been used to detect cellular markers of bladder cancer in exfoliated cells from voided urine. The ImmunoCyt assay uses three fluorescently labeled monoclonal antibodies to detect carcinoembryonic antigen and two mucin glycoproteins that are expressed on most bladder cancer cells but not on normal cells.",
"   </p>",
"   <p>",
"    The test requires urine fixation with ethanol or isopropyl alcohol before shipment to a reference cytopathology laboratory. A minimum evaluation of 500 epithelial cells is required, and the presence of one cell with fluorescence constitutes a positive test. ImmunoCyt is FDA approved for use in conjunction with urine cytology and cystoscopy.",
"   </p>",
"   <p>",
"    The reported sensitivity and specificity of the test usually vary between 70 and 80 percent and 60 and 70 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/33\">",
"     33",
"    </a>",
"    ]. Many studies have reported that adding ImmunoCyt to a standard urine cytology protocol increases sensitivity to around 86 to 90 percent without significantly decreasing specificity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/58-64\">",
"     58-64",
"    </a>",
"    ]. However, the presence of microhematuria, cystitis and BPH can lead to false-positive results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/59,60\">",
"     59,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Difficulties associated with the ImmunoCyt assay include a steep learning curve, substantial interobserver variability, the need for constant quality control, and a relatively high rate of test failure due to inadequate specimen cellularity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     DD23 monoclonal antibody",
"    </span>",
"    &nbsp;&mdash;&nbsp;DD23 is a monoclonal antibody that detects a protein dimer expressed on bladder tumor cells. It has been integrated into an alkaline phosphatase-conjugated immunocytochemical assay for exfoliated tumor cells in the urine.",
"   </p>",
"   <p>",
"    Initial reports suggest that the sensitivity of this marker is between 70 and 80 percent and the specificity around 60 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. The sensitivity increases slightly when DD23 is used in combination with cytology (78 to 85 percent). The marker has a reasonable sensitivity to detect both low grade (range 55 to 72 percent) and high grade (range 76 to 87 percent) tumors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Lewis X antigen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glycoproteins are proteins that contain oligosaccharide chains (glycans) covalently attached to their polypeptide and are important structural components of cells. Glycoproteins also act as antigens.",
"   </p>",
"   <p>",
"    The most commonly studied glycoprotein antigen in bladder cancer is the blood antigen, stage-specific embryonic antigen 1 or the sialyl Lewis X (commonly referred to as Lewis X). The Lewis X determinant is a tumor-associated antigen in the urothelium and is visualized in exfoliated tumor cells in the urine by an immunocytochemical assay using anti-Lewis X monoclonal antibody [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/67\">",
"     67",
"    </a>",
"    ]. At least 100 cells are required for evaluation, and slides showing more than 5 percent positive cells for Lewis X are considered positive.",
"   </p>",
"   <p>",
"    The sensitivity and specificity of this marker range from 80 to 85 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/67-71\">",
"     67-71",
"    </a>",
"    ]. Immunocytology for Lewis X antigen on two consecutive voided samples instead of one may increase the sensitivity of the test by almost 15 percent points [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/68,70\">",
"     68,70",
"    </a>",
"    ]. The sensitivity of the antibody also increases with increasing stage and grade of the tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/72\">",
"     72",
"    </a>",
"    ]. More recent reports have indicated that the test has higher sensitivity than BTA stat, NMP22, and UroVysion approaches, although the specificity was the lowest (range, 33 to 37 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. However, the expression of Lewis X antigen by benign umbrella cells of the urothelium shed in the urine may interfere with the assay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/67,75\">",
"     67,75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     UroVysion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bladder cancers frequently exhibit well-defined chromosomal alterations. These abnormalities can be detected by fluorescent in situ hybridization (FISH) assays, in which hybridization of fluorescently labeled DNA probes to chromosome centromeres or other loci on exfoliated cells is detected with a fluorescent microscope.",
"   </p>",
"   <p>",
"    The UroVysion test is a multitarget, multicolor FISH assay using probes that can detect aneuploidy of chromosomes 3, 7, or 17, or loss of the 9p21 locus. Based upon the package insert, the criteria for positivity are &ge;4 of 25 morphologically abnormal cells showing a gain of &ge;2 chromosomes in the same cell, or &ge;12 of the 25 cells having a loss of 9p21. If neither criterion is met, additional cells are analyzed until four cells with a gain of multiple chromosomes have been detected, or 12 cells with loss of 9p21 are detected, or the entire sample has been analyzed. However, many studies using this assay have employed variations of these criteria.",
"   </p>",
"   <p>",
"    The sensitivity and specificity of UroVysion for bladder cancer detection vary between 69 and 87 percent, and 89 to 96 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/76-78\">",
"     76-78",
"    </a>",
"    ]. Better performance has been reported in detecting carcinoma in situ and high-grade tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/79\">",
"     79",
"    </a>",
"    ]. In a prospective validation study on patients at risk for bladder cancer with atypical cytology, UroVysion was unnecessary when the tumor was obvious on cystoscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/80\">",
"     80",
"    </a>",
"    ]. However, it was useful in patients with atypical cytology and equivocal or negative cytoscopy.",
"   </p>",
"   <p>",
"    UroVysion detects some occult tumors in urine of patients under surveillance that are not visible on cystoscopy. Chromosomal abnormalities in exfoliated cells have preceded bladder tumors identifiable by cystoscopy within one year in 41 to 89 percent patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/81-84\">",
"     81-84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Automated image cytometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities in DNA ploidy and nuclear shape are characteristic of tumor cells. While cytologists rely on identification of these changes in urine specimens, automated image analysis identifies changes on a more objective basis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One system (Quanticyt) employs image analysis to identify DNA ploidy abnormalities and nuclear morphometry [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/85\">",
"       85",
"      </a>",
"      ]. The karyometric system is based on two nuclear features: the 2c-deviation index (2cDI) and the mean of a nuclear shape feature, MPASS. Samples are scored as low-, intermediate-, or high-risk that have been predetermined by correlation with histologic data. A study has shown that prediction of a cystoscopic lesion by routine cytology and by Quanticyt was similar, and the latter was superior to predict tumor recurrence after a normal cystoscopy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/86\">",
"       86",
"      </a>",
"      ].The Quanticyt system has reported sensitivity and specificity rates of 59 to 69 percent and 73 to 93 percent, respectively for the detection of bladder cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/87,88\">",
"       87,88",
"      </a>",
"      ]. Use of Quanticyt to analyze consecutive bladder washes may increase the detection rate of invasive disease in samples that are labeled high-risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/89\">",
"       89",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Artificial intelligence and neural network technology have been used to develop a digitized cell image diagnosis system that identifies potentially abnormal cells in bladder washings by algorithmic analysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/90\">",
"       90",
"      </a>",
"      ]. Two independent neural networks reanalyze the digitized cell images. One selects single cells and the other cell clusters, regardless of cell shape, overlapping, or staining. The selected cells or cell clusters are displayed on a high-resolution computer screen for evaluation by a cytopathologist.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a pilot study, the neural network-based diagnosis system showed 92 percent sensitivity in diagnosing histologically confirmed tumors, as opposed to 69 percent for Quanticyt and 50 percent for routine cytology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40041/abstract/90\">",
"     90",
"    </a>",
"    ]. While the major advantage of these cytometric analyses is label-free quantification that closely mimics the routine cytology procedure, a drawback is the need for a bladder wash sample instead of voided urine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bladder cancer remains an important cause of morbidity and mortality. Although the diagnosis is often made early in the natural history of the disease, recurrences are frequent and life-long follow-up is often required.",
"   </p>",
"   <p>",
"    Improved diagnostic techniques are required both for individuals in whom there is a high suspicion of bladder cancer and for those under surveillance after treatment for early non-muscle-invasive bladder cancer. Numerous urine biomarkers have been developed or are being studied (",
"    <a class=\"graphic graphic_table graphicRef70530 \" href=\"mobipreview.htm?16/29/16859\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef59814 \" href=\"mobipreview.htm?13/17/13595\">",
"     table 2",
"    </a>",
"    ). These approaches have demonstrated a substantially higher sensitivity than urine cytology, but with a significantly lower specificity. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Urine biomarkers'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Currently, cystoscopy remains the procedure of choice, both for initial diagnosis and for surveillance in previously treated patients. Additional studies are required to determine the optimal way to integrate these newer techniques into patient management. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22039?source=see_link\">",
"     \"Screening for bladder cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/11/40122?source=see_link&amp;anchor=H42#H42\">",
"     \"Treatment of non-muscle-invasive bladder cancer\", section on 'Posttreatment management'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/1\">",
"      Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/2\">",
"      Mitra AP, Cote RJ. Molecular screening for bladder cancer: progress and potential. Nat Rev Urol 2010; 7:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/3\">",
"      Tilki D, Burger M, Dalbagni G, et al. Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. Eur Urol 2011; 60:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/4\">",
"      Cheng ZZ, Corey MJ, P&auml;repalo M, et al. Complement factor H as a marker for detection of bladder cancer. Clin Chem 2005; 51:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/5\">",
"      Schroeder GL, Lorenzo-Gomez MF, Hautmann SH, et al. A side by side comparison of cytology and biomarkers for bladder cancer detection. J Urol 2004; 172:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/6\">",
"      Halling KC, King W, Sokolova IA, et al. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. J Urol 2002; 167:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/7\">",
"      Boman H, Hedelin H, Jacobsson S, Holm&auml;ng S. Newly diagnosed bladder cancer: the relationship of initial symptoms, degree of microhematuria and tumor marker status. J Urol 2002; 168:1955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/8\">",
"      Guti&eacute;rrez Ba&ntilde;os JL, Rebollo Rodrigo MH, Antol&iacute;n Ju&aacute;rez FM, Mart&iacute;n Garc&iacute;a B. NMP 22, BTA stat test and cytology in the diagnosis of bladder cancer: a comparative study. Urol Int 2001; 66:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/9\">",
"      Lokeshwar VB, Schroeder GL, Selzer MG, et al. Bladder tumor markers for monitoring recurrence and screening comparison of hyaluronic acid-hyaluronidase and BTA-Stat tests. Cancer 2002; 95:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/10\">",
"      Raitanen MP, Kaasinen E, Lukkarinen O, et al. Analysis of false-positive BTA STAT test results in patients followed up for bladder cancer. Urology 2001; 57:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/11\">",
"      Raitanen MP, Marttila T, Nurmi M, et al. Human complement factor H related protein test for monitoring bladder cancer. J Urol 2001; 165:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/12\">",
"      Walsh IK, Keane PF, Ishak LM, Flessland KA. The BTA stat test: a tumor marker for the detection of upper tract transitional cell carcinoma. Urology 2001; 58:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/13\">",
"      Gibanel R, Ribal MJ, Filella X, et al. BTA TRAK urine test increases the efficacy of cytology in the diagnosis of low-grade transitional cell carcinoma of the bladder. Anticancer Res 2002; 22:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/14\">",
"      Mahnert B, Tauber S, Kriegmair M, et al. Measurements of complement factor H-related protein (BTA-TRAK assay) and nuclear matrix protein (NMP22 assay)--useful diagnostic tools in the diagnosis of urinary bladder cancer? Clin Chem Lab Med 2003; 41:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/15\">",
"      Malkowicz SB. The application of human complement factor H-related protein (BTA TRAK) in monitoring patients with bladder cancer. Urol Clin North Am 2000; 27:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/16\">",
"      Mattioli S, Seregni E, Caperna L, et al. BTA-TRAK combined with urinary cytology is a reliable urinary indicator of recurrent transitional cell carcinoma (TCC) of the bladder. Int J Biol Markers 2000; 15:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/17\">",
"      Priolo G, Gontero P, Martinasso G, et al. Bladder tumor antigen assay as compared to voided urine cytology in the diagnosis of bladder cancer. Clin Chim Acta 2001; 305:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/18\">",
"      Miyanaga N, Akaza H, Tsukamoto S, et al. Usefulness of urinary NMP22 to detect tumor recurrence of superficial bladder cancer after transurethral resection. Int J Clin Oncol 2003; 8:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/19\">",
"      Abd El Gawad IA, Moussa HS, Nasr MI, et al. Comparative study of NMP-22, telomerase, and BTA in the detection of bladder cancer. J Egypt Natl Canc Inst 2005; 17:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/20\">",
"      Raitanen MP, FinnBladder Group. The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies. World J Urol 2008; 26:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/21\">",
"      Bassi P, De Marco V, De Lisa A, et al. Non-invasive diagnostic tests for bladder cancer: a review of the literature. Urol Int 2005; 75:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/22\">",
"      Grossman HB, Messing E, Soloway M, et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 2005; 293:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/23\">",
"      Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology 2003; 61:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/24\">",
"      Eissa S, Swellam M, Sadek M, et al. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors. J Urol 2002; 168:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/25\">",
"      Ponsky LE, Sharma S, Pandrangi L, et al. Screening and monitoring for bladder cancer: refining the use of NMP22. J Urol 2001; 166:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/26\">",
"      Grossman HB, Soloway M, Messing E, et al. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA 2006; 295:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/27\">",
"      Shariat SF, Savage C, Chromecki TF, et al. Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with nonmuscle-invasive bladder cancer and negative cytology: a decision-curve analysis. Cancer 2011; 117:2892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/28\">",
"      Attallah AM, Sakr HA, Ismail H, et al. An office-based immunodiagnostic assay for detecting urinary nuclear matrix protein 52 in patients with bladder cancer. BJU Int 2005; 96:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/29\">",
"      Getzenberg RH, Konety BR, Oeler TA, et al. Bladder cancer-associated nuclear matrix proteins. Cancer Res 1996; 56:1690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/30\">",
"      Myers-Irvin JM, Landsittel D, Getzenberg RH. Use of the novel marker BLCA-1 for the detection of bladder cancer. J Urol 2005; 174:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/31\">",
"      Konety BR, Nguyen TS, Dhir R, et al. Detection of bladder cancer using a novel nuclear matrix protein, BLCA-4. Clin Cancer Res 2000; 6:2618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/32\">",
"      Van Le TS, Miller R, Barder T, et al. Highly specific urine-based marker of bladder cancer. Urology 2005; 66:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/33\">",
"      Lokeshwar VB, Selzer MG. Urinary bladder tumor markers. Urol Oncol 2006; 24:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/34\">",
"      S&aacute;nchez-Carbayo M, Herrero E, Meg&iacute;as J, et al. Comparative sensitivity of urinary CYFRA 21-1, urinary bladder cancer antigen, tissue polypeptide antigen, tissue polypeptide antigen and NMP22 to detect bladder cancer. J Urol 1999; 162:1951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/35\">",
"      Pariente JL, Bordenave L, Michel P, et al. Initial evaluation of CYFRA 21-1 diagnostic performances as a urinary marker in bladder transitional cell carcinoma. J Urol 1997; 158:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/36\">",
"      S&aacute;nchez-Carbayo M, Urrutia M, Silva JM, et al. Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA 21-1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer. J Urol 2001; 165:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/37\">",
"      Nisman B, Barak V, Shapiro A, et al. Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma. Cancer 2002; 94:2914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/38\">",
"      Fatela-Cantillo D, Fern&aacute;ndez-Su&aacute;rez A, Men&eacute;ndez V, et al. Low utility of CYFRA 21-1 serum levels for diagnosis and follow-up in bladder cancer patients. J Clin Lab Anal 2005; 19:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/39\">",
"      Fernandez-Gomez J, Rodr&iacute;guez-Mart&iacute;nez JJ, Barmadah SE, et al. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer. Eur Urol 2007; 51:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/40\">",
"      Lokeshwar VB, Obek C, Pham HT, et al. Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade. J Urol 2000; 163:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/41\">",
"      Passerotti CC, Srougi M, Bomfim AC, et al. Testing for urinary hyaluronate improves detection and grading of transitional cell carcinoma. Urol Oncol 2011; 29:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/42\">",
"      Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266:2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/43\">",
"      Kavaler E, Landman J, Chang Y, et al. Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerase activity. Cancer 1998; 82:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/44\">",
"      Cassel A, Rahat MA, Lahat N, et al. Telomerase activity and cytokeratin 20 as markers for the detection and followup of transitional cell carcinoma: an unfulfilled promise. J Urol 2001; 166:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/45\">",
"      Birkhahn M, Mitra AP, Cote RJ. Molecular markers for bladder cancer: the road to a multimarker approach. Expert Rev Anticancer Ther 2007; 7:1717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/46\">",
"      Shariat SF, Casella R, Khoddami SM, et al. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol 2004; 171:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/47\">",
"      Margulis V, Lotan Y, Shariat SF. Survivin: a promising biomarker for detection and prognosis of bladder cancer. World J Urol 2008; 26:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/48\">",
"      Smith SD, Wheeler MA, Plescia J, et al. Urine detection of survivin and diagnosis of bladder cancer. JAMA 2001; 285:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/49\">",
"      Moussa O, Abol-Enein H, Bissada NK, et al. Evaluation of survivin reverse transcriptase-polymerase chain reaction for noninvasive detection of bladder cancer. J Urol 2006; 175:2312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/50\">",
"      Kenney DM, Geschwindt RD, Kary MR, et al. Detection of newly diagnosed bladder cancer, bladder cancer recurrence and bladder cancer in patients with hematuria using quantitative rt-PCR of urinary survivin. Tumour Biol 2007; 28:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/51\">",
"      Pu XY, Wang ZP, Chen YR, et al. The value of combined use of survivin, cytokeratin 20 and mucin 7 mRNA for bladder cancer detection in voided urine. J Cancer Res Clin Oncol 2008; 134:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/52\">",
"      Tsihlias J, Grossman HB. The utility of fibrin/fibrinogen degradation products in superficial bladder cancer. Urol Clin North Am 2000; 27:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/53\">",
"      Schmetter BS, Habicht KK, Lamm DL, et al. A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer. J Urol 1997; 158:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/54\">",
"      Topsakal M, Karadeniz T, Ana&ccedil; M, et al. Assessment of fibrin-fibrinogen degradation products (Accu-Dx) test in bladder cancer patients. Eur Urol 2001; 39:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/55\">",
"      Berger AP, Parson W, Stenzl A, et al. Microsatellite alterations in human bladder cancer: detection of tumor cells in urine sediment and tumor tissue. Eur Urol 2002; 41:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/56\">",
"      Bartoletti R, Cai T, Dal Canto M, et al. Multiplex polymerase chain reaction for microsatellite analysis of urine sediment cells: a rapid and inexpensive method for diagnosing and monitoring superficial transitional bladder cell carcinoma. J Urol 2006; 175:2032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/57\">",
"      Christensen M, Wolf H, Orntoft TF. Microsatellite alterations in urinary sediments from patients with cystitis and bladder cancer. Int J Cancer 2000; 85:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/58\">",
"      T&ecirc;tu B, Tiguert R, Harel F, Fradet Y. ImmunoCyt/uCyt+ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma. Mod Pathol 2005; 18:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/59\">",
"      Mian C, Pycha A, Wiener H, et al. Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract. J Urol 1999; 161:1486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/60\">",
"      Lodde M, Mian C, Wiener H, et al. Detection of upper urinary tract transitional cell carcinoma with ImmunoCyt: a preliminary report. Urology 2001; 58:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/61\">",
"      Pfister C, Chautard D, Devonec M, et al. Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study. J Urol 2003; 169:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/62\">",
"      Mian C, Lodde M, Comploj E, et al. The value of the ImmunoCyt/uCyt+ test in the detection and follow-up of carcinoma in situ of the urinary bladder. Anticancer Res 2005; 25:3641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/63\">",
"      Mian C, Maier K, Comploj E, et al. uCyt+/ImmunoCyt in the detection of recurrent urothelial carcinoma: an update on 1991 analyses. Cancer 2006; 108:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/64\">",
"      Lodde M, Mian C, Comploj E, et al. uCyt+ test: alternative to cystoscopy for less-invasive follow-up of patients with low risk of urothelial carcinoma. Urology 2006; 67:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/65\">",
"      Gilbert SM, Veltri RW, Sawczuk A, et al. Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma of the bladder in patients with a history of bladder cancer. Urology 2003; 61:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/66\">",
"      Sawczuk IS, Pickens CL, Vasa UR, et al. DD23 Biomarker: a prospective clinical assessment in routine urinary cytology specimens from patients being monitored for TCC. Urol Oncol 2002; 7:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/67\">",
"      Sheinfeld J, Reuter VE, Melamed MR, et al. Enhanced bladder cancer detection with the Lewis X antigen as a marker of neoplastic transformation. J Urol 1990; 143:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/68\">",
"      Golijanin D, Sherman Y, Shapiro A, Pode D. Detection of bladder tumors by immunostaining of the Lewis X antigen in cells from voided urine. Urology 1995; 46:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/69\">",
"      Planz B, Striepecke E, Jakse G, B&ouml;cking A. Use of Lewis X antigen and deoxyribonucleic acid image cytometry to increase sensitivity of urinary cytology in transitional cell carcinoma of the bladder. J Urol 1998; 159:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/70\">",
"      Pode D, Golijanin D, Sherman Y, et al. Immunostaining of Lewis X in cells from voided urine, cytopathology and ultrasound for noninvasive detection of bladder tumors. J Urol 1998; 159:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/71\">",
"      Planz B, Synek C, Deix T, et al. Diagnosis of bladder cancer with urinary cytology, immunocytology and DNA-image-cytometry. Anal Cell Pathol 2001; 22:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/72\">",
"      Shirahama T, Ikoma M, Muramatsu T, Ohi Y. Expression of SSEA-1 carbohydrate antigen correlates with stage, grade and metastatic potential of transitional cell carcinoma of the bladder. J Urol 1992; 148:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/73\">",
"      Friedrich MG, Hellstern A, Hautmann SH, et al. Clinical use of urinary markers for the detection and prognosis of bladder carcinoma: a comparison of immunocytology with monoclonal antibodies against Lewis X and 486p3/12 with the BTA STAT and NMP22 tests. J Urol 2002; 168:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/74\">",
"      Toma MI, Friedrich MG, Hautmann SH, et al. Comparison of the ImmunoCyt test and urinary cytology with other urine tests in the detection and surveillance of bladder cancer. World J Urol 2004; 22:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/75\">",
"      Loy TS, Alexander CJ, Calaluce RD. Lewis X antigen immunostaining in the diagnosis of transitional cell carcinoma. Mod Pathol 1995; 8:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/76\">",
"      Black PC, Brown GA, Dinney CP. Molecular markers of urothelial cancer and their use in the monitoring of superficial urothelial cancer. J Clin Oncol 2006; 24:5528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/77\">",
"      Yoder BJ, Skacel M, Hedgepeth R, et al. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol 2007; 127:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/78\">",
"      Hajdinjak T. UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing. Urol Oncol 2008; 26:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/79\">",
"      Lokeshwar VB, Habuchi T, Grossman HB, et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology 2005; 66:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/80\">",
"      Schlomer BJ, Ho R, Sagalowsky A, et al. Prospective validation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. J Urol 2010; 183:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/81\">",
"      Halling KC, King W, Sokolova IA, et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol 2000; 164:1768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/82\">",
"      Bubendorf L, Grilli B, Sauter G, et al. Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am J Clin Pathol 2001; 116:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/83\">",
"      Sarosdy MF, Schellhammer P, Bokinsky G, et al. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 2002; 168:1950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/84\">",
"      Skacel M, Fahmy M, Brainard JA, et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol 2003; 169:2101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/85\">",
"      van der Poel HG, Witjes JA, van Stratum P, et al. Quanticyt: karyometric analysis of bladder washing for patients with superficial bladder cancer. Urology 1996; 48:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/86\">",
"      van der Poel HG, Boon ME, van Stratum P, et al. Conventional bladder wash cytology performed by four experts versus quantitative image analysis. Mod Pathol 1997; 10:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/87\">",
"      Van der Poel HG, Van Balken MR, Schamhart DH, et al. Bladder wash cytology, quantitative cytology, and the qualitative BTA test in patients with superficial bladder cancer. Urology 1998; 51:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/88\">",
"      Wiener HG, Mian C, Haitel A, et al. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer? J Urol 1998; 159:1876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/89\">",
"      van der Poel HG, van Rhijn BW, Peelen P, et al. Consecutive quantitative cytology in bladder cancer. Urology 2000; 56:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40041/abstract/90\">",
"      Vriesema JL, van der Poel HG, Debruyne FM, et al. Neural network-based digitized cell image diagnosis of bladder wash cytology. Diagn Cytopathol 2000; 23:171.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2968 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.122.249.114-555B9DE994-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_6_40041=[""].join("\n");
var outline_f39_6_40041=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      POTENTIAL APPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      URINE BIOMARKERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Bladder tumor antigen (BTA) assays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Nuclear matrix protein 22",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other NMPs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Nuclear matrix protein 52",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - BLCA-4 and BLCA-1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cytokeratins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      HA and HAase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Telomerase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Survivin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Fibrin degradation products",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Microsatellite analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ImmunoCyt",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DD23 monoclonal antibody",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Lewis X antigen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      UroVysion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Automated image cytometry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2968\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2968|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/29/16859\" title=\"table 1\">",
"      Test molc markers urine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/17/13595\" title=\"table 2\">",
"      Test exfol cells urine",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/47/20217?source=related_link\">",
"      Clinical presentation, diagnosis, and staging of bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26586?source=related_link\">",
"      Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34746?source=related_link\">",
"      Etiology and evaluation of hematuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/45/1754?source=related_link\">",
"      Malignancies of the renal pelvis and ureter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22039?source=related_link\">",
"      Screening for bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/11/40122?source=related_link\">",
"      Treatment of non-muscle-invasive bladder cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_6_40042="Treatment of psoriasis";
var content_f39_6_40042=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of psoriasis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/6/40042/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/6/40042/contributors\">",
"     Steven R Feldman, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/6/40042/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/6/40042/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/6/40042/contributors\">",
"     Kristina Callis Duffin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/6/40042/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/6/40042/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/6/40042/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psoriasis is a common chronic skin disorder typically characterized by erythematous papules and plaques with a silver scale, although other presentations occur. Most cases are not severe enough to affect general health and are treated in the outpatient setting. Rare life-threatening presentations can occur that require intensive inpatient management.",
"   </p>",
"   <p>",
"    This topic reviews the treatment of psoriatic skin disease. The epidemiology, clinical manifestations, and diagnosis of psoriatic skin disease are discussed in detail separately, as are psoriatic arthritis and the management of psoriasis in pregnant women and special populations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27625?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of psoriasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/18/40234?source=see_link\">",
"     \"Treatment of psoriatic arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/3/23608?source=see_link\">",
"     \"Pathogenesis of psoriatic arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/49/30488?source=see_link\">",
"     \"Clinical manifestations and diagnosis of psoriatic arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/4/41030?source=see_link\">",
"     \"Management of psoriasis in pregnant women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/31/14842?source=see_link\">",
"     \"Treatment selection for moderate to severe plaque psoriasis in special populations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     APPROACH",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     General",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous topical and systemic therapies are available for the treatment of psoriasis. Treatment modalities are chosen on the basis of disease severity, relevant comorbidities, patient preference (including cost and convenience), efficacy, and evaluation of individual patient response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the relatively poor adherence to treatment regimens frequently seen with topical therapies, patient preference is a key aspect of decision making. Additionally, patients are typically started on safer therapies and then progress to more aggressive therapies if the response is inadequate. Clinicians need to carefully review the risk-benefit profiles of proposed therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Psychosocial aspects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psoriasis can be a frustrating disease for the patient and the provider. The clinician needs to be empathetic and spend adequate time with the patient. It may be helpful for the clinician to touch the patient when appropriate to communicate physically that the skin disorder is neither repulsive nor contagious.",
"   </p>",
"   <p>",
"    Clinicians should lay out reasonable aims of treatment, making it clear to the patient that the primary goal of treatment is control of the disease rather than cure.",
"   </p>",
"   <p>",
"    Educating the patient about psoriasis is important and referral to an organization such as the National Psoriasis Foundation (",
"    <a class=\"external\" href=\"file://www.psoriasis.org/\">",
"     www.psoriasis.org",
"    </a>",
"    ) is often helpful.",
"   </p>",
"   <p>",
"    Psoriasis may affect patients' perceptions of themselves and this can potentially initiate or exacerbate psychological disorders such as depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Patients with limited skin disease may still have significant psychosocial disability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/4\">",
"     4",
"    </a>",
"    ]. Some patients with psoriasis may benefit from counseling",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    treatment with psychoactive medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Choice of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most patients, the initial decision point around therapy will be between topical and systemic therapy. However, even patients on systemic therapy will likely continue to need some topical agents. Topical therapy may provide symptomatic relief, minimize required doses of systemic medications, and may even be psychologically cathartic for some patients.",
"   </p>",
"   <p>",
"    For purposes of treatment planning, patients may be grouped into mild-to-moderate and moderate-to-severe disease categories. Limited, or mild-to-moderate, skin disease can often be managed with topical agents, while patients with moderate-to-severe disease may need systemic therapy. The location of the disease and the presence of psoriatic arthritis also affect the choice of therapy. Psoriasis of the hand, foot, or face can be debilitating functionally or socially and may deserve a more aggressive treatment approach. The treatment of psoriatic arthritis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/18/40234?source=see_link\">",
"     \"Treatment of psoriatic arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Moderate-to-severe psoriasis is typically defined as involvement of more than 5 to 10 percent of the body surface area (the entire palmar surface, including fingers, of one hand is approximately 1 percent of the body surface area [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/5\">",
"     5",
"    </a>",
"    ]) or involvement of the face, palm or sole, or disease that is otherwise disabling. Patients with more than 5 to 10 percent body surface area affected are generally candidates for systemic therapy, since application of topical agents to a large area is not usually practical or acceptable for most patients. Attempts to treat extensive disease with topical agents are often met with failure, can add cost, and lead to frustration in the patient-clinician relationship.",
"   </p>",
"   <p>",
"    There is ample evidence of efficacy of the newer systemic therapies (\"biologics\"); however, cost is a major consideration with these agents. Established therapies such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and phototherapy continue to play a role in the management of moderate to severe plaque psoriasis. The management of patients with extensive or recalcitrant disease is a challenge even for experienced dermatologists.",
"   </p>",
"   <p>",
"    Widespread pustular disease requires aggressive treatment, which may include hospitalization. The treatment of psoriatic arthritis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/18/40234?source=see_link\">",
"     \"Treatment of psoriatic arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Mild-to-moderate disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited plaque psoriasis responds well to topical corticosteroids and emollients. Alternatives include tar, topical retinoids (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/17/19732?source=see_link\">",
"     tazarotene",
"    </a>",
"    ), and vitamin D analogs including calcipotriene and calcitriol. For facial or intertriginous areas, topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/41/29332?source=see_link\">",
"     pimecrolimus",
"    </a>",
"    may be used as alternatives or as corticosteroid sparing agents, though improvement may not be as rapid. Localized phototherapy is another option for recalcitrant disease.",
"   </p>",
"   <p>",
"    Combinations of potent topical corticosteroids (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"mobipreview.htm?38/56/39809\">",
"     table 1",
"    </a>",
"    ) and either calcipotriene, calcitriol,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/17/19732?source=see_link\">",
"     tazarotene",
"    </a>",
"    , or UVB phototherapy are commonly prescribed by dermatologists. Calcipotriene in combination with Class I topical corticosteroids is highly effective for short-term control. Calcipotriene alone can then be used continuously and the combination with potent corticosteroids used intermittently (on weekends) for maintenance. A combination product containing calcipotriene and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    dipropionate is available for this use. With proper adherence, considerable improvement with topical therapies may be seen in as little as one week, though several weeks may be required to demonstrate full benefits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Severe disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe psoriasis requires phototherapy or systemic therapies such as retinoids,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , or biologic immune modifying agents. Biologic agents used in the treatment of psoriasis include the anti-TNF agents",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    and the",
"    <span class=\"nowrap\">",
"     anti-IL-12/23",
"    </span>",
"    antibody",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/46/742?source=see_link\">",
"     ustekinumab",
"    </a>",
"    . Improvement usually occurs within weeks. Patients with severe psoriasis generally require care by a dermatologist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Intertriginous psoriasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intertriginous (inverse) psoriasis should be treated with class VI and VII low potency corticosteroids (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"mobipreview.htm?38/56/39809\">",
"     table 1",
"    </a>",
"    ) due to an increased risk of corticosteroid-induced cutaneous atrophy in the intertriginous areas. Topical calcipotriene or calcitriol and the topical calcineurin inhibitors",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/41/29332?source=see_link\">",
"     pimecrolimus",
"    </a>",
"    are additional first-line treatments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. These agents may be used alone or in combination with topical corticosteroids as corticosteroid sparing agents for long term maintenance therapy. Calcipotriene, tacrolimus, and pimecrolimus are more expensive options than topical corticosteroids. Some concerns have been raised about the safety of the calcineurin inhibitors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27625?source=see_link&amp;anchor=H12#H12\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of psoriasis\", section on 'Inverse psoriasis'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H22\">",
"     'Calcineurin inhibitors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Guttate psoriasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guttate psoriasis generally responds to UVB phototherapy (broadband or 311 nm), with or without medium potency topical corticosteroids. This variant of psoriasis has been strongly associated with streptococcal infections. Streptococcal infections should be treated if present. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27625?source=see_link&amp;anchor=H11#H11\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of psoriasis\", section on 'Guttate psoriasis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Case reports and a small prospective study have documented resolution of guttate psoriasis after tonsillectomy in patients with recurrent streptococcal tonsillopharyngitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. However, there have been no high-quality trials investigating the therapeutic effect of tonsillectomy in this setting. Until further studies support the efficacy of tonsillectomy for guttate psoriasis, the procedure cannot be routinely recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Localized pustular psoriasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Localized pustular psoriasis (palms and soles) is difficult to treat. Approaches include potent topical corticosteroids and topical bath PUVA. Data are limited on the use of systemic retinoids for localized pustular psoriasis. However, these drugs appear to be particularly effective in the treatment of pustular psoriasis, and we consider them first line therapy.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/1/39958?source=see_link\">",
"     Acitretin",
"    </a>",
"    is the retinoid that is used most often for this indication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Nail psoriasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although nail involvement alone is uncommon, many patients with psoriasis have disease that involves the nails. Psoriasis pathology resides in the nail matrix, nail bed, and hyponychium. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27625?source=see_link&amp;anchor=H13#H13\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of psoriasis\", section on 'Nail psoriasis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Physical maneuvers to improve nail appearance or comfort may be helpful for some patients. Patients can thin their nails by scraping them with a file or shaving them down with the edge of a glass slide. Thick toenails that are painful or interfere with footwear can be removed by a podiatrist.",
"   </p>",
"   <p>",
"    Despite advances in the treatment of cutaneous disease, the treatment of psoriasis of the nails remains difficult. There is relatively little evidence to guide the choice of therapies for nail disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Topical therapies are sometimes tried; however, delivering topical treatment is difficult because of the physical barrier of the nail plate. If improvement in nail appearance occurs, it can be expected to be slow, as 8 to 12 months are needed to generate a new, healthy nail.",
"   </p>",
"   <p>",
"    There is no standardized regimen for the treatment of nail psoriasis with topical agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/11\">",
"     11",
"    </a>",
"    ]. For distal nail onycholysis (separation of the nail from the nail bed), we suggest starting with a class I or II topical corticosteroid (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"mobipreview.htm?38/56/39809\">",
"     table 1",
"    </a>",
"    ), such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/16/10502?source=see_link\">",
"     clobetasol",
"    </a>",
"    0.05% solution, combined with calcipotriene 0.005% solution dripped into the nail bed and hyponychium twice daily. For patients with nail pitting and other superficial nail defects, the pathologic process is occurring under the proximal nail fold. We typically use a high potency topical corticosteroid (class I or II) and a topical vitamin D analog applied once or twice daily under an occlusive dressing. The use of a combination product containing both a corticosteroid and a vitamin D analog may simplify treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/12\">",
"     12",
"    </a>",
"    ]. Cutaneous atrophy is a potential adverse effect of the long-term use of potent topical corticosteroids.",
"   </p>",
"   <p>",
"    For severe or recalcitrant nail disease, intralesional therapy with corticosteroids is a reasonable next option.",
"   </p>",
"   <p>",
"    Systemic therapy may be more effective than topical therapy. A randomized trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    in patients with moderate to severe psoriasis (82 percent of whom had nail psoriasis) found marked improvements in nail pathology compared with baseline and with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/13\">",
"     13",
"    </a>",
"    ]. Treatment with other biologic agents, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/24/35206?source=see_link\">",
"     golimumab",
"    </a>",
"    have also led to improvement in nail psoriasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/14-16\">",
"     14-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oral retinoids have been utilized in the treatment of nail psoriasis with some success. A study of low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/1/39958?source=see_link\">",
"     acitretin",
"    </a>",
"    (0.2-0.3",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    given to 36 patients with isolated nail psoriasis for six months led to complete or almost complete clearance in 25 percent, moderate improvement in 25 percent, mild improvement in 33 percent, and no improvement in 11 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/17\">",
"     17",
"    </a>",
"    ]. At a six month follow-up visit after the end of treatment, recurrence of nail psoriasis was noted. However, patients who improved with acitretin had less severe nail findings than at the start of treatment. (See",
"    <a class=\"local\" href=\"#H33\">",
"     'Retinoids'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Photochemotherapy (PUVA) and pulsed dye laser therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/18\">",
"     18",
"    </a>",
"    ] have also been used for the treatment of nail psoriasis. Evidence for the efficacy of PUVA is limited to reports from small, uncontrolled studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In choosing among treatments, serious consideration must be given to the risks of systemic therapy and photochemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Erythrodermic psoriasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no high quality evidence to support specific recommendations for the management of erythrodermic psoriasis. Based upon data from open-label or retrospective studies and case reports, a panel of experts suggested that patients with severe, unstable disease should be treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    due to the rapid onset and high efficacy of these agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/21\">",
"     21",
"    </a>",
"    ]. Patients with less acute disease can be treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/1/39958?source=see_link\">",
"     acitretin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    as first-line agents. The panel advised against the use of systemic glucocorticoids due to the potential for these drugs to induce a flare of psoriasis upon withdrawal of therapy. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Systemic therapies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Data are limited on the efficacy of biologic agents other than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    for the treatment of erythrodermic psoriasis.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     Etanercept",
"    </a>",
"    was effective in an open-label study of 10 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/22\">",
"     22",
"    </a>",
"    ], and case reports have documented successful treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/46/742?source=see_link\">",
"     ustekinumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, patients with erythrodermic psoriasis should be cared for by a dermatologist and may require hospitalization",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    combinations of systemic treatments. Topical therapies, such as mid-potency topical corticosteroids, emollients, wet dressings, and oatmeal baths can be used in concordance with systemic treatment to manage symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/21\">",
"     21",
"    </a>",
"    ]. Long-term maintenance therapy for psoriasis is required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3704961\">",
"    <span class=\"h2\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;The immediate and long-term adverse effects of therapies for psoriasis are of particular concern in the pediatric population. Many agents used in the treatment of adult psoriasis have also been used for children. However, high quality studies on the efficacy and safety of therapies for psoriasis in children are limited. Guidelines for the treatment of children based upon the available evidence have been published [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20559477\">",
"    <span class=\"h2\">",
"     Special populations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of psoriasis in pregnant women and patients with hepatitis B, hepatitis C, human immunodeficiency virus infection, latent tuberculosis, or malignancy is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/31/14842?source=see_link\">",
"     \"Treatment selection for moderate to severe plaque psoriasis in special populations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/4/41030?source=see_link\">",
"     \"Management of psoriasis in pregnant women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Referral to a dermatologist should be considered in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Confirmation of the diagnosis is needed.",
"     </li>",
"     <li>",
"      The response to treatment is inadequate as measured by the physician, patient, or both.",
"     </li>",
"     <li>",
"      There is significant impact on quality of life.",
"     </li>",
"     <li>",
"      The primary care physician is not familiar with the treatment modality recommended such as PUVA, phototherapy, or immunosuppressive medications.",
"     </li>",
"     <li>",
"      The patient has widespread severe disease.",
"     </li>",
"     <li>",
"      In cases of psoriatic arthritis, referral",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      collaboration with a rheumatologist is indicated. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/18/40234?source=see_link\">",
"       \"Treatment of psoriatic arthritis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TOPICAL THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient adherence may be the largest barrier to treatment success with topical therapies; frequent patient follow-up (initially every week) may improve adherence. Published guidelines for the treatment of psoriasis with topical therapies are available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Emollients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hydration and emollients are valuable and inexpensive adjuncts to psoriasis treatment. Keeping psoriatic skin soft and moist minimizes the symptoms of itching and tenderness. Additionally, maintaining proper skin hydration can help prevent irritation and thus the potential for subsequent Koebnerization (development of new psoriatic lesions at sites of trauma).",
"   </p>",
"   <p>",
"    The most effective are ointments such as petroleum jelly or thick creams, especially when applied immediately after a hydrating bath or shower.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical corticosteroids remain the mainstay of topical psoriasis treatment despite the development of newer agents. The mechanism of action of corticosteroids in psoriasis is not fully understood. Corticosteroids exert antiinflammatory, antiproliferative, and immunosuppressive actions by affecting gene transcription.",
"   </p>",
"   <p>",
"    The inherent potency of a topical corticosteroid is frequently reported using a I to VII scale based on vasoconstrictive assays (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"mobipreview.htm?38/56/39809\">",
"     table 1",
"    </a>",
"    ). Although ointments are sometimes thought to be inherently more effective because of their occlusive properties, this is not uniformly correct. In practice, the",
"    <span class=\"nowrap\">",
"     efficacy/potency",
"    </span>",
"    of a topical corticosteroid is dependent on many factors including skin type, plaque thickness, and, perhaps most importantly, compliance.",
"   </p>",
"   <p>",
"    To minimize adverse effects and maximize compliance, the site of application needs to be considered in choosing the appropriately potent corticosteroid:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      On the scalp or in the external ear canal, potent corticosteroids in a solution or foam vehicle (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/56/30596?source=see_link\">",
"       fluocinonide",
"      </a>",
"      0.05% or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/16/10502?source=see_link\">",
"       clobetasol",
"      </a>",
"      propionate 0.05%) are frequently indicated. Clobetasol 0.05% shampoo or spray can also be used for scalp involvement.",
"     </li>",
"     <li>",
"      On the face and intertriginous areas, a low potency cream (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      1%) is often sufficient.",
"     </li>",
"     <li>",
"      For thick plaques on extensor surfaces, potent preparations (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44120?source=see_link\">",
"       betamethasone",
"      </a>",
"      0.05% or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/16/10502?source=see_link\">",
"       clobetasol",
"      </a>",
"      propionate 0.05%) are often required.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The typical regimen consists of twice daily application of topical corticosteroids. Most patients will show a rapid decrease in inflammation with such therapy, but complete normalization of skin or lasting remission is unpredictable.",
"   </p>",
"   <p>",
"    Topical corticosteroids generally can be continued as long as the patient has thick active lesions. Skin atrophy from topical corticosteroids usually is not a problem unless the medication is continuously applied after the skin has returned to normal thickness. Once clinical improvement occurs, the frequency of application should be reduced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/26\">",
"     26",
"    </a>",
"    ]. For patients in whom lesions recur quickly, topical corticosteroids can be applied intermittently (such as on weekends only) to maintain improvement. The addition of non-corticosteroid treatments can also facilitate the avoidance of long-term daily topical corticosteroids. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Mild-to-moderate disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The risks of cutaneous and systemic side effects associated with chronic topical corticosteroid use are increased with high potency formulations. Current data support limiting the continuous application of Class I topical corticosteroids to two to four weeks; thus, close clinician supervision should be employed if longer treatment durations are required (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"mobipreview.htm?38/56/39809\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/26\">",
"     26",
"    </a>",
"    ]. Data are less clear regarding treatment durations for less potent topical corticosteroids. Side effects of topical corticosteroids, including the potential for suppression of the hypothalamic axis, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23208?source=see_link\">",
"     \"Pharmacologic use of glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/6/27752?source=see_link\">",
"     \"General principles of dermatologic therapy and topical corticosteroid use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The cost of topical corticosteroids varies widely. The price of a 60 gram tube of a potent corticosteroid brand name product can be as high as $80 or more. There are now generic preparations in each potency class that have reduced the cost somewhat. Examples of available generics include, in order of increasing potency,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    1%,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    0.1%,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/56/30596?source=see_link\">",
"     fluocinonide",
"    </a>",
"    0.05%,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    dipropionate 0.05%, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/16/10502?source=see_link\">",
"     clobetasol",
"    </a>",
"    0.05%.",
"   </p>",
"   <p>",
"    Different formulations have been developed in an effort to enhance the delivery of topical corticosteroids.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44120?source=see_link\">",
"     Betamethasone",
"    </a>",
"    valerate in a foam was found to have superior efficacy for scalp psoriasis and was preferred by patients when compared with betamethasone valerate lotion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/27\">",
"     27",
"    </a>",
"    ]. The foam becomes a liquid on contact with skin and is also well tolerated by patients with trunk and extremity psoriasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/28\">",
"     28",
"    </a>",
"    ]. A",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/16/10502?source=see_link\">",
"     clobetasol",
"    </a>",
"    propionate spray is also available; like foams, sprays are easy to apply to large areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/29\">",
"     29",
"    </a>",
"    ]. The main advantage of these newer preparations is likely greater patient acceptance, which may translate into greater adherence; the main disadvantage is cost.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Topical vitamin D analogs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical vitamin D analogs for the treatment of psoriasis include calcipotriene (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/54/5988?source=see_link\">",
"     calcipotriol",
"    </a>",
"    ), calcitriol, and tacalcitol. Although topical vitamin D analogs are effective as monotherapy for some patients, a systematic review found that combination therapy with a topical corticosteroid is more effective than either treatment alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Until 2009, calcipotriene was the only topical vitamin D analog available in the United States. Calcipotriene is obtainable as a cream, solution, ointment, or foam (Dovonex, Calcitrenec, Sorilux), or as a combination ointment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    dipropionate (Taclonex). Topical calcitriol ointment has been prescribed in Europe for years, and is now available in the United States (Vectical). When compared with calcipotriene, calcitriol appears to induce less irritation in sensitive areas of the skin (eg, skin folds) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Calcipotriene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcipotriene (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/54/5988?source=see_link\">",
"     calcipotriol",
"    </a>",
"    ) is an established therapy in psoriasis. The precise mechanism is not clear, but a major effect is the hypoproliferative effect on keratinocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/32\">",
"     32",
"    </a>",
"    ]. An immune modulating effect has been postulated for calcipotriene, but has not been shown to be significant in psoriasis to date [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a systematic review of randomized controlled trials, calcipotriene was at least as effective as potent topical corticosteroids, calcitriol, short contact dithranol, tacalcitol,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/43/44724?source=see_link\">",
"     coal tar",
"    </a>",
"    and combined coal tar 5%, allantoin 2%, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    0.5% [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/34\">",
"     34",
"    </a>",
"    ]. Only potent topical corticosteroids appeared to have comparable efficacy at eight weeks. Skin irritation is the main adverse event associated with calcipotriene.",
"   </p>",
"   <p>",
"    Combined use of calcipotriene and superpotent corticosteroids has demonstrated increased clinical response and tolerance in clinical trials compared to either agent used alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. One regimen employed daily use of both calcipotriene ointment and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/44/9925?source=see_link\">",
"     halobetasol",
"    </a>",
"    ointment for two weeks, followed by weekend use of the halobetasol ointment and weekday use of calcipotriene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/35\">",
"     35",
"    </a>",
"    ]. This regimen produced six-month remission maintenance in 76 percent compared with 40 percent with weekend halobetasol alone. A similar regimen with calcipotriene ointment and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/16/10502?source=see_link\">",
"     clobetasol",
"    </a>",
"    propionate foam also appears to be effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, a randomized trial found that a preparation that combines calcipotriene with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    dipropionate (0.064%) was effective with once daily usage, and more effective than once daily therapy with either betamethasone or calcipotriene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/39\">",
"     39",
"    </a>",
"    ]; this combination preparation (Taclonex) typically costs more than $400 for a 60 g tube. Patients who use topical corticosteroids in combination with calcipotriene must be monitored for adverse effects as with corticosteroid monotherapy. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Corticosteroids'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Thus, topical calcipotriene may be used as an alternative or adjunct to topical corticosteroid therapy. It is applied twice daily when used as monotherapy. No controlled trials guide how best to use topical corticosteroids in conjunction with calcipotriene. Once daily use of each may be adequate. Acidic products can inactivate topical calcipotriene, and some topical corticosteroids may be acidic. A reasonable approach to combination therapy is to have patients apply topical calcipotriene and topical corticosteroids each once daily at different times of day.",
"   </p>",
"   <p>",
"    Other than skin irritation, side effects of topical calcipotriene are usually minimal; the risk of hypercalcemia is low when the drug is used appropriately [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/40\">",
"     40",
"    </a>",
"    ]. However, topical calcipotriene is more expensive than most potent corticosteroids (approximately $300 in the United States for 100 grams).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Calcitriol",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism of action of calcitriol is thought to be similar to that of calcipotriene and involves the drug's ability to inhibit keratinocyte proliferation and stimulate keratinocyte differentiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/41\">",
"     41",
"    </a>",
"    ]. In addition, it has been demonstrated that calcitriol inhibits T cell proliferation and other inflammatory mediators [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/41\">",
"     41",
"    </a>",
"    ]. In two randomized trials with a total of 839 patients with mild to moderate plaque psoriasis, calcitriol 3",
"    <span class=\"nowrap\">",
"     mcg/g",
"    </span>",
"    ointment was more effective than vehicle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/42\">",
"     42",
"    </a>",
"    ]. At the end of the study periods (up to eight weeks), 39.6 and 32.7 percent of the calcitriol groups versus 21.2 and 12 percent of the vehicle groups exhibited at least marked global improvement.",
"   </p>",
"   <p>",
"    In a systematic review, calcipotriene and calcitriol were equally effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/30\">",
"     30",
"    </a>",
"    ]. However, on sensitive areas of the skin, calcitriol appears to be less irritating than calcipotriene. An intraindividual randomized trial of 75 patients compared treatment with calcitriol 3",
"    <span class=\"nowrap\">",
"     mcg/g",
"    </span>",
"    ointment to calcipotriene 50",
"    <span class=\"nowrap\">",
"     mcg/g",
"    </span>",
"    ointment for mild to moderate psoriasis on facial, hairline, retroauricular, and flexural areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/31\">",
"     31",
"    </a>",
"    ]. Perilesional erythema, perilesional edema, and stinging or burning sensations were significantly lower in the areas treated with calcitriol. A 52-week open-label study of the safety of calcitriol ointment did not reveal an adverse effect on calcium homeostasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Calcitriol ointment is expensive; the cost of a 100 gram tube is approximately $400. The drug is applied twice daily.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Tar",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of tar is a time-honored modality for treating psoriasis, although newer (and less messy) treatment options have reduced its popularity. The precise mechanism of action of tar is not known; it has an apparent antiproliferative effect.",
"   </p>",
"   <p>",
"    Tar can be helpful as an adjunct to topical corticosteroids. There are no commercially available",
"    <span class=\"nowrap\">",
"     corticosteroid/tar",
"    </span>",
"    combinations. Tar products are available without a prescription in the form of shampoos, creams, lotions, ointments, and oils. Newer products include a solution (Psorent) and a foam (Scytera). Some patients may prefer the less messy new formulations.",
"   </p>",
"   <p>",
"    Tar can also be compounded into creams and ointments. A commonly used compound is 2 or 3 percent crude",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/43/44724?source=see_link\">",
"     coal tar",
"    </a>",
"    in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    cream 0.1 percent applied twice daily to individual plaques. An alternative is 4 to 10 percent LCD (liquor carbonis detergens, a tar distillate) in triamcinolone cream or ointment, used similarly. A preparation of 1 percent tar in a fatty-acid based lotion (Exorex) may be superior to conventional 5 percent tar products [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/44\">",
"     44",
"    </a>",
"    ] and appears to have efficacy similar to that of calcipotriene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Topical tar preparations, including shampoos, creams, and other preparations, can be used once daily. Patients should be warned that tar products have the potential to stain hair, skin, and clothing. It may help to use them at night and wear inexpensive night clothes (eg, old pajamas) as they tend to be messy. Patients may also find the odor of tar products unpleasant.",
"   </p>",
"   <p>",
"    For shampoos, the emphasis should be on making sure the product reaches the scalp. Tar shampoo should be left in place for 5 to 10 minutes before rinsing it out.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Tazarotene",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/17/19732?source=see_link\">",
"     Tazarotene",
"    </a>",
"    is a topical retinoid that was found to be safe and effective in two randomized, vehicle-controlled trials that included 1303 patients with psoriasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/46\">",
"     46",
"    </a>",
"    ]. The 0.1 percent cream was somewhat more effective than 0.05 percent cream, but with a slightly higher rate of local side effects. Another study found that once daily administration of tazarotene gel, 0.05 or 0.1 percent, compared favorably with the twice daily administration of topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/56/30596?source=see_link\">",
"     fluocinonide",
"    </a>",
"    0.05 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/47\">",
"     47",
"    </a>",
"    ]. Absorption of tazarotene was minimal over the 12-week course of the study, suggesting that systemic toxicity is unlikely during long-term therapy. A small uncontrolled study of short contact tazarotene found that a 20 minute application followed by washing appeared to be less irritating than traditional use, and seemed to have similar efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Calcineurin inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    0.1 percent and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/41/29332?source=see_link\">",
"     pimecrolimus",
"    </a>",
"    1 percent are effective in the treatment of psoriasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/49-52\">",
"     49-52",
"    </a>",
"    ]. Facial and intertriginous areas may be suited to these treatments, which can allow patients to avoid chronic topical corticosteroid use:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An eight-week randomized trial in 167 patients ages 16 and older found that twice daily treatment to intertriginous and facial lesions with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      0.1 percent ointment resulted in more patients achieving clearance of lesions or excellent improvement compared with placebo (65 versus 32 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An eight-week randomized trial in 57 adults with moderate to severe inverse psoriasis found that twice daily treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/41/29332?source=see_link\">",
"       pimecrolimus",
"      </a>",
"      1 percent cream resulted in more patients clearing or almost clearing lesions compared with placebo (71 versus 21 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/41/29332?source=see_link\">",
"     pimecrolimus",
"    </a>",
"    are generally well-tolerated when used to treat facial and intertriginous psoriasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. However, corticosteroid therapy may be more effective, at least compared to pimecrolimus. This was suggested in a four-week randomized trial in 80 patients with intertriginous psoriasis that compared various therapies applied once daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/55\">",
"     55",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44120?source=see_link\">",
"     Betamethasone",
"    </a>",
"    valerate 0.1 percent was more effective than pimecrolimus 1 percent.",
"   </p>",
"   <p>",
"    In 2005, the US Food and Drug Administration (FDA) issued an alert about a possible link between topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/41/29332?source=see_link\">",
"     pimecrolimus",
"    </a>",
"    and cases of lymphoma and skin cancer in children and adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/56\">",
"     56",
"    </a>",
"    ], and in 2006 placed a \"black box\" warning on the prescribing information for these medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/57\">",
"     57",
"    </a>",
"    ]. No definite causal relationship has been established; however, the FDA recommended that these agents only be used as second line agents for atopic dermatitis. If these drugs are used for the treatment of psoriasis, it would be reasonable to follow the additional safety recommendations made by the FDA for their use in atopic dermatitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/37/10842?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of atopic dermatitis (eczema)\", section on 'Topical calcineurin inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     ULTRAVIOLET LIGHT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultraviolet (UV) irradiation has long been recognized as beneficial for the control of psoriatic skin lesions. As an example, patients often notice improvement in skin lesions during the summer months. UV radiation may act via antiproliferative effects (slowing keratinization) and anti-inflammatory effects (inducing apoptosis of pathogenic T-cells in psoriatic plaques). In choosing UV therapy, consideration must be given to the potential for UV radiation to accelerate photodamage and increase the risk of cutaneous malignancy.",
"   </p>",
"   <p>",
"    Phototherapy and photochemotherapy require the supervision of a dermatologist trained in these treatment modalities. The American Academy of Dermatology has provided guidelines for the treatment of psoriasis with ultraviolet light [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/58\">",
"     58",
"    </a>",
"    ]. Despite high efficacy and safety, the use of office-based phototherapy has declined in the United States because of administrative issues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Modalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic doses of ultraviolet light can be administered in several ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Phototherapy refers to treatment with ultraviolet B (UVB) radiation (290 to 320 nm). This treatment is used in patients with extensive disease, alone or in combination with topical tar. The mechanism of action of UVB is likely through its immunomodulatory effects [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/60\">",
"       60",
"      </a>",
"      ]. Patients receive near-erythema-inducing doses of UVB at least three times weekly until remission is achieved, after which a maintenance regimen is usually recommended to prolong the remission.",
"     </li>",
"     <li>",
"      Narrow band UVB (311 nm) is an alternative to standard (broadband- 290 to 320 nm) UVB in the treatment of psoriasis. Suberythemogenic doses of narrow band UVB are more effective than broadband UVB in clearing plaque psoriasis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/61\">",
"       61",
"      </a>",
"      ]. Apoptosis of T cells is also more common with 311 nm than with broadband UVB. However, the higher cost of narrow band UVB bulbs compared with broadband bulbs currently limits its availability.",
"     </li>",
"     <li>",
"      Photochemotherapy (PUVA) involves treatment with either oral or bath psoralen followed by ultraviolet A (UVA) radiation (320 to 400 nm) under strict medical supervision. UVA penetrates deeper into the dermis than UVB and does not have the latter's potential for burning the skin. A number of possible mechanisms have been postulated to explain PUVA's effects [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/62\">",
"       62",
"      </a>",
"      ]. With oral PUVA, patients ingest the photosensitizing drug, 8-methoxypsoralen, followed within two hours by exposure to UVA; this sequence is performed three times weekly in increasing doses until remission, then twice or once weekly as a maintenance dose. With bath PUVA, the psoralen capsules are dissolved in water, and affected skin (hands, feet, or total body) is soaked for 15 to 30 minutes prior to UVA exposure. Some patients take psoralen prior to coming into the",
"      <span class=\"nowrap\">",
"       office/clinic",
"      </span>",
"      for PUVA and increased photosensitivity is typically present starting one hour after an oral dose and resolves after eight hours. Pre and post treatment photoprotection (eg, hat, sunscreen, sun protective goggles) are critical in preventing serious burn injury to the skin and eyes from being outside. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/24/33160?source=see_link\">",
"       \"Psoralen plus ultraviolet A (PUVA) photochemotherapy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pretreatment emollients have long been thought to improve results with UVB. However, while thin oils do not impede UV penetration, emollient creams can actually inhibit the penetration of the UV and should not be applied before treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/63\">",
"     63",
"    </a>",
"    ]. Gentle removal of plaques by bathing does help prior to UV exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Home phototherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative to office-based phototherapy is the use of a home ultraviolet B (UVB) phototherapy unit prescribed by the treating clinician. This option may be preferred by patients who are not in close proximity to an office-based phototherapy center, whose schedules do not permit frequent office visits, or for whom the costs of in-office treatment exceed those of a home phototherapy unit. Home units cost about $3000, but may prove cost-effective in the long term, particularly when compared to biologic therapies. Insurance coverage of these units varies.",
"   </p>",
"   <p>",
"    For some dermatologists, uncertainty regarding the safety of home units has led to a reluctance to prescribe them. Some have expressed concern for the potential for improper or excessive usage of these devices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/64\">",
"     64",
"    </a>",
"    ]. In contrast, a randomized trial of 196 subjects found that narrowband UVB administered via home units was as safe and effective as office-based treatments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/64\">",
"     64",
"    </a>",
"    ]. Home phototherapy units that are equipped with electronic controls that allow only a prescribed number of treatments are available and may help to mitigate clinician concerns.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Excimer laser",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another development in ultraviolet therapy for psoriasis involves use of a high energy 308 nm excimer laser. The laser allows treatment of only involved skin; thus, considerably higher doses of UVB can be administered to psoriatic plaques at a given treatment compared with traditional phototherapy. Uncontrolled trials suggest that laser therapy results in faster responses than conventional phototherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. As an example, one study of excimer laser therapy involved 124 patients with stable mild to moderate plaque psoriasis, of whom 80 completed the entire protocol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/65\">",
"     65",
"    </a>",
"    ]. Treatments were scheduled twice weekly. After 10 or fewer treatments, 84 and 50 percent of patients achieved the outcomes of 75 percent or better and 90 percent or better clearing of plaques, respectively. This number of treatments was far fewer than that typically required of phototherapy (25 or more). Side effects of laser therapy included erythema and blistering; these were generally well tolerated, and no patient discontinued therapy because of adverse effects.",
"   </p>",
"   <p>",
"    A common sequela of excimer laser therapy is the induction of UV-induced hyperpigmentation (tanning) in treated areas, which can be cosmetically distressing for some patients. Hyperpigmentation resolves after the discontinuation of treatment.",
"   </p>",
"   <p>",
"    Like 311 nm UVB, the excimer laser represents a therapeutic advance toward specific wavelength therapies for psoriasis. While both the excimer laser and narrow band UVB are approved for use in psoriasis, inconsistencies in third party coverage for these treatments limit their current utilization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Cancer risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;A concern with PUVA is an increased risk of nonmelanoma skin cancer and melanoma. Ongoing monitoring is indicated in patients who have received prolonged courses of PUVA. In general, phototherapy is contraindicated in patients with a history of melanoma or extensive nonmelanoma skin cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/24/33160?source=see_link&amp;anchor=H31513976#H31513976\">",
"     \"Psoralen plus ultraviolet A (PUVA) photochemotherapy\", section on 'Skin cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Folate deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Folate deficiency has been associated with health disorders such as neural tube defects in fetuses of affected pregnant women, anemia, and hyperhomocysteinemia (a risk factor for cardiovascular disease). In an in vitro study, exposure of plasma to UVA led to a 30 to 50 percent decrease in the serum folate level within 60 minutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/67\">",
"     67",
"    </a>",
"    ]. However, folate deficiency secondary to UVA exposure has not been proven to occur in vivo. In a small randomized trial of healthy subjects, no difference in serum folate levels was identified between subjects irradiated with UVA for six sessions and untreated subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/68\">",
"     68",
"    </a>",
"    ]. In addition, an observational study of 35 psoriasis patients found that narrow band UVB had no effect on serum folate levels after 18 treatment sessions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Saltwater baths",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, exposure to natural sunlight has been observed to improve psoriasis. Bathing in sea water in combination with sun exposure (climatotherapy) has also been used as a therapy for psoriasis, as has the use of salt water baths with artificial UV exposure (balneophototherapy).",
"   </p>",
"   <p>",
"    A large, open, randomized trial found that treatment with UVB after a saltwater bath had greater efficacy than UVB after a tap-water bath, and similar efficacy to bath PUVA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/70\">",
"     70",
"    </a>",
"    ]. Although the raters of disease severity were intended to be blinded, treatment assignment was known to the raters in nearly 60 percent of cases. Additionally, less than half the patients were considered to have met the study's prespecified criteria for having been eligible and treated per protocol. In per-protocol analyses, no difference was found between saltwater and tap-water baths, and bath PUVA was superior to UVB after a saltwater bath.",
"   </p>",
"   <p>",
"    Additional studies are required to demonstrate that combining saltwater baths with phototherapy is superior to tap-water baths plus phototherapy or to phototherapy alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SYSTEMIC THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of systemic medications are used for the treatment of psoriasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/71-73\">",
"     71-73",
"    </a>",
"    ], particularly for patients with more than 10 percent body surface area involvement or less extensive, but debilitating disease. In 2008 and 2009, the American Academy of Dermatology published",
"    <a class=\"external\" href=\"file://www.aad.org/education-and-quality-care/clinical-guidelines/current-and-upcoming-guidelines\">",
"     guidelines",
"    </a>",
"    for the management of psoriasis with systemic therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/71,72\">",
"     71,72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Options for systemic therapy include immunosuppressive or immunomodulatory drugs such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , and biologic agents. Systemic retinoids, which improve psoriasis through effects on epidermal proliferation and differentiation as well as immunomodulation, are also used for the treatment of this condition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    antagonist",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    has been used successfully in the treatment of psoriasis for over 30 years. It is also effective for the treatment of psoriatic arthritis and psoriatic nail disease. Initial thoughts on the mechanism of action centered around the antiproliferative effects of methotrexate on DNA synthesis in epidermal cells; more recent evidence supports the concept that it is the immunosuppressive effects of methotrexate on activated T-cells that controls psoriasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    appears to be less effective than at least some of the biologic agents (see",
"    <a class=\"local\" href=\"#H36\">",
"     'Biologic agents'",
"    </a>",
"    below). In one trial, 271 patients with moderate to severe plaque psoriasis were randomized to receive methotrexate,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    , or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/75\">",
"     75",
"    </a>",
"    ]. After 16 weeks, the proportion of patients achieving a 75 percent improvement in symptoms with methotrexate was more than that with placebo but less than with adalimumab (36, 19, and 80 percent respectively).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    is usually administered in an intermittent low-dose regimen such as",
"    <strong>",
"     once weekly",
"    </strong>",
"    . Similar regimens are currently in use in patients with rheumatoid arthritis. Administration can be oral, intravenous, intramuscular, or subcutaneous; the usual dose range is between 7.5 mg and 25 mg per week. Unlike",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , which is generally used for only limited courses of treatment, methotrexate can be used for long-term therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32169?source=see_link\">",
"     \"Use of methotrexate in the treatment of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H34\">",
"     'Systemic calcineurin inhibitors'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     Folic acid",
"    </a>",
"    , 1 mg daily, protects against some of the common side effects seen with low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    such as stomatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/76\">",
"     76",
"    </a>",
"    ]. Folate does not appear to protect against pulmonary toxicity, and it is uncertain whether it protects against hepatic toxicity; monitoring for bone marrow suppression and hepatotoxicity are necessary during therapy. Concurrent use of other medications that interfere with folic acid metabolism, such as sulfa antibiotics, can increase the toxicity of methotrexate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11223?source=see_link\">",
"     \"Major side effects of low-dose methotrexate\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with one or more risk factors for hepatotoxicity from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , use of a different systemic drug should be considered. (See",
"    <a class=\"local\" href=\"#H32\">",
"     'Hepatotoxicity and liver biopsy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Hepatotoxicity and liver biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, the American Academy of Dermatology (AAD) recommended that all patients with psoriasis undergo liver biopsy to evaluate for hepatotoxicity after every 1 to 1.5 g of cumulative",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/77\">",
"     77",
"    </a>",
"    ]. In 2009, the AAD and the National Psoriasis Foundation updated this recommendation with monitoring guidelines that are dependent upon the presence or absence of risk factors for hepatotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/71,78\">",
"     71,78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk factors for hepatotoxicity from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/78\">",
"     78",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      History of more than moderate alcohol consumption",
"     </li>",
"     <li>",
"      Persistent abnormal liver chemistry studies",
"     </li>",
"     <li>",
"      History of liver disease, such as chronic hepatitis B or C",
"     </li>",
"     <li>",
"      Family history of inherited liver disease (eg, hemochromatosis)",
"     </li>",
"     <li>",
"      Diabetes mellitus",
"     </li>",
"     <li>",
"      Obesity",
"     </li>",
"     <li>",
"      History of significant exposure to hepatotoxic drugs (other than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ) or chemicals",
"     </li>",
"     <li>",
"      Absence of folate supplementation during",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      therapy",
"     </li>",
"     <li>",
"      Hyperlipidemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients without risk factors for hepatotoxicity should have liver chemistries drawn every one to three months. If five out of nine serum AST levels are elevated over the course of 12 months, or if the serum albumin level is decreased in the context of normal nutritional status and well-controlled psoriasis, a liver biopsy should be performed.",
"   </p>",
"   <p>",
"    Liver biopsy should also be considered after a cumulative dose of 3.5 to 4 g of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    has been administered. Once patients have reached this dose, options include proceeding with a liver biopsy, continuing to monitor without a liver biopsy, or discontinuing methotrexate therapy.",
"   </p>",
"   <p>",
"    In patients with risk factors for hepatotoxicity in whom the decision is made to proceed with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , a liver biopsy should be performed at or near the beginning of therapy. Since a fair number of patients will discontinue therapy within the first two to six months, it is reasonable to perform the biopsy after this time period. For patients who continue methotrexate, liver biopsies should be performed after every 1 to 1.5 g of cumulative methotrexate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Retinoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic retinoids (derivatives of vitamin A) are utilized for patients with severe psoriasis, including pustular and erythrodermic forms, and in patients with HIV-associated psoriasis. The retinoid of choice in psoriasis is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/1/39958?source=see_link\">",
"     acitretin",
"    </a>",
"    (Soriatane). In a pilot study, 6 of 11 patients with psoriasis and HIV infection achieved good to excellent results with acitretin therapy, with four achieving complete clearing of their skin disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/79\">",
"     79",
"    </a>",
"    ]. The usual dose range of acitretin is 25 mg every other day to 50 mg daily.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/1/39958?source=see_link\">",
"     Acitretin",
"    </a>",
"    can be used in combination with UVB or PUVA therapy. Used in this way, patients have higher response rates with better tolerance and less UV exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/80,81\">",
"     80,81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Monitoring for hypertriglyceridemia and hepatotoxicity are required with retinoid therapy. Common side effects include cheilitis and alopecia.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/1/39958?source=see_link\">",
"     Acitretin",
"    </a>",
"    is teratogenic; it is only indicated in men and in women of non-reproductive potential. Pregnancy is contraindicated for",
"    <strong>",
"     three years",
"    </strong>",
"    after discontinuing the drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Systemic calcineurin inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The T-cell suppressor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    is effective in patients with severe psoriasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. Usual doses are in the range of 3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day orally. Improvement is generally observed within four weeks.",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    in psoriasis is based upon multiple studies supporting its status as a highly and rapidly effective treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/71,85-87\">",
"     71,85-87",
"    </a>",
"    ]. As an example, a placebo-controlled randomized trial found that after eight weeks of treatment with 3, 5, or 7.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of cyclosporine per day, 36, 65, and 80 percent of patients, respectively, were rated as clear or almost clear of psoriasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/85\">",
"     85",
"    </a>",
"    ]. All three regimens were superior to placebo, and patients who received the 5 mg dose were least likely to require dose alterations due to side effects or lack of efficacy.",
"   </p>",
"   <p>",
"    A few randomized trials have compared the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , utilizing varying treatment regimens and providing different results. Although a 16-week randomized trial in 88 patients failed to find a significant difference in the effects of cyclosporine (3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) and methotrexate (15 to 22.5 mg per week) on moderate to severe plaque psoriasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/88\">",
"     88",
"    </a>",
"    ], a subsequent 12-week randomized trial of 84 patients with moderate to severe plaque psoriasis found results that indicated superiority of cyclosporine (3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) over methotrexate (7.5 to 15 mg per week) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/89\">",
"     89",
"    </a>",
"    ]. A smaller trial of patients with severe psoriasis found superior efficacy of methotrexate over cyclosporine (3 to 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day), but utilized much higher doses of methotrexate than are typically prescribed in clinical practice (0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per week) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Close monitoring is required since renal toxicity and hypertension are common and often limit the long-term use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    in patients with psoriasis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/61/41945?source=see_link\">",
"     \"Cyclosporine and tacrolimus nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An investigational oral calcineurin inhibitor, ISA247, has also shown efficacy in randomized trials in patients with moderate to severe plaque psoriasis, and may have less nephrotoxicity than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Biologic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biologic agents are important treatment options for moderate to severe plaque type psoriasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/92-94\">",
"     92-94",
"    </a>",
"    ]. The available biologics for psoriasis have been shown in clinical trial programs to have excellent short-term and long-term efficacy and favorable tolerability. &nbsp;",
"   </p>",
"   <p>",
"    There is a concern that all TNF-alpha inhibitors have the potential to activate latent infections such as tuberculosis and increased rates of infection have been seen in patients with rheumatoid arthritis treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    . TNF-alpha inhibitors have also been associated with an increased risk of malignancies, including lymphoma and leukemia, and the development of new-onset psoriasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/95\">",
"     95",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/49/32538?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/38/24169?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors and mycobacterial infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33624?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: Risk of malignancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/55/40825?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     Etanercept",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TNF-alpha inhibitor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    (Enbrel) is of benefit in psoriasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/96-98\">",
"     96-98",
"    </a>",
"    ]. It is approved by the FDA for psoriatic arthritis and for adults with chronic moderate to severe plaque psoriasis. A randomized trial of etanercept in 652 adult patients with active but stable plaque psoriasis involving at least 10 percent of the body surface area found three doses of subcutaneous etanercept (25 mg weekly, 25 mg twice weekly, 50 mg twice weekly) significantly superior to placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/97\">",
"     97",
"    </a>",
"    ]. After 12 weeks, there was at least a 75 percent improvement in a psoriasis area and severity index (PASI) score in 14, 34, 49, and 4 percent, respectively. After 24 weeks, such an improvement was seen in 25, 44, and 59 percent, respectively (no patients received placebo for more than 12 weeks). Etanercept was well tolerated with adverse events and infections occurring at similar rates in all four groups.",
"   </p>",
"   <p>",
"    A 12-week randomized trial found similar benefits with subcutaneous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    50 mg twice weekly, and also found that, compared with placebo, patients receiving etanercept had significant improvements in measures of fatigue and depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/99\">",
"     99",
"    </a>",
"    ]. Another randomized trial demonstrated efficacy in children and adolescents with moderate to severe plaque psoriasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/100\">",
"     100",
"    </a>",
"    ]. The long-term safety of etanercept for psoriasis is supported by a 96-week study of etanercept 50 mg twice weekly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h3\">",
"     Infliximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TNF-alpha inhibitor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    (Remicade) is of benefit in patients with moderate to severe plaque psoriasis and appears to generally be well-tolerated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/102-105\">",
"     102-105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, a multicenter randomized trial in 249 patients with severe plaque psoriasis found that compared with placebo, more patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    or 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (given intravenously at weeks zero, two, and six) achieved at least a 75 percent improvement in the PASI score at week 10 (6 percent versus 72 and 88 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/104\">",
"     104",
"    </a>",
"    ]. The duration of response appeared to be longer with the higher dose. More patients treated with infliximab had serious adverse events (12 versus 0), including four cases that the authors felt were reasonably related to treatment: squamous cell carcinoma, cholecystitis, diverticulitis, and pyelonephritis with sepsis.",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    given at weeks 0, 2, 6, 14, and 22) was compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (15 to 20 mg per week) in a 26-week open-label randomized trial in patients with moderate to severe psoriasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/106\">",
"     106",
"    </a>",
"    ]. At week 16, patients who did not achieve at least 50 percent improvement were able to switch to the alternative therapy. The trial found that patients treated with infliximab (n = 653) exhibited greater improvement (78 versus 42 percent achieved 75 percent improvement in the PASI score by week 16) and were much less likely than patients in the methotrexate group (n = 215) to require switching to the alternative therapy (1 versus 29 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/106\">",
"     106",
"    </a>",
"    ]. In addition, patients who were transitioned from methotrexate to infliximab fared better than those who switched to methotrexate from infliximab; 73 versus 11 percent achieved 75 percent improvement in the PASI score.",
"   </p>",
"   <p>",
"    Maintenance therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    also appears to be effective. A randomized trial using the dosing schedule above with infliximab 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    through six weeks, but then adding maintenance dosing of infliximab 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every eight weeks through 46 weeks found that 61 percent of patients had at least a 75 percent improvement in the PASI score at week 50 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/105\">",
"     105",
"    </a>",
"    ]. Infliximab was generally well tolerated. The use of maintenance therapy was further supported by a randomized trial that found that patients treated with continuous therapy (infusion every eight weeks after induction therapy at 0, 2, and 6 weeks) maintained the response to treatment better than patients who received intermittent &ldquo;as needed&rdquo; therapy after induction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies in inflammatory bowel disease and rheumatoid arthritis have suggested that the production of antibodies to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    may contribute to the loss of response to infliximab in some patients with these diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/108-110\">",
"     108-110",
"    </a>",
"    ]. The impact of anti-infliximab antibodies on treatment efficacy in psoriasis remains unclear. A small retrospective study in patients with psoriasis suggested a role for pre-treatment levels of antinuclear antibodies as markers of increased risk for the development of anti-infliximab antibodies and loss of response to infliximab; however, further studies are necessary to confirm this finding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h3\">",
"     Adalimumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"     Adalimumab",
"    </a>",
"    (Humira), a humanized monoclonal antibody with activity against TNF-alpha, was originally used for patients with rheumatoid arthritis and is also effective for psoriatic arthritis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/18/40234?source=see_link\">",
"     \"Treatment of psoriatic arthritis\"",
"    </a>",
"    .) Adalimumab is approved by the FDA for treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.",
"   </p>",
"   <p>",
"    Examples of studies supporting the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial in 147 patients with moderate to severe plaque psoriasis compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      by subcutaneous injection 40 mg every other week, 40 mg weekly, and placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/112\">",
"       112",
"      </a>",
"      ]. After 12 weeks, more patients treated with adalimumab every other week or weekly achieved at least a 75 percent improvement in the PASI score (53 and 80 percent, respectively), versus 4 percent with placebo. In an open label extension of the study, improvements were sustained for 60 weeks.",
"     </li>",
"     <li>",
"      A randomized trial in 490 patients with moderate to severe psoriasis who had achieved a 75 percent improvement in the PASI score after 32 weeks of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      found that continuing adalimumab resulted in a higher percentage of patients maintaining their response at 52 weeks (95 versus 72 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/113\">",
"       113",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      was superior to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      in a randomized trial involving 271 patients with moderate to severe psoriasis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/75\">",
"       75",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Methotrexate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A randomized trial found that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      was more effective than placebo for the treatment of moderate to severe chronic plaque psoriasis involving the hands or feet [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/114\">",
"       114",
"      </a>",
"      ]. After 16 weeks, disease was cleared or almost cleared in 15 out of 49 patients in the adalimumab group (31 percent) compared with 1 out of 23 patients in the placebo group (4 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"     Adalimumab",
"    </a>",
"    may be an effective alternative for patients who fail to respond to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/115-117\">",
"     115-117",
"    </a>",
"    ]. In a multicenter, open-label study, patients who did not improve with 50 mg of etanercept twice weekly (n = 50) or who worsened following a dose reduction of etanercept to 50 mg once weekly (n = 35) were treated with 40 mg of adalimumab every other week [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/115\">",
"     115",
"    </a>",
"    ]. After 12 weeks, psoriasis was cleared or almost cleared in 34 percent (95% CI 20-48) of patients who had failed etanercept and 31 percent (95% CI 15-48) of patients who had disease recurrence on the lower dose of etanercept. Treatment success rates approached 50 percent when adalimumab (40 mg weekly or every other week) was given for an additional 12 weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h3\">",
"     Ustekinumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/46/742?source=see_link\">",
"     Ustekinumab",
"    </a>",
"    (Stelara) is a human monoclonal antibody that targets IL-12 and IL-23. In September 2009, ustekinumab was approved by the US Food and Drug Administration for the treatment of adult patients with moderate to severe psoriasis who are candidates for phototherapy or systemic therapy.",
"   </p>",
"   <p>",
"    A phase 2 randomized trial suggested that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/46/742?source=see_link\">",
"     ustekinumab",
"    </a>",
"    is highly effective in the treatment of moderate to severe plaque psoriasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/118\">",
"     118",
"    </a>",
"    ], and phase 3 trials have confirmed these results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/119-121\">",
"     119-121",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial in 766 patients with moderate to severe plaque psoriasis found that more patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/46/742?source=see_link\">",
"       ustekinumab",
"      </a>",
"      45 mg or 90 mg achieved at least a 75 percent improvement in the PASI score at week 12 than those treated with placebo (67 and 66 versus 3 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/119\">",
"       119",
"      </a>",
"      ]. Ustekinumab was administered monthly by subcutaneous injection for the first two doses and then every 12 weeks. Responders who were kept on therapy generally maintained improvements in psoriasis out to at least 76 weeks. Serious adverse events were seen at similar rates in the ustekinumab and placebo arms.",
"     </li>",
"     <li>",
"      A second similarly designed trial in 1230 patients with moderate to severe plaque psoriasis also found that more patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/46/742?source=see_link\">",
"       ustekinumab",
"      </a>",
"      45 mg or 90 mg achieved at least a 75 percent improvement in the PASI score at week 12 than those treated with placebo (67 and 76 versus 4 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/120\">",
"       120",
"      </a>",
"      ]. Patients who achieved a partial response at week 28 were randomly assigned to continue every 12 week dosing or escalate to every 8 week dosing. More frequent dosing did not enhance response rates at one year in patients receiving 45 mg, but did enhance 75 percent improvement rates in those receiving 90 mg (69 versus 33 percent with continued 12 week dosing). Serious adverse events were again seen at similar rates in the ustekinumab and placebo arms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/46/742?source=see_link\">",
"     ustekinumab",
"    </a>",
"    appears to persist over time. Follow-up data from one of the phase 3 randomized trials above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/119\">",
"     119",
"    </a>",
"    ] demonstrated maintenance of a high level of drug efficacy over the course of three years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/122\">",
"     122",
"    </a>",
"    ]. In addition, treatment for up to four years appears to be well-tolerated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/122-125\">",
"     122-125",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A randomized trial reported superior efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/46/742?source=see_link\">",
"     ustekinumab",
"    </a>",
"    over",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    for the treatment of psoriasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/126\">",
"     126",
"    </a>",
"    ]. In this trial, 903 patients with moderate to severe psoriasis received 90 mg of ustekinumab at weeks 0 and 4, 45 mg of ustekinumab at weeks 0 and 4, or 50 mg of etanercept twice weekly. After 12 weeks, 75 percent improvement in the PASI score was observed in 73.8, 67.5, and 56.8 percent of patients in the 90 mg ustekinumab, 45 mg ustekinumab, and etanercept groups, respectively. In addition, some patients who did not respond to etanercept benefited from treatment with ustekinumab. Twelve weeks after crossover to 90 mg of ustekinumab (administered at weeks 16 and 20), 48.9 percent achieved 75 percent improvement in the PASI score. The incidence of serious adverse effects was similar between treatment groups.",
"   </p>",
"   <p>",
"    Because of its immunomodulatory mechanism of action, there is concern that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/46/742?source=see_link\">",
"     ustekinumab",
"    </a>",
"    may increase the risk for infections and malignancy. However, pooled data from phase 2 and phase 3 randomized trials with up to four years of follow-up do not suggest an increase in risk of infection or malignancy in treated patients when compared to expected population rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/125\">",
"     125",
"    </a>",
"    ]. Uncommon drug-related adverse effects, such as reversible posterior leukoencephalopathy syndrome and a lymphomatoid drug eruption have occurred in two separate patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/127,128\">",
"     127,128",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/16/43273?source=see_link\">",
"     \"Reversible posterior leukoencephalopathy syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reports of major adverse cardiovascular events during phase 2 and 3 studies for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/46/742?source=see_link\">",
"     ustekinumab",
"    </a>",
"    and briakinumab, another",
"    <span class=\"nowrap\">",
"     anti-IL-12/23",
"    </span>",
"    agent, led to the performance of a meta-analysis of placebo-controlled randomized trials evaluating the relationship between",
"    <span class=\"nowrap\">",
"     anti-IL-12/23",
"    </span>",
"    therapy and major adverse cardiovascular events in patients with chronic plaque psoriasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/129\">",
"     129",
"    </a>",
"    ]. The meta-analysis found that more major adverse cardiovascular events were reported in patients who received active treatment with ustekinumab or briakinumab than in those who received placebo (10 out of 3179 patients versus 0 out of 1474 patients). Although the difference in events was not statistically significant, the trial lengths were short (12 to 20 weeks), and the meta-analysis may have been underpowered to detect a significant difference.",
"   </p>",
"   <p>",
"    A review of pooled data from phase 2 and phase 3 trials with up to four years follow-up did not reveal an increased risk for major adverse cardiovascular events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/125\">",
"     125",
"    </a>",
"    ]. Additional studies are necessary to explore the relationship between these",
"    <span class=\"nowrap\">",
"     anti-IL-12/23",
"    </span>",
"    agents and cardiovascular morbidity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28956885\">",
"    <span class=\"h3\">",
"     Alefacept",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recombinant protein alefacept (Amevive) was effective for the treatment of psoriasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/130-132\">",
"     130-132",
"    </a>",
"    ]. However, in late 2011, production and distribution of alefacept was discontinued by the drug manufacturer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/133\">",
"     133",
"    </a>",
"    ]. The discontinuation of production was neither due to new safety concerns nor a mandatory recall. Alefacept was generally considered to be less effective for psoriasis than other biologic therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20847807\">",
"    <span class=\"h2\">",
"     Other immunosuppressive agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other immunosuppressive agents are sometimes used in selected cases of severe psoriasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/84\">",
"     84",
"    </a>",
"    ]. These drugs include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    , 6-thioguanine, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , which have a place in the treatment of psoriasis when other systemic modalities cannot be used, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , which is similar to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and requires larger studies before it can be considered an accepted alternative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/71\">",
"     71",
"    </a>",
"    ]. Daclizumab, which is used for prevention of renal transplant rejection, and the cancer chemotherapeutic drug",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    are also under investigation for use in severe psoriasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/134,135\">",
"     134,135",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1117107\">",
"    <span class=\"h2\">",
"     Fumaric acid esters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fumaric acid esters (fumarates) have been used to treat psoriasis in Northern Europe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/136\">",
"     136",
"    </a>",
"    ]. In a randomized trial of 60 patients with moderate to severe psoriasis, reductions in disease severity after treatment with fumaric acid esters were similar to those observed with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/137\">",
"     137",
"    </a>",
"    ]. Additional trials of fumarates are being performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h1\">",
"     FUTURE THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interleukins in the Th17 pathway play a pivotal role in the pathogenesis of psoriasis and have become targets for drug development. Phase III placebo-controlled randomized trials have supported the efficacy of briakinumab, another monoclonal antibody targeting",
"    <span class=\"nowrap\">",
"     IL-12/23,",
"    </span>",
"    in moderate to severe plaque psoriasis, and the drug has exhibited efficacy superior to that of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/138-141\">",
"     138-141",
"    </a>",
"    ]. However, concerns have been raised regarding a potential relationship between briakinumab treatment and major cardiovascular adverse events (see",
"    <a class=\"local\" href=\"#H42\">",
"     'Ustekinumab'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/129\">",
"     129",
"    </a>",
"    ]. Marketing plans for briakinumab have been suspended, and it remains uncertain whether the drug will become available for clinical use.",
"   </p>",
"   <p>",
"    Phase II trials have demonstrated efficacy of an anti-IL-17 monoclonal antibody (ixekizumab) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/142\">",
"     142",
"    </a>",
"    ], an anti-IL-17 receptor monoclonal antibody (brodalumab) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/143\">",
"     143",
"    </a>",
"    ], an anti-IL-17A monoclonal antibody (secukinumab) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/144,145\">",
"     144,145",
"    </a>",
"    ], and a humanized anti-TNF monoclonal antibody Fab fragment linked to polyethylene glycol (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/6/39014?source=see_link\">",
"     certolizumab pegol",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/146\">",
"     146",
"    </a>",
"    ] in moderate to severe plaque psoriasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/142,143\">",
"     142,143",
"    </a>",
"    ]. Other potential therapies include various small molecules that target the interruption of cellular signaling; such signaling is critical to propagation of the inflammatory response. Examples of small molecules that are being studied for the treatment of psoriasis include molecules that block janus kinases (JAK) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/147-150\">",
"     147-150",
"    </a>",
"    ], lipids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/151\">",
"     151",
"    </a>",
"    ], and a protein kinase C inhibitor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/152\">",
"     152",
"    </a>",
"    ]. Oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/49/18198?source=see_link\">",
"     tofacitinib",
"    </a>",
"    , a JAK inhibitor approved and marketed for the treatment of rheumatoid arthritis, demonstrated efficacy for moderate to severe plaque psoriasis in a phase II placebo-controlled randomized trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/149\">",
"     149",
"    </a>",
"    ]. In addition, a phase II randomized trial found that a topical formulation of tofacitinib was more effective for plaque psoriasis than vehicle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/148\">",
"     148",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Apremilast, a phosphodiesterase 4 inhibitor, may be a promising agent for the treatment of psoriasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/153-156\">",
"     153-156",
"    </a>",
"    ]. In a phase II randomized trial of 352 adults with moderate to severe plaque psoriasis treated with apremilast at various doses (10 mg twice daily, 20 mg twice daily, or 30 mg twice daily) or placebo for 16 weeks, patients treated with 20 or 30 mg of apremilast twice daily were significantly more likely to achieve 75 percent improvement in the psoriasis area and severity index (PASI-75) than patients in the placebo group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/155\">",
"     155",
"    </a>",
"    ]. Among patients treated with 30 mg twice daily, 20 mg twice daily, 10 mg twice daily, and placebo, PASI-75 was achieved by 41, 29, 11, and 6 percent of patients, respectively. These results were supported by a 12-week phase II randomized trial of 259 adults with moderate to severe plaque psoriasis that compared apremilast 20 mg twice daily, apremilast 20 mg once daily, and placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/6/40042/abstract/156\">",
"     156",
"    </a>",
"    ]. Patients treated with the 20 mg twice daily dose of apremilast were more likely to achieve PASI-75 than patients in the placebo group (24 versus 10 percent). A significant difference in response between the apremilast 20 mg once daily and placebo groups was not detected (10 versus 10 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/9/3218?source=see_link\">",
"       \"Patient information: Psoriasis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/11/3252?source=see_link\">",
"       \"Patient information: Psoriasis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The National Psoriasis Foundation is a nonprofit organization that provides useful information to patients with psoriasis and their physicians. Membership includes access to a newsletter that provides information on current areas of research and new treatments.",
"   </p>",
"   <p>",
"    &nbsp;National Psoriasis Foundation",
"   </p>",
"   <p>",
"    &nbsp;6600 SW 92nd Ave., Suite 300",
"   </p>",
"   <p>",
"    &nbsp;Portland, OR 97223-7195",
"   </p>",
"   <p>",
"    &nbsp;1-800-723-9166",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.psoriasis.org/\">",
"     www.psoriasis.org",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous topical and systemic therapies are available for the treatment of psoriasis. Treatment modalities are chosen on the basis of disease severity, relevant comorbidities, patient preference (including cost and convenience), efficacy, and evaluation of individual patient response. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Approach'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest that patients with mild-to-moderate plaque psoriasis be initially treated with topical corticosteroids and emollients (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Mild-to-moderate disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Alternatives include tar, topical retinoids (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/17/19732?source=see_link\">",
"     tazarotene",
"    </a>",
"    ), and topical vitamin D. For facial or intertriginous areas, topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/41/29332?source=see_link\">",
"     pimecrolimus",
"    </a>",
"    may be used as alternatives or as corticosteroid sparing agents. Improvement can be anticipated within one or two months. Combination regimens may be required, including localized phototherapy. Patient adherence may be the largest barrier to treatment success with topical therapies; frequent patient follow-up (initially every week) may improve compliance. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Topical therapies'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H23\">",
"     'Ultraviolet light'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest that most patients with moderate-to-severe plaque psoriasis be initially treated with phototherapy if possible (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Severe disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The topical therapies discussed above are generally also required as adjuvant therapy and for symptomatic relief (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Topical therapies'",
"    </a>",
"    above). In patients with contraindications to phototherapy such as history of melanoma or extensive nonmelanoma skin cancer, or in patients with moderate-to-severe disease who also have psoriatic arthritis, we suggest treatment with a systemic agent (",
"    <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"     Grade 2B",
"    </a>",
"    ). Patients who fail to respond to phototherapy are also candidates for systemic therapy.",
"   </p>",
"   <p>",
"    Financial considerations or time constraints may also make systemic therapy preferable to phototherapy for some patients. Systemic agents include retinoids,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , and biologic immune modifying agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/46/742?source=see_link\">",
"     ustekinumab",
"    </a>",
"    . Treatment of psoriatic arthritis is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/18/40234?source=see_link\">",
"     \"Treatment of psoriatic arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Improvement should be observed within weeks. Such patients will generally require care by a dermatologist. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Severe disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    for the management of psoriasis, the decision to perform a liver biopsy should be individualized based upon a patient's risk factors, liver chemistry results, and cumulative methotrexate dose, in accord with updated guidelines from the American Academy of Dermatology (AAD). (See",
"    <a class=\"local\" href=\"#H32\">",
"     'Hepatotoxicity and liver biopsy'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/1\">",
"      Menter A, Griffiths CE. Current and future management of psoriasis. Lancet 2007; 370:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/2\">",
"      Esposito M, Saraceno R, Giunta A, et al. An Italian study on psoriasis and depression. Dermatology 2006; 212:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/3\">",
"      Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol 2010; 146:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/4\">",
"      Perrott SB, Murray AH, Lowe J, Mathieson CM. The psychosocial impact of psoriasis: physical severity, quality of life, and stigmatization. Physiol Behav 2000; 70:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/5\">",
"      Thomas CL, Finlay AY. The 'handprint' approximates to 1% of the total body surface area whereas the 'palm minus the fingers' does not. Br J Dermatol 2007; 157:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/6\">",
"      Kalb RE, Bagel J, Korman NJ, et al. Treatment of intertriginous psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2009; 60:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/7\">",
"      American Academy of Dermatology Work Group, Menter A, Korman NJ, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol 2011; 65:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/8\">",
"      McMillin BD, Maddern BR, Graham WR. A role for tonsillectomy in the treatment of psoriasis? Ear Nose Throat J 1999; 78:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/9\">",
"      Saita B, Ishii Y, Ogata K, et al. Two sisters with guttate psoriasis responsive to tonsillectomy: case reports with HLA studies. J Dermatol 1979; 6:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/10\">",
"      Hone SW, Donnelly MJ, Powell F, Blayney AW. Clearance of recalcitrant psoriasis after tonsillectomy. Clin Otolaryngol Allied Sci 1996; 21:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/11\">",
"      Jiaravuthisan MM, Sasseville D, Vender RB, et al. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol 2007; 57:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/12\">",
"      Rigopoulos D, Gregoriou S, Daniel Iii CR, et al. Treatment of nail psoriasis with a two-compound formulation of calcipotriol plus betamethasone dipropionate ointment. Dermatology 2009; 218:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/13\">",
"      Rich P, Griffiths CE, Reich K, et al. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol 2008; 58:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/14\">",
"      Van den Bosch F, Manger B, Goupille P, et al. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. Ann Rheum Dis 2010; 69:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/15\">",
"      Luger TA, Barker J, Lambert J, et al. Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol 2009; 23:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/16\">",
"      Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009; 60:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/17\">",
"      Tosti A, Ricotti C, Romanelli P, et al. Evaluation of the efficacy of acitretin therapy for nail psoriasis. Arch Dermatol 2009; 145:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/18\">",
"      Treewittayapoom C, Singvahanont P, Chanprapaph K, Haneke E. The effect of different pulse durations in the treatment of nail psoriasis with 595-nm pulsed dye laser: a randomized, double-blind, intrapatient left-to-right study. J Am Acad Dermatol 2012; 66:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/19\">",
"      Marx JL, Scher RK. Response of psoriatic nails to oral photochemotherapy. Arch Dermatol 1980; 116:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/20\">",
"      Handfield-Jones SE, Boyle J, Harman RR. Local PUVA treatment for nail psoriasis. Br J Dermatol 1987; 116:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/21\">",
"      Rosenbach M, Hsu S, Korman NJ, et al. Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol 2010; 62:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/22\">",
"      Esposito M, Mazzotta A, de Felice C, et al. Treatment of erythrodermic psoriasis with etanercept. Br J Dermatol 2006; 155:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/23\">",
"      Richetta AG, Maiani E, Carlomagno V, et al. Treatment of erythrodermic psoriasis in HCV+ patient with adalimumab. Dermatol Ther 2009; 22 Suppl 1:S16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/24\">",
"      Santos-Juanes J, Coto-Segura P, Mas-Vidal A, Galache Osuna C. Ustekinumab induces rapid clearing of erythrodermic psoriasis after failure of antitumour necrosis factor therapies. Br J Dermatol 2010; 162:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/25\">",
"      de Jager ME, de Jong EM, van de Kerkhof PC, Seyger MM. Efficacy and safety of treatments for childhood psoriasis: a systematic literature review. J Am Acad Dermatol 2010; 62:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/26\">",
"      Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009; 60:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/27\">",
"      Franz TJ, Parsell DA, Halualani RM, et al. Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy. Int J Dermatol 1999; 38:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/28\">",
"      Lebwohl M, Ali S. Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J Am Acad Dermatol 2001; 45:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/29\">",
"      Clobetasol propionate (Clobex) spray for psoriasis. Med Lett Drugs Ther 2006; 48:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/30\">",
"      Mason AR, Mason J, Cork M, et al. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev 2009; :CD005028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/31\">",
"      Ortonne JP, Humbert P, Nicolas JF, et al. Intra-individual comparison of the cutaneous safety and efficacy of calcitriol 3 microg g(-1) ointment and calcipotriol 50 microg g(-1) ointment on chronic plaque psoriasis localized in facial, hairline, retroauricular or flexural areas. Br J Dermatol 2003; 148:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/32\">",
"      Jensen AM, Llad&oacute; MB, Skov L, et al. Calcipotriol inhibits the proliferation of hyperproliferative CD29 positive keratinocytes in psoriatic epidermis in the absence of an effect on the function and number of antigen-presenting cells. Br J Dermatol 1998; 139:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/33\">",
"      Vissers WH, Berends M, Muys L, et al. The effect of the combination of calcipotriol and betamethasone dipropionate versus both monotherapies on epidermal proliferation, keratinization and T-cell subsets in chronic plaque psoriasis. Exp Dermatol 2004; 13:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/34\">",
"      Ashcroft DM, Po AL, Williams HC, Griffiths CE. Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. BMJ 2000; 320:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/35\">",
"      Lebwohl M, Yoles A, Lombardi K, Lou W. Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement. J Am Acad Dermatol 1998; 39:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/36\">",
"      Papp KA, Guenther L, Boyden B, et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol 2003; 48:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/37\">",
"      Kragballe K, van de Kerkhof PC. Consistency of data in six phase III clinical studies of a two-compound product containing calcipotriol and betamethasone dipropionate ointment for the treatment of psoriasis. J Eur Acad Dermatol Venereol 2006; 20:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/38\">",
"      Koo J, Blum RR, Lebwohl M. A randomized, multicenter study of calcipotriene ointment and clobetasol propionate foam in the sequential treatment of localized plaque-type psoriasis: short- and long-term outcomes. J Am Acad Dermatol 2006; 55:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/39\">",
"      Kaufmann R, Bibby AJ, Bissonnette R, et al. A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris. Dermatology 2002; 205:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/40\">",
"      Bourke JF, Berth-Jones J, Hutchinson PE. Hypercalcaemia with topical calcipotriol. BMJ 1993; 306:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/41\">",
"      Rizova E, Corroller M. Topical calcitriol--studies on local tolerance and systemic safety. Br J Dermatol 2001; 144 Suppl 58:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/42\">",
"      Lebwohl M, Menter A, Weiss J, et al. Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies. J Drugs Dermatol 2007; 6:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/43\">",
"      Lebwohl M, Ortonne JP, Andres P, Briantais P. Calcitriol ointment 3 microg/g is safe and effective over 52 weeks for the treatment of mild to moderate plaque psoriasis. Cutis 2009; 83:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/44\">",
"      Goodfield M, Kownacki S, Berth-Jones J. Double-blind, randomised, multicentre, parallel group study comparing a 1% coal tar preparation (Exorex) with a 5% coal tar preparation (Alphosyl) in chronic plaque psoriasis. J Dermatolog Treat 2004; 15:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/45\">",
"      Tzaneva S, H&ouml;nigsmann H, Tanew A. Observer-blind, randomized, intrapatient comparison of a novel 1% coal tar preparation (Exorex) and calcipotriol cream in the treatment of plaque type psoriasis. Br J Dermatol 2003; 149:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/46\">",
"      Weinstein GD, Koo JY, Krueger GG, et al. Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol 2003; 48:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/47\">",
"      Lebwohl M, Ast E, Callen JP, et al. Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis. J Am Acad Dermatol 1998; 38:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/48\">",
"      Veraldi S, Caputo R, Pacifico A, et al. Short contact therapy with tazarotene in psoriasis vulgaris. Dermatology 2006; 212:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/49\">",
"      Freeman AK, Linowski GJ, Brady C, et al. Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. J Am Acad Dermatol 2003; 48:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/50\">",
"      Wilsmann-Theis D, Hagemann T, Dederer H, et al. Successful treatment of acrodermatitis continua suppurativa with topical tacrolimus 0.1% ointment. Br J Dermatol 2004; 150:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/51\">",
"      Mrowietz U, Wustlich S, Hoexter G, et al. An experimental ointment formulation of pimecrolimus is effective in psoriasis without occlusion. Acta Derm Venereol 2003; 83:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/52\">",
"      Yamamoto T, Nishioka K. Topical tacrolimus: an effective therapy for facial psoriasis. Eur J Dermatol 2003; 13:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/53\">",
"      Lebwohl M, Freeman AK, Chapman MS, et al. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol 2004; 51:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/54\">",
"      Gribetz C, Ling M, Lebwohl M, et al. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol 2004; 51:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/55\">",
"      Kreuter A, Sommer A, Hyun J, et al. 1% pimecrolimus, 0.005% calcipotriol, and 0.1% betamethasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled study. Arch Dermatol 2006; 142:1138.",
"     </a>",
"    </li>",
"    <li>",
"     www.fda.gov/cder/drug/advisory/elidel_protopic.htm (Accessed on May 10, 2007).",
"    </li>",
"    <li>",
"     www.fda.gov/bbs/topics/news/2006/NEW01299.html (Accessed on May 10, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/58\">",
"      Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol 2010; 62:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/59\">",
"      Housman TS, Rohrback JM, Fleischer AB Jr, Feldman SR. Phototherapy utilization for psoriasis is declining in the United States. J Am Acad Dermatol 2002; 46:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/60\">",
"      Cooper KD, Oberhelman L, Hamilton TA, et al. UV exposure reduces immunization rates and promotes tolerance to epicutaneous antigens in humans: relationship to dose, CD1a-DR+ epidermal macrophage induction, and Langerhans cell depletion. Proc Natl Acad Sci U S A 1992; 89:8497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/61\">",
"      Walters IB, Burack LH, Coven TR, et al. Suberythemogenic narrow-band UVB is markedly more effective than conventional UVB in treatment of psoriasis vulgaris. J Am Acad Dermatol 1999; 40:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/62\">",
"      Stern RS. Psoralen and ultraviolet a light therapy for psoriasis. N Engl J Med 2007; 357:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/63\">",
"      Lebwohl M, Martinez J, Weber P, DeLuca R. Effects of topical preparations on the erythemogenicity of UVB: implications for psoriasis phototherapy. J Am Acad Dermatol 1995; 32:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/64\">",
"      Koek MB, Buskens E, van Weelden H, et al. Home versus outpatient ultraviolet B phototherapy for mild to severe psoriasis: pragmatic multicentre randomised controlled non-inferiority trial (PLUTO study). BMJ 2009; 338:b1542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/65\">",
"      Feldman SR, Mellen BG, Housman TS, et al. Efficacy of the 308-nm excimer laser for treatment of psoriasis: results of a multicenter study. J Am Acad Dermatol 2002; 46:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/66\">",
"      Gerber W, Arheilger B, Ha TA, et al. Ultraviolet B 308-nm excimer laser treatment of psoriasis: a new phototherapeutic approach. Br J Dermatol 2003; 149:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/67\">",
"      Branda RF, Eaton JW. Skin color and nutrient photolysis: an evolutionary hypothesis. Science 1978; 201:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/68\">",
"      Gambichler T, Bader A, Sauermann K, et al. Serum folate levels after UVA exposure: a two-group parallel randomised controlled trial. BMC Dermatol 2001; 1:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/69\">",
"      Rose RF, Batchelor RJ, Turner D, Goulden V. Narrowband ultraviolet B phototherapy does not influence serum and red cell folate levels in patients with psoriasis. J Am Acad Dermatol 2009; 61:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/70\">",
"      Schiener R, Brockow T, Franke A, et al. Bath PUVA and saltwater baths followed by UV-B phototherapy as treatments for psoriasis: a randomized controlled trial. Arch Dermatol 2007; 143:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/71\">",
"      Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009; 61:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/72\">",
"      Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/73\">",
"      Hsu S, Papp KA, Lebwohl MG, et al. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol 2012; 148:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/74\">",
"      Gottlieb SL, Gilleaudeau P, Johnson R, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1995; 1:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/75\">",
"      Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/76\">",
"      Morgan SL, Baggott JE, Vaughn WH, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann Intern Med 1994; 121:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/77\">",
"      Roenigk HH Jr, Auerbach R, Maibach H, et al. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998; 38:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/78\">",
"      Kalb RE, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2009; 60:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/79\">",
"      Buccheri L, Katchen BR, Karter AJ, Cohen SR. Acitretin therapy is effective for psoriasis associated with human immunodeficiency virus infection. Arch Dermatol 1997; 133:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/80\">",
"      Tanew A, Guggenbichler A, H&ouml;nigsmann H, et al. Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study. J Am Acad Dermatol 1991; 25:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/81\">",
"      Lebwohl M, Drake L, Menter A, et al. Consensus conference: acitretin in combination with UVB or PUVA in the treatment of psoriasis. J Am Acad Dermatol 2001; 45:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/82\">",
"      Lam J, Polifka JE, Dohil MA. Safety of dermatologic drugs used in pregnant patients with psoriasis and other inflammatory skin diseases. J Am Acad Dermatol 2008; 59:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/83\">",
"      Rosmarin DM, Lebwohl M, Elewski BE, et al. Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2010; 62:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/84\">",
"      Strober BE, Siu K, Menon K. Conventional systemic agents for psoriasis. A systematic review. J Rheumatol 2006; 33:1442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/85\">",
"      Ellis CN, Fradin MS, Messana JM, et al. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med 1991; 324:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/86\">",
"      Faerber L, Braeutigam M, Weidinger G, et al. Cyclosporine in severe psoriasis. Results of a meta-analysis in 579 patients. Am J Clin Dermatol 2001; 2:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/87\">",
"      Ho VC, Griffiths CE, Albrecht G, et al. Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group. Br J Dermatol 1999; 141:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/88\">",
"      Heydendael VM, Spuls PI, Opmeer BC, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003; 349:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/89\">",
"      Flytstr&ouml;m I, Stenberg B, Svensson A, Bergbrant IM. Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial. Br J Dermatol 2008; 158:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/90\">",
"      Sandhu K, Kaur I, Kumar B, Saraswat A. Efficacy and safety of cyclosporine versus methotrexate in severe psoriasis: a study from north India. J Dermatol 2003; 30:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/91\">",
"      Papp K, Bissonnette R, Rosoph L, et al. Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study. Lancet 2008; 371:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/92\">",
"      Callen JP. New psoriasis treatments based upon a deeper understanding of the pathogenesis of psoriasis vulgaris and psoriatic arthritis: a personal appraisal of their use in practice. J Am Acad Dermatol 2003; 49:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/93\">",
"      Kupper TS. Immunologic targets in psoriasis. N Engl J Med 2003; 349:1987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/94\">",
"      Boehncke WH, Prinz J, Gottlieb AB. Biologic therapies for psoriasis. A systematic review. J Rheumatol 2006; 33:1447.",
"     </a>",
"    </li>",
"    <li>",
"     www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm174474.htm (Accessed on August 31, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/96\">",
"      Iyer S, Yamauchi P, Lowe NJ. Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy. Br J Dermatol 2002; 146:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/97\">",
"      Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349:2014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/98\">",
"      Bagel J, Lynde C, Tyring S, et al. Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept. J Am Acad Dermatol 2012; 67:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/99\">",
"      Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006; 367:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/100\">",
"      Paller AS, Siegfried EC, Langley RG, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 2008; 358:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/101\">",
"      Tyring S, Gordon KB, Poulin Y, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007; 143:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/102\">",
"      Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357:1842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/103\">",
"      Gottlieb AB, Masud S, Ramamurthi R, et al. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol 2003; 48:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/104\">",
"      Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004; 51:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/105\">",
"      Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/106\">",
"      Barker J, Hoffmann M, Wozel G, et al. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). Br J Dermatol 2011; 165:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/107\">",
"      Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007; 56:31.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/108\">",
"      Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004; 2:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/109\">",
"      Stern R, Wolfe F. Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis. J Rheumatol 2004; 31:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/110\">",
"      Han PD, Cohen RD. Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease. Drugs 2004; 64:1767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/111\">",
"      Hoffmann JH, Hartmann M, Enk AH, Hadaschik EN. Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction. Br J Dermatol 2011; 165:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/112\">",
"      Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006; 55:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/113\">",
"      Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/114\">",
"      Leonardi C, Langley RG, Papp K, et al. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial. Arch Dermatol 2011; 147:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/115\">",
"      Bissonnette R, Bolduc C, Poulin Y, et al. Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept. J Am Acad Dermatol 2010; 63:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/116\">",
"      Van L&uuml;mig PP, Lecluse LL, Driessen RJ, et al. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept. Br J Dermatol 2010; 163:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/117\">",
"      Strober BE, Poulin Y, Kerdel FA, et al. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study. J Am Acad Dermatol 2011; 64:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/118\">",
"      Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007; 356:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/119\">",
"      Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/120\">",
"      Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/121\">",
"      Lebwohl M, Yeilding N, Szapary P, et al. Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations. J Am Acad Dermatol 2010; 63:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/122\">",
"      Kimball AB, Gordon KB, Fakharzadeh S, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol 2012; 166:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/123\">",
"      Lebwohl M, Leonardi C, Griffiths CE, et al. Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. J Am Acad Dermatol 2012; 66:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/124\">",
"      Gordon KB, Papp KA, Langley RG, et al. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. J Am Acad Dermatol 2012; 66:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/125\">",
"      Reich K, Papp KA, Griffiths CE, et al. An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. J Drugs Dermatol 2012; 11:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/126\">",
"      Griffiths CE, Strober BE, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010; 362:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/127\">",
"      Gratton D, Szapary P, Goyal K, et al. Reversible posterior leukoencephalopathy syndrome in a patient treated with ustekinumab: case report and review of the literature. Arch Dermatol 2011; 147:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/128\">",
"      Jung J, Levin EC, Jarrett R, et al. Lymphomatoid drug reaction to ustekinumab. Arch Dermatol 2011; 147:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/129\">",
"      Ryan C, Leonardi CL, Krueger JG, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA 2011; 306:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/130\">",
"      Roberts JL, Ortonne JP, Tan JK, et al. The safety profile and sustained remission associated with response to multiple courses of intramuscular alefacept for treatment of chronic plaque psoriasis. J Am Acad Dermatol 2010; 62:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/131\">",
"      Ellis CN, Krueger GG, Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001; 345:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/132\">",
"      Krueger GG, Papp KA, Stough DB, et al. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002; 47:821.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.psoriasis.org/page.aspx?pid=2311 (Accessed on March 18, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/134\">",
"      Lebwohl M. Psoriasis. Lancet 2003; 361:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/135\">",
"      Ehrlich A, Booher S, Becerra Y, et al. Micellar paclitaxel improves severe psoriasis in a prospective phase II pilot study. J Am Acad Dermatol 2004; 50:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/136\">",
"      Harries MJ, Chalmers RJ, Griffiths CE. Fumaric acid esters for severe psoriasis: a retrospective review of 58 cases. Br J Dermatol 2005; 153:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/137\">",
"      Fallah Arani S, Neumann H, Hop WC, Thio HB. Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial. Br J Dermatol 2011; 164:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/138\">",
"      Gottlieb AB, Leonardi C, Kerdel F, et al. Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol 2011; 165:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/139\">",
"      Reich K, Langley RG, Papp KA, et al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med 2011; 365:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/140\">",
"      Gordon KB, Langley RG, Gottlieb AB, et al. A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J Invest Dermatol 2012; 132:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/141\">",
"      Strober BE, Crowley JJ, Yamauchi PS, et al. Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol 2011; 165:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/142\">",
"      Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012; 366:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/143\">",
"      Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012; 366:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/144\">",
"      Rich P, Sigurgeirsson B, Thaci DP, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomised, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/145\">",
"      Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol 2013; 168:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/146\">",
"      Reich K, Ortonne JP, Gottlieb AB, et al. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. Br J Dermatol 2012; 167:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/147\">",
"      Punwani N, Scherle P, Flores R, et al. Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. J Am Acad Dermatol 2012; 67:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/148\">",
"      Ports WC, Khan S, Lan S, et al. A randomised Phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/149\">",
"      Papp KA, Menter A, Strober B, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol 2012; 167:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/150\">",
"      Boy MG, Wang C, Wilkinson BE, et al. Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis. J Invest Dermatol 2009; 129:2299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/151\">",
"      Gudjonsson JE, Johnston A, Ellis CN. Novel systemic drugs under investigation for the treatment of psoriasis. J Am Acad Dermatol 2012; 67:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/152\">",
"      Wagner J, von Matt P, Faller B, et al. Structure-activity relationship and pharmacokinetic studies of sotrastaurin (AEB071), a promising novel medicine for prevention of graft rejection and treatment of psoriasis. J Med Chem 2011; 54:6028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/153\">",
"      Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol 2010; 159:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/154\">",
"      Gottlieb AB, Strober B, Krueger JG, et al. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin 2008; 24:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/155\">",
"      Papp K, Cather JC, Rosoph L, et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet 2012; 380:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/6/40042/abstract/156\">",
"      Papp KA, Kaufmann R, Tha&ccedil;i D, et al. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study. J Eur Acad Dermatol Venereol 2012.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5666 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-203.80.222.8-5CA963D2D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_6_40042=[""].join("\n");
var outline_f39_6_40042=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H45\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      General",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Psychosocial aspects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Choice of therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Mild-to-moderate disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Severe disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Intertriginous psoriasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Guttate psoriasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Localized pustular psoriasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Nail psoriasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Erythrodermic psoriasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3704961\">",
"      Children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20559477\">",
"      Special populations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Referral",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TOPICAL THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Emollients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Topical vitamin D analogs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Calcipotriene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Calcitriol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Tar",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Tazarotene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Calcineurin inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      ULTRAVIOLET LIGHT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Modalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Home phototherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Excimer laser",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Cancer risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Saltwater baths",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SYSTEMIC THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Hepatotoxicity and liver biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Retinoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Systemic calcineurin inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Biologic agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - Etanercept",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      - Infliximab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      - Adalimumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      - Ustekinumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28956885\">",
"      - Alefacept",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20847807\">",
"      Other immunosuppressive agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1117107\">",
"      Fumaric acid esters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      FUTURE THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/5666\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5666|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/56/39809\" title=\"table 1\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/49/30488?source=related_link\">",
"      Clinical manifestations and diagnosis of psoriatic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/61/41945?source=related_link\">",
"      Cyclosporine and tacrolimus nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27625?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of psoriasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/6/27752?source=related_link\">",
"      General principles of dermatologic therapy and topical corticosteroid use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11223?source=related_link\">",
"      Major side effects of low-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/4/41030?source=related_link\">",
"      Management of psoriasis in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/3/23608?source=related_link\">",
"      Pathogenesis of psoriatic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/11/3252?source=related_link\">",
"      Patient information: Psoriasis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/9/3218?source=related_link\">",
"      Patient information: Psoriasis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23208?source=related_link\">",
"      Pharmacologic use of glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/24/33160?source=related_link\">",
"      Psoralen plus ultraviolet A (PUVA) photochemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/16/43273?source=related_link\">",
"      Reversible posterior leukoencephalopathy syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/37/10842?source=related_link\">",
"      Treatment of atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/18/40234?source=related_link\">",
"      Treatment of psoriatic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/31/14842?source=related_link\">",
"      Treatment selection for moderate to severe plaque psoriasis in special populations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/38/24169?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors and mycobacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/55/40825?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: An overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/49/32538?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33624?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Risk of malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32169?source=related_link\">",
"      Use of methotrexate in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_6_40043="Likelihood vaginitis by symptom";
var content_f39_6_40043=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F81449&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F81449&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Likelihood of common vaginal infections",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Infection",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sign/symptom",
"       </td>",
"       <td class=\"subtitle1\">",
"        Likelihood ratio*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"5\">",
"        Candidiasis",
"       </td>",
"       <td>",
"        Pruritus absent",
"       </td>",
"       <td>",
"        0.18 to 0.79",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pruritus as chief complaint",
"       </td>",
"       <td>",
"        3.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inflammatory signs present",
"       </td>",
"       <td>",
"        1.4 to 8.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Curdlike discharge with pruritus",
"       </td>",
"       <td>",
"        150",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Yeast not seen on KOH wet prep",
"       </td>",
"       <td>",
"        0.51 to 0.66",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Bacterial vaginosis",
"       </td>",
"       <td>",
"        No complaint of odor",
"       </td>",
"       <td>",
"        0.07",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Complaint of malodorous discharge",
"       </td>",
"       <td>",
"        1.6 to 3.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Trichomoniasis",
"       </td>",
"       <td>",
"        Inflammatory signs present",
"       </td>",
"       <td>",
"        6.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trichomonads on saline wet mount",
"       </td>",
"       <td>",
"        51 to 310",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trichomonads absent on saline wet mount",
"       </td>",
"       <td>",
"        0.34 to 0.51",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     KOH: Potassium hydroxide.",
"     <br>",
"      * Confidence intervals are wide, but significant.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Anderson, MR, Klink, K, Cohrssen, A. JAMA 2004; 291:1368.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_6_40043=[""].join("\n");
var outline_f39_6_40043=null;
var title_f39_6_40044="Microbiology necrotizing infection";
var content_f39_6_40044=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F83456&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F83456&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Microbiology of necrotizing soft tissue infection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Organism",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of cases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Streptococccus",
"        </em>",
"        species*",
"       </td>",
"       <td class=\"centered\">",
"        31",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Staphylococcus aureus",
"        </em>",
"       </td>",
"       <td class=\"centered\">",
"        26",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Klebsiella",
"        </em>",
"        species",
"       </td>",
"       <td class=\"centered\">",
"        17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Enterococci",
"        </em>",
"       </td>",
"       <td class=\"centered\">",
"        14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Acinetobacter baumanii",
"        </em>",
"       </td>",
"       <td class=\"centered\">",
"        13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Eschericia coli",
"        </em>",
"       </td>",
"       <td class=\"centered\">",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Pseudomonas aeruginosa",
"        </em>",
"       </td>",
"       <td class=\"centered\">",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Enterobacter",
"        </em>",
"        species",
"       </td>",
"       <td class=\"centered\">",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Proteus",
"        </em>",
"        species",
"       </td>",
"       <td class=\"centered\">",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Bacteroides",
"        </em>",
"        species",
"       </td>",
"       <td class=\"centered\">",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fungi (",
"        <em>",
"         Candida",
"        </em>",
"        species)",
"       </td>",
"       <td class=\"centered\">",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Peptostreptococcus",
"        </em>",
"        species",
"       </td>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Clostridium",
"        </em>",
"        species",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        10",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     *",
"     <em>",
"      Streptococcus pyogenes",
"     </em>",
"     (14 cases), group B",
"     <em>",
"      Streptococcus",
"     </em>",
"     (13), group G",
"     <em>",
"      Streptococcus",
"     </em>",
"     (3), and",
"     <em>",
"      Streptococcus milleri",
"     </em>",
"     (1).",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Includes",
"     <em>",
"      Chryseobacterium",
"     </em>",
"     species (1 case),",
"     <em>",
"      Meningosepticum",
"     </em>",
"     species (1),",
"     <em>",
"      Propionibacterium",
"     </em>",
"     species (2),",
"     <em>",
"      Morganella morgagni",
"     </em>",
"     (1),",
"     <em>",
"      Veillonella",
"     </em>",
"     species (1),",
"     <em>",
"      Bacillus",
"     </em>",
"     species (1),",
"     <em>",
"      Aeromonas",
"     </em>",
"     species (1),",
"     <em>",
"      Burkholderia pseudomallei",
"     </em>",
"     (1), and",
"     <em>",
"      Vibrio vulnificus",
"     </em>",
"     .",
"    </div>",
"    <div class=\"reference\">",
"     From: Anaya DA, Dellinger EP. Necrotizing soft-tissue infection: Diagnosis and management. Clin Infect Dis 2007; 44:705. By permission of the Infectious Diseases Society of America. Copyright &copy; 2012 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_6_40044=[""].join("\n");
var outline_f39_6_40044=null;
var title_f39_6_40045="Plasmapheresis in recurrent FGS";
var content_f39_6_40045=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F51857&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F51857&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 537px\">",
"   <div class=\"ttl\">",
"    Graph showing effect on protein excretion of removal of a circulating factor in recurrent focal and segmental glomerulosclerosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 517px; height: 234px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mean reduction in protein excretion following treatment with a protein adsorption column in eight patients with recurrent focal glomerulosclerosis after renal transplantation. Three patients also underwent plasma exchange at a different time. The degree of proteinuria fell with both modalities by the end of the treatment period and then began to return toward baseline. These findings suggest the presence of a circulating factor toxic to the glomerular capillary wall.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Dantal, J, Bigot, E, Bogers, W, et al, N Engl J Med 1994; 330:7.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_6_40045=[""].join("\n");
var outline_f39_6_40045=null;
var title_f39_6_40046="Gardner Diamond syndrome";
var content_f39_6_40046=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F80842&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F80842&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Skin lesions in Gardner-Diamond syndrome (Psychogenic purpura)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 204px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photograph of skin lesions in a 53-year-old woman admitted to the hospital with an atraumatic painful shoulder ecchymosis, recent psychosocial stress, and a past diagnosis of Gardner-Diamond syndrome. The inked lines on the photograph show the extent of bruising that appeared on the patient's chest when told of hospital discharge that she considered premature. After physicians relented and granted additional hospital time, the purpura retreated within hours to the small central discoloration within the marked lines.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bostwick JM, Imig MW. Gardner-Diamond Syndrome: Bruising Feeling. Mayo Clinic Proceedings 2008; 83:572. Copyright &copy; 2008 Dowden Health Media.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_6_40046=[""].join("\n");
var outline_f39_6_40046=null;
var title_f39_6_40047="Enteral tube feeding algorithm";
var content_f39_6_40047=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F59070&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F59070&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Enteral tube decision tree",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 567px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PEG: percutaneous endoscopic gastrostomy; PEJ: percutaneous endoscopic jejunostomy; TPN: total parenteral nutrition.",
"     <br>",
"      * Enteral feeding should also be given since it is trophic for enteric mucosa.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_6_40047=[""].join("\n");
var outline_f39_6_40047=null;
